var title_f27_63_28656="Echogenic liver";
var content_f27_63_28656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echogenic liver mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of the liver in a fetus at 20 weeks gestational age shows a well-defined echogenic mass (calipers) consistent with a hemangioma. No other abnormalities were seen, and this did not change during gestation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28656=[""].join("\n");
var outline_f27_63_28656=null;
var title_f27_63_28657="Normal intraoperative cholangiogram after cholecystectomy";
var content_f27_63_28657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal intraoperative cholangiogram after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nathaniel J Soper, MD, FACS",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28657=[""].join("\n");
var outline_f27_63_28657=null;
var title_f27_63_28658="Mycobacterium marinum nodules";
var content_f27_63_28658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycobacterium marinum infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAYsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1RXbaCy8+wqVeeJQvXgiqnmBchSOeD60qsSdi8+5FfUOJ8emaG9QAOAvXI4zQzKMHkH0qmCVBO3I6Y9KDKCFD9fQ9RUcpdy6ZBgBc+9KHVODkk+lUA424XcB2xTtzcFSMCjkHcuBgCSvU04HOF5z3quj7QvoaeWJJwDk96loaLStt4LcetDSDJB5AqrvIwGI56e3/AOqkBJONw9uORU8o7lrzldMbuP50vmbAAg5qqJVKADjv3/rTlYEfL0+lHKMuBs4w2T1qZHCnKnOKoo4Vuv4+lTIw25qJRKRbjlJJbGAKlVsj5ucelVI3PpgZ656/4d6sRuoBIOB2rKSLQ2d8LhQAR3IrEuATOO/PNas6ZyV5rMMZaYHB4PvW9LQzmaWnJ7cVrxDAGD/OqdiOFAGPrV4bVPGMmuWrK7NILQa5IBzioOQM5qWcKAec+lU5mwPapgrjZYWUEjBH0q3C+4fNnPtWLE+OSeTV+CXdgetOpTsEWaaNgelOycc1XibGMn8QDU27jvXM0bIdnikLY/GombFM3nPGf1oURXLAc0pY/j71CjcgE8/WhyCMq2CBRyjuPeQY5qnJcJl1yCQc1UvL5YTtkIXJwD2J/pWRPdyyXAW2gmlcZyEQnK/lXRTo9yW+xo3snKtngMMj2qpNP8uf4fWmi3vbjOIJFPUBxtJx7VaOlTgAPIgJPpuC1tzwhuxqhUnsjnruciRx2Pf1pnhts32cdTt5x1rorjw1DdR7Z5pyDzuVQoB+neprHQLSzQonntMuH81m5yO2AMYqpYykotFxwFVu5oxKCpZRkkDcvr74qN3dWDp86t26E/8A16uW1v8AKOhYncDx09TU7QbHDHZkc5HT6/WvPddI6o4J/aZj3CXAeICN/mHI/wDr1F5csmUjKhz8vJzmtxkDM4kbDcYGcce9QlwIVUKCp6Y459T6Cp+ttbI3jl8OrZWgsZRHhT+8ZsjPr3J9qjlVYd7NIHlJ25BBYn09AKtETiZtsSEqBjdJ8qnqAcdT3qG9yIYYpTNGj8O4UKPUgEc5ODzUOvJm0MLTi0rGZcWP25/NaFpQQAcSYHr1/rWfNYsVbyLeNCreUCF349TgcVtWkNp9hgK4KE/KSxH6ikVJQrmN96l2Eag9Aevbuc1k6sn1O2EFHRIoQ2LC3L3kg3RjaY0HHHbjrVK8s5GQiFZAzEDbGSqr6lmHP4Ctq+R3tlZA7bSu5WA5O4ZH9PxqyjNIzFUbZjBY45I7Co9ozRK2pxv2drIyKygzFcK/l/MpPGeRwB145+pqWe2itIokleJUTD7pAR5n4H8/fvXSR2KXDoXzkjJZ+pP8qrXWgW1xKEmy6rk4J4PpU87NeeF9TAuGaSaPynacbGfBGCXHQ+3GcDsBXQDyCAXaNWIGQ3Wq9xZnYcgj5FQuONp5GT61cgnjhhSN0G5BtPA7UufuTOPMlynHbgJDuIY59OlOLrvLbju7VTLMwIUkCiMlUw3PpzX2bifniLokZslX/A96RiSQFyx7nFVo3KqMZyehpYpisjZdeeuTU8pSLseVA2jPrxT97KSoGM+i9arAFk+Y9eQOKd8yhS2Mdjgfh/hUWLLG1WG45BHpmpxMeCMj86qqWCs2FHvgcVJDtbqAMe3T0qWikWg5kPyrjA9aj3bn5PPc9frUDS7ZQFY4I96MH7wOWPINTYe44TEMw7DrxwfWpEfdkkjAPfn2pgLbVwMfp9KRAq54Dc5B9ff+lA0W4nOzkEf1qYMBg/fz9KqIdx2oDj05H4VOsb8EKzc9xUOxai3si2JAQM9O+OKnU8Y6j0yOKrRRTBeIz+Rp375TjYcVi7bXNOSXYnYF2+Xp9KiSEmXLdPbNOTOc7Wx3+Xg1Lk9/xOMUr22E4svQkKuB17VN5mMA9e9VIpB0HNShskH2rnlHUtCyLk5JqtPgKQP0qySD9fxqGRCFJY046CaMpyU/OrNpL3yDz1qrfqck54qvayESgE4BOMV18vNEy2Z1EDkjp+lWAcLiqlrnYpIPPTIqwWOK8+dkzrhCT2QMc/8A16izzkdPapfLLex+tCQDeCeg/WodSMTohhJy30BAW5PHpSeUWPD/AJj/AAqb5EYbtwA596M56ZGOcVhKu+h208HFb6kP2WLO14YixHUjI/OpSWGcY46c4NKfmyMduahj4c7vuHuecfjWMqre7OuFBRWiJHHzAOPmByPf8aIgrJ8pOOvepQ4Y8SFW7gjBH+fWh5FDOSCRkc96TkNQuNZfMAO4/LyQTkYpzEoVYox4yeMkmiFkLtt27uu0jHFSNjywEXAJOc0uYOWzsM2tIuSPmj+ZcjDJn+lO3q4UsCMcMAc/T86cRCWwybZCeMk/n9KY6SRyK+M8YIAHIpNiSuKUOQ3AYdCOv1pjwHyUjjJVmOOB09aeqYb7wQEdAP0zTZWK4bLE9Fx79TSuVrfQbHaxpcRqoxgEgK3Q/wCR1rPuHeW2njJWRo2OznqVP9P8a0IZN0u3ZIzEAK4XA79yazcyvFPbmJ/LMrZSJ1L5JySfTBJ5p8xUU76loW8ryu0ccUat96Pd8r/l0+tRWqh1K4idCTiUEnn0J4GTSyLcug823mlT+NUKbV45JBILVG07XPmwW0chLEmQkGNlxwQobv79BjNJsqN2tGUZWkZH8weZAkhSXY2CSD345Axzg/yNae2MxSPHuLOOeTkHHH6URWsYtIkit08tFAjIkAAHtjJNVBBJbrELrbKPuxqpIU/7JzyePXjism2b3UiFJbiWaSOPLFT8rL8qe+euT9KW0uZ2l8pztlUbhg5B5PB/CtASBpI2COm3AJboAeD06VXt4vNG0jaY8ZccnOSf8/WlYbmnui2yLLbkcYZTn8ayxbSsAQm7IBzu61ZEpYPDIMsDg7fQjr9OtS/ZWkAdHfaQMbTgY/Khu7IXubnmzygsyIWDd6icOVx5vzHrz0q2Iz90Zz6mkkUqoCjn8a+6ufn1iOPcRhiFA9DUgibcBtXHqTSxgghTyB9atrb3EjDYrNnoOenaolJLc0jBy0SI1Q7AQfmHv/8AWqQE8hvpjj8q0INLuHHzME9cHJq/b6TGoyzNKw7twK5J4qnHrc7IYGrLpYwfLYn5RlOmODViK2llzsiYjvlcV0lvZBCSEUA88VYaDaB39q5p47+VHZDLl9qRziaRIwJYqueuKuQ6QDhTKx9hWwkQxknBp7tHCBhcsa5pYypLqdUcFRjpa5nx6PbqfmDNnuTirCafbR4Kxg/UZoJlkbJAUdgKkjDH72fwrGVeb3Z0Rw0I6pImS3jA+VFH0p6xgDgCmnaoznd+NHn4yVANZOoWqfYUQbiCc0G328/mKaLhiDkqP60gmYrkuoAx1qeZl+zY4MFOB09KkKoRyvv04qv5ymRuuPXpTww42scU+YHTHmOE44IPuOtRCIbm2ZOBTi+4bAPpUqKVxgfh3pqo+5LpJborGHjPy4PNI8LYBBz7GrQXIGST7UEBjt7fXrVKtJdSJYeEt4mZPp7T4y4UHrxnFXrTTbe3HyRDf/fYZP8A9arSKPSpmHyhQKc8TNq1yKeEpwd0iuV4698UqoD1HtUnl8d8etNPyjHWufnOpQXQMYwBzSsOD0BPqaaJe2ASffpUck3J3Y4/nSbuVGDEkBCnCnPQDNRSPMEAwzAc9t34dj9OM04ThnOenc9hTBcI0jDdwvHH61LRvGD7EsE3mxkoMgYyMEZ9/wDPpUpAxgY3dx6/Ws7zDFctMoyMYP0J5H54P5+tXmlDjDAAA/5xWbZcoNbEUqrgZLDHQ56ew9KqSzSrJEoZmxktHIm44zgH6VOZ/lZSCACQzYy3+fcUrohZXRd6gcleMA9//r0r32KUbfEMa6njZi8UbRqMHypMtj6Hrz6GpIr0NFI2A4UcDBXH1BA/SoYwGadWxIq4II4Oeeo9RRLFJ9ilRDudE6g/6xccZHqORn2pcw3COxqAloYiWjBAxgHOf/rVNu8xFcZ68Ejms+yi3xoysTBOolQ4+6SAfyIP6e9WrdGRJAuVy+7joe3T39qpSuc04pEu0lgCxI74p6BUBABJPoOT+NMAJbp196VER3ORkHpzQiXsVnmf7ZNGXRFCK4AOTwSOv5VXsrpI5ZEaNsHbJvXqxIwc5+g5pzbIr2F8HbxGeBnDcfzAqwbZEEbAZLAxnccAg8j+VNMtqKWq3KdzG0s0jx7TIQqDPPPYn881JJaLJaGNgqqABuA5HuD3PfJ71JscTSKj5kKq/IxnB6/yzUzvgESoQrDqcEDFSHM9Eivpjb4IRcBPtOCp2/d+UkcfXGfxqSdAX3H7q8Beo56/4Vm6ezxBJGjfZJ9CVOODnvwOvt3zWmk3nIDCCVY4LNwB/WpKmuWV0VNzrMZCC0iqyt/tAHp78HiqGgMy285YqVEz7f8Ad3HAxWtMR5iDcAsuVYgdDn0rP0+NWmu4hzliyP7nBYY+uTSsUpLld0WpFJlNwDgAAfr1pskalyS8wPcKcCrDFdgjCjYBwP6UCUx/IRyPQDFOxnzM88gtJZV+XK7e7Vet9MQtmVnb6DArVjgKoOAKspAcckHPpXv1MZOWzseNSwFGG6uUrexhTGxOavQW+XyFOBx1xQwVMFW5B796cJdznk4H4Vxyqt7ndGnZe4rIsKoUc4wKduXOew54qurDDMQWA7etWlj/AHYDEbwOSPXvWbkFktx6kEjGcU98KvYe5qDcoBweMdahYkHBzio5g5LskkcKeagI6npnrTJiTzjGPTvUq7imT19KlyN1C2o15NoGOmO1KZCQu44yOcVVnk28g/NzknoBVaSVy/LHJHTuKS1OiNK6NJpQMBQwOMZqrLNkEBiR2xVMy5G7JI9aieVlOd3fvVJXNoULF1LoMQBnA59c0NOQeAeOtZ4uIwThuSe3SpVlVhnLEmtFBlOmkyeK4y/O7dWhHISvQDjpWCsv78AKfl9q0YLjYcOuM9umKUlYVSl2NSJ+QCRj19anD5yR1xWWkil+h9Ktq2Shx8oByc9O3+NZt2MJUrF2MrjBJPamRsfMOB8vUUxWAUnPFSwcpnPXoKm5Dja5aTo2cYPenK4yQPzJpqEbe1ROfnCryahszULsmeRCVLkZPAGefyqld3IQbVJaiYLEQcAs2T65rL1G4x909+h54qonRSpKT0HPdknBbAB7VXN6xchTkA49zWc0geUs33W4461DPdxQzFV2lj1x0zV3SPQhhr6JGjLdYchScelSwzpkBRg+uay7e7XZIQgC9Bkcfge1KkoIJ3fKM5B/Opbub+x6WN4SklCQTGeCf7wqS2ciHyxyIjhWPUqemf5fhWbZyFkQuzEAHgnI+n0q6cQqZguEz0GTweP54rOS6nJOCWhMhDzNkMgLbgT7DmooriWK4XZ8hOVyORz7VMke796SF4yRjIA9/Tk4pbiMtgRY3cD61Ek2QnG9mLEiefviz5oGflbaWHGf/relSrG4ZgvzKDuQ8ZHqB6jpwfWoEQiRAeDuGGGchv8A6/I/Kp3d1eCQEMAdjn8MdvfH60jOS1sJokx+yCI8PC5jI7YJJGPbr9MVqzxqy/KCGz17/WsaRAl3FJHhCylOO7KQw/TfWwJleQgg7v4ccjg4oT6HPVWvMgUksTu+XoQB7Usaj5/LbLA4+o9qQjBV9vDfI3PQ9Qf6fjTZhtaOQ8YOOvrx/WquZbjmQOrKSvI9ORzTpEk8jy1ZRIFyGHIVuxxSsoEkezBRgQc/Uc1YXJ6nmqWpDlYpyjY6MMbSMfMmcVV1CI4kjVT5LjbiM4OcnPHXp6VoFMqYyflOen8qgVDKvlMD5kWUJ6bvf+RpPUqEramHJFFZLEiW/nKBglc70x6Z5/AVcgbfAJZJDvPIbux+vQ/Q0++BQrIFBYKNyjoeCefccU3EUkTz2j+bG6Hf8pPUY4+h61FtTocrxuxLljNHImB50XzKSvXByOPWs6V2tpUkUERGTBXuM5Kkn0PIq5f3Aco6LI3lOWBjUn5lGcZ9O2D1zSFba6tHNudpd1aEY2nJw3Q0rXeg4y5VrsyeVjNbM8LtySUBHQ/54/CqnnjAyIicDOTz9KpSXdxZ6nJZzkYdC8MQ5LnI3DI6djVO+V5Lp3APOPuqMdKTlZlxo3WuxsBogDtPJ46UyMo5PUHsKdGiqpAzk9qkj2And1HIr0LnmaK9iu0Adsk4PrUnkc+g/OkkuVI6f7Qqt9sKglsc1PNqaJTki4FIZAASByWB79s1LJ5mwLnA7n19qowzAscE8+9TSSjYWHpUtj5HcRpCgwzdOeTTBIWK4zzzUBO/gtgD8aZHKpb0wvOPWs7nSoF8jcCAcqOM47+lV7iZFOM4B4PPSo5J1CqBkknA9z9aybm5IGNw3ludvpUtm9Gi5bl2W4AbCg49+1U5nONqMS5HaoXkJztznGPYCqr3IRWLZG0AYBwDW0Y9DshTsrlxpmT5WGCBnmqzymQrg/KDWXNetIwUtyw7Va09JJkG0gMAN2TgfWuiKSNfY2XNItRN9oc7UCqDx7/jVuUMsfycYGCM4xTbOFFlZ5SjQRsA+3kkZx8vr+laNsgkDWc6AR5LPI4IbGOM4/z60OajuZ1WlstEYqs4KsQ6N04HSrCzkY+8VAGdxq/PZwsgkt2cxqMEseT7/wD1qz3XYDtYZXklhSkrq6KpzjMvW1yo2YKsc5II61swTGbCjBJ71xRujDIcnGeOR/Kugs5y0Me0qWfkk/y+tcrepWIw1kpI2yRsXrj09KsxuSMIM8dcVmeYdowT1wCPSrUbAphS27pj2pM86dPQuq/UE8jrnnNMmk2OcncAPToKakZCDn5R0OetLMpAZR1yCP51BkkkzPuZQibuF3HHJ61i38oVGkIO7sCe9XtQdUfy0wycnJ9O3+fasqVvMifjk5J4xVxPToQtZkCMSvyBBuBbJOBVV8tuKjLDJJPFaDKpw45AXhT3q/puiy3lzas5ZQHDO4YdAc4P17denNUkdLrwprmloc7aQTzOdgLZyq9hkDO0e5HP4GokvHiZVUExkAgA5we9aeuSWFhqX2VbsW8y3jSIkiER4AOFbB4zkgH+VT2ljHp9+8KMsoglLtKyhlwRlR6EEflSik9jd1ly88lurrS39dCOK7ZVjLjGVDKM98cf1rTaZp7DDH5H+Ugtweefx4rGuGjuL93RFRHYFkQEbSc9M1q28kltbuVU4IBOQMn1GeuMZ6YPFJrc5qyVk0tTX07bNBGksihSDk44U9/wqxczu8DMu6QD+LHC9OBj2zVJrdUjy4aIvMMA5AwcEbQM7jzz9atlUhgZR5hG1iu5eQRwPY5IIqXseZO3NzIdLIqWzqo+XGcj9CajtCRYZYncMBiw6kMKh4dDKzB0GUxnAPTJH0BPWo4nkkIix8wcK2w4BIJPXqTgZ/Csm9SlBcrJddV7eASx4Zo5hKqZ68ENz/usa2o0aNI3z8ysFJHfJxiqFxAt1ozxKCvmxHBHGd2MfjU9pI62cbSYziFj69iTQlrc56jvBLqmaBZFXa5wCeB7YJ/wqvcsJLdVUsrYyOcZ75pLl0iRJOm4sU9xtJ/OpWZIxGGX5owQe5BxkVXkc6VtSSHeQhccE7ifQjtUqMoZV3YJXrnrVWOQPGjZ4kRWIzjjvSzOSYGx8uC2QueMc8U07EuNx6TLPIVJDDOMLnn3rOeci+miktyzg85U/Mu3GQfTNWbiQq9nJ5jY34OOcgjj9aZKyrcNJIzkKShII6AZ69h/jQ2VBJdOhWtZYg4ClQyMG2k7SfYE9fWobm58uyu1hDxO0jFUAwdx68dO+c1dZFaIxTYeKSJcow64x/TmsHVYnitZxBCBFbMsmFOdh4OBnkZx07E+9Q72Nocspalq+vIocvC/7hdqcAkMSD8pHY44Hvx34sWs8VzK0BZJYAc4YcYBxxn6iseWZZy1zEgjj+ZmfJCsMYIPqoDEYqnpDmzw8sjlMSQswOSo4K7vfHXHYA+tJSuzZ0Vy+Zu6tbIlxa3UjM8YbO4HLR5OMZPUcjg9MVVZRKxbdjkjh8dOOlTa1dyG1kVANyx7lZh1I9Prz+Fc7c6g0FzNHjaRI2QQcg5ORTdmRTjJxVzpnk2IOpzimk/JnGfx/wA81SjfzBkNjjpTiWwSpz3Jrrb1ONU7KxHcfKfvDBbvSELK+3gAcdabdMTHt+UZ7HqR6imRyFmd8gyNUX1OlRfKTqGQnv6U+Zy/JJLdeajjkwDgAt3zTXl2ncVYZ/P6U2JJ3FLhcNnB7H0qFGLtINoDMcjIqaVgsf3QTkcdyTUEWTLK6naEwWOOg9ajqbw2uVLreJCoYhhkAZqhhiflXheRuHB/xqXJG/J35Y7WOemcdPfr+NBBZXIB3MM8+lOMep3JW0IXlZF2hsgAisuVzM+0Bgh656cVYu2xCwwTIPugdu+T61lifZFjJXceT+nFbwVjohHsWoU8y4YKOEwM4rpbC2jw6ThHO3AUnof8eK5a1lFrbtKzDyv42BwfwqZdRmTS3vC0AVjtUu5BAHHH9fpWjkorUudCdXSL02+Zv6RC9xfSeWwVDIX3f3R39vpXQzbIInkQgDZy3fr3rmdCgvZLZhblVjlI2ytxkk9DW3qml3lxpi28cu/ZlSkpx5w4xggcHr7VwczleRx4txjWjCUtCPSNzPJAhDRrlyQc4XtUOrWskTkBuCA3/wBaq1i1tY3MccUckkRTyvmPIXryasWYa4M0YV0dMgE85Xtn6iuyjPnVgnFwqOotjnLlSZAQzFielbOlShYFU/e6Af3T6+4xn9KydUhWzl65YnBPPSrmmKJAiM+GBABbAGMj8utZyWp6lS0qSfQ6PzFIQDK8AYHrj/8AXWlARuRduMcEnqef0rKAEYh80jEbABB1ycEk/wAvwrYtFBWI7gOQN3PIqGjxa9kizMT5bHeOW4Gefwpks0Z8xw4J8skhFzjoPx9fwqxaopt4yg44kLEfkPrinTpAsG9iByCqjqSBwD7EVNjhUknY5bVFKyqvXcpGAc5A5IHtWZPMsNqzKAWbpz0960PESFAgc8Hc2NvBHHzDvzz+Vc3NcF42wQU3dRxn6ULue5hoc8EzR01nkuDtyoYAj0HP+eleg3Pladpk0wkKxqpb06jGM+ucc1xHgSRLjWjFHtG1dxYnqRxjH9K0PitqIj0NLKKU+a86h1BxwAGGfbJU/hVN2jdHJiaTr4yGH2/yPPLmNtVF099E00T2z3pUzL5i4GBkv1x8o/vEdK0vAWo3UFzZaVMFRnby4mI+fYcsFIxg9ec9vanato6yWMV3qamJFCfu0H3mAyMGsrS7XUP+Egj1GFxIQxmhLqDyhUEMOoxuHJxnPFc0VKm0z6KU6WJoShdW6dk1tb9Tt9VsJIbgXMpQS3DEjaQMc46DjirdlbzXdsQiksFyUZQTx3A/XHHUVJqLXF/FaXPleXGUEm1SuyNed5yeck7QB9TUtjKsF9DkBYRhJtmQcEkAN6n5csPT6V0nzzqTdNX3X6dCa6JszAZGMAeNoywk4PcFCe/JJ9hUcJeaC2sTOEkeQ4kyQCoUcEe/X3rVu4oZ1je8XZMk3mIoIcHAOC3GMdfT0zWNKIhey3W9VkH+rJXkr6HPGTzj8KhnPTkprz/XoXrYo80yMrBX4O/HJVSceg6jj/69V7IRi7hiUESyROSG5Ctsxj8ev0qS4WP7I3nmRQkwbcuSCGHysPfkDn0qnHvGpG4mCkxttlCjjIUfMPwI5rOStuOHvc1uxq2Z3W4RCS8cKyH8MDH86stPtnuckNGy5jULyNv8Poef51FGAL2VZCIjKhG0Lxtzw3HfrRaNugjJZSwkfd2OST09OlPY5p2bv/X9XQ2+lVEtoi3DT5QDoUIJPTpgVf8AMWa8ITLcjODgbtuetYt3Kxn2xYaOyzMeM8Ffl/QjitKzDRRJsVtyj58jnccZ/XcalbinFKKfUsIpHmfKAqIy+vYVL80UwiVicjCZ7cc/jzVGOUb3d2yWLDaD1GQWx74xT1cQhZGzhX3cnt3/AEFVczcO5FfvFGYLYjMjMQFGfuhDyPxI/Ol3KiushVpMAk4x8xGMGqSNJc3ZuHKoGlQRbs42ENxxznNN1OdUVQpwWYQlvXkc49MjtnrRc0UNo9epemufIBmUII0XK9Pn+n5Z96zzKH0+FWVvnRmkCjk55ZsjuxOR6ZqjqUzSWbrAnyhxCo6/KHAY/mCB9KmtswXl5HGA9u8aumDgqzdvQA5/SjVvQr2ajHme/wDX+ZSWRFf7ETtDMsbkDcGAJJYEeoK/n7UjWZiaa3kkG6W584bT93AB69QCuAPoaxi8kOvusrKiqcCMkkct1H0bv/tVcaRoNRGwkF2CuFOQrgnDL/styMe9To0dLg4vR+ZsWJi8qaCQnytrsWI+4Mnj+Vcrdj7VcPM4UuxwxIzyOP6VrwSJcQRlWMkckazbsjIBzxnsfX/drKNrdFmaC4UROxdQ3JG455/Ok76JBBJSbZuwOyKBxuxxkkU+CRWR1ZgSnynsRVeJnkhAIBdMhvUEd/x61WjuHN4wChfOXaQOeR0xXVJ6nKocyZbZD5n3WYZ5HcD2pofy3ZcffGAT068/ypTIPLjAUh5Arbgen4VWu5GiuAYTu24JH/1qktJvQ1Fb92CoAwOPcVE2zec9TyPSoYJcQyDOAHxnHY8jGPrSpIZpC/yD5OCP4jxkmqM1FoeXzN1YKg2jHrVKSRh5wUsCWA+XIO0Dk/yFSsuybYWwFG45OMcfpVC4uEW5O3O5sE72z7/4VLR1Ul2JmkRZEDDCsuDxnP8A9ekw8oO1V2NnDsCBtAz+HFVLh5TKPLHLHYGA554/QZqe8xHbLHE5QzcBkcbWXPO4Ac9Me1XFdzota1jn7qZ3iRGYANztXrk5x1/zzVJEBfY7c5IJ6ge9aerxv5jyNG7gH5iTwuOAFPoMr+grHjlw+5wCAQpGe/0rVKyO6m+ZXRqS20lxAi2i5II+UrkMM9xV7WNG1C28O2tqstuytM0pyMkEjDZ9Bgjn/CrPhd919AB8pVw2fpzXQeJZvtM2lRugid4iyIOeGOPTqRjj3orpctznWLqU68aa2Wv4Mn0MRhIASUi80A/NnGB1z0PPf0rX1BkmiwrMTjHHH5GuUudZgsLuTT5NiTREoQSMKfw+tXV1TMSxooZjESvPB47etckfhaPOr4epKoqlt9jP06zlXUb+KUhgyALkfX/JrVsrHy7hG2tvPyMwPDADjI9egrP8IyXM80s1yu5o15J75rtIQjSIzDazDZ0zyQTn68U6DcLM3x1eUJuH5eh594iI+2SBkyCSqtjrjr9Kq6beeUZIZW2QEKzFeGxnt7/XitrxbbwxCMIgEzjccdsZBz69Otc/YHyL0NKhYeWw2hsE5Hp7DtXRLVnpYdxnh9v6R1uPNgQsSIYSdwwc/MWLZ914PHGDV2O5+RFZQECbiACMYI6ZrNtI45RcHzFkjWDBReRHsw2PUkKAv4mtazkM17IpjItoiwJP8WBlQR9GGf8AdrOR5lW1vQ2bEMJSm0lFUgOTkn60k8ccqo7PvAdslBz0P6jFVNMSWELHO5eR9jFS2AF5x+oP1zSSTmK3jZdo5KoWIGSQQN34YOfakec4e/ozlvFKtGLWBYSirGfLBO7cM9c+p71ybxGQ7Fz16V1PiZroPZLdRII0jZIpEbiQ8bjjt2rl5N6zRgdUXGc44pH02CuqSLOh6pLoGqpcyLhHUK6kZ4z1Hpx3xWj4lu538RmLUljG1SewAHXrn0IrFhl8yR8J5hVMuM8lO4+nXpUkCJqdtEuoSk3IH2dXLAq+0YCls5BPAz7im1pZGkqcfae2ktbWffyNTxFPBcW0tzaEeWYQCgbIQggAgdPYY9KTwwI4fDct5BCvnuuwzyEgKxZsL05AAHPP8xWPrcbJ4YiTTg3kTEiRIoiWQgYweSSSRknjnNdD4b0u6t/DK2EkyPdu4l8pjwh4659BjJ96x1c7GclTp4RK/wBr52Xf0NfWHa10XRJ12uTbvEflLD51BBx9R196zNLWR5LaIebOyupkTfyv3gSPVgTn8D1qXxjFLZGzhWQq0MY2bDwy7if0xgCmafPGA10Q0VuZzjZncDg9D7AkHJGd3StpWucVJWoXWt7/AJv/ADOmuo3t4Y2BmDowKo8nyvg5Iboc85wf1pltHEiStG3noXLoFXJ+XA2+/TnHWo5UKMLzndMVkVJsZgfI+Y8Z+6BkHoafp26JmxKWSFCdwXbtJOSpz1PJxSscD0huZsrXP2acJHgW7Ovlkk5C8qWHocED6VJZuJHmBwyPCsgZuCHwRtz6EdPcGreoDzL0bS3zRb07n3zn1zx/hWVpIYaMmdrMyK23dk9ZF/p+lZy0ZrFqUL+hvxSr59vdlT865IHJHJXH6ioVuFtLjyvuIUwQy8M69AD9CPyqNkCtahWd0kDAFupA2kfQ4akEYuGtvnLJGTyTkBiSQfwIGaHc57R3e3/DkNlKP7R1JC2HZYIpFY5ION35AH8hXQW8qlSH4Zmb7xzyB0+nNclZ3JOs3t+qnzFkMbouMqAqDJPfGR+BrYEu+ZnRPmYYAzkZHb8qSdgq0+b+vImaRIL2IjaUAwfMIHfjPrxVfUZWk8i3fkySGMhOOOpyfoMU1AszESIr5GOecY5yKZI26aIhV3ocAocMM5JI/T8KkpJJp9UWJZjCiGTauyRDub0zjPf1wazNUuEubJ4oJdsqGM/KPm378gA+xAOPQGrU53WREpK+YMEqMkcgjA/CsOLyzf3XlLtzhsk42kjGceu3d+dDeqKpwTTl1RYRkksoFA8yITRq5bqAHwCSO5NOvrxbO6uEnYRL5MU3mZPOJCMD17cdevtVFr0WkjxxgyBjvi2qTk552jue/tz6VgeILq/e+ijnkNsbLbcTyBhu8pnXqRwQMBio5+Ue9WtEa+y5n5FjV9yTLJIPL2uI2fbkhsZG459eo9zmrOoTx30SvEdxcmLhsgBj8p/76CY9az9Wv473TGi5gk2Iv2cKQRhiWJPfIOR67hVKykEYXT1KxRyxsLOUjG1lGdh9wcEH0PtWe2hqotrmfQ1jqCwlfIjEY2yT4bnLcCRPwIJzWjFIPKjxHwFA5c56e1YOt3EUrafexgiOSF/MToAGCgOo7kcH8Kl0+Z3s48FztBTKHAODjP6Va0dzJw5kjetGS5kE0LN5bL8ynjnHGR64zms/U98BSdTvQSD/AAqlp93CoeKNmSIFgC7ZJB+YduwP6fWrepNI9ljKeZFIBlT04yD9a1lqiKacJWfUv6XPvkdbkrgtsQ5yfUDHvnIp6p5008jRkRoRGxzyDnmsnRpW3yiSNWcs0TEH+7yMe+CcfStdJ9scsWN2xwWKtnJPH9M/jSjqkKouWTsOCLAsiZBDxkqe/wAvI4+hP5VDpiXAWWRlA8vZHkjOcnP6Z6e1M1GKdXRZMOySjG1uAmOVzjsMg1bWMW8ETAAGZGd0X+EEkj+f6VXUnmtHvcb80r+YYyDOxCr/AHxjjH/oWfQVnPFDPfW8G8MuFL7mzk8ggH0xzg1rFQ+mtKrfNB8rZGABwBj3zkfnWfCZ1upGj8oQvJ0LEB1UA4GBnn+eKdtRwqbtFxLUQWgnk3HzZFkhy4U7d3Ge/I6fjWfs86+aRflJl2sqLgZ43AAdeAfyrRMayfZYGZIQxJ2gn7yoMKDjr0JH0qkhItxPclFbyXcgED5jnHA468Y7/StEVTqPV9X/AF+hk+ILYw2sQEcmZGc7iDxxu2k+vI/LPNc1AF+1OG5IOA3Xiuv8SKkVq0E4VbyLzN5T5VboR+ee/TjHpXHANATHujcrgZU525z8p7Z602z1MJK8NTptIiVpIt0hjQnDbep9vaup8a3Esl1ZyWhSMxxyOOAw3IVZc+vJ6fzrhbKRpJVgDryeNrHkgn2rrrqFbuKWW4jO4IYl2NuG/wDvcjocE8YIp1lencxqR5cRCcvP8TG1jX9Rk0+ey1KGNw8omhlWMIyEtluR2IJx355zTvCl+1vZSpcMgjVtyF/1H5Gtq601LyGzXYrYO0k5ORgn+YrP1fQhaQjYwdGRWYA8KM9OnWuFcy96Jr9Zw84ewas2yxa+L7FHWOOMhST8xwK7DQrgalIk7Aqm3K4zyT/gP515ta+GVglZ2+WNiONxJcjkdq9V8LwpDpG90jRATjB4VBwP5VtTTl7zOLNIYalH9xe7OT8a3kra0tvGuyQ4AI64OR+WOtcuZg88Oz5PmBAHJGau+Krlbm/WePalsg/dheNgPU/n1rJF04mjKeWfKcFeo3YP8q0lo9T1MHT5aEUl0OzkiVI7Se1aYC4i8iVHO1ldVAHv6H8KcGuE2uXOJN7FgON4QYwO/p+NVo5t8++6eFjuW5CjJY7shlz24/h7mrEdzDDAAqNGEf8AdLIclQ+CrEjj269hSkcD5rW3/r9NDUsJWmmExkTeCLhomOAAS2eOmeBzWvbquYZFMewxlwWcnbnh8H8vyNcQbiTS2s7tJW2zIQuCCVxwcjsM/wBau22vPDbvHLsMnm7g6jjIHJ/X86RhWwk5e9Db+kyj4wmD6y4EaxSKCH4+c44Bc5xyAMY7GuUu5GLqMAHHU11/iFvt9vFJviRlbciLEA2G7E+nf6k9OlcTfSjzMK3zL69qmx6+B+BLsXbCLzZZ0O3dtXY4GCMkfmKna2fT5c26pHazqZ0RWPDqB8y989OnTk9qi0O+az1SC5JjG0BXaQcRqeC3B7CuqudNEsd1pkEr+VBMZ4pSMiBQCeWHYqTjHXNJ6tNDrVnTnZ7P+vw0/rehffZ4Zra4tHb7FKRi3Od8RGGwx/iBLH5j0GM1Z0uc2N/c6jqkTBGi+0RKCQ7huVHB+6MEE8isqa+i8q9KCQXBRowjucFHI8zBzlgGDHB55U+tYuo6jPeXZ+0SRsEUxxmIfIF3E8DA9e4z61Tkk7mdPDupHkfz79/+HZra9rU+q6izTDaCMKmMbV54Htz+dbXhK9n+y2gmmU7H228T42hj1OeMYXsc/rXDRM+Q7OzHkjn24HNdToEtyrRRwTG3WNWuvPkTEaMi4b5j1B+Ueo5z7w5dTTF0IRoqEUrI7G5fzLNJGWVjNL5SnoW4O4575IJwfT2qLS7rz0bCqTcAHb2IBPX9TVWa4DSTCSIeWAdiMwKDgFmyOMbiTkcVB5aRxvHaSS+WQAGByrpkHIycg5GM98VT3PHVNcln/X9aGoxeK6O19xctCItxJVdpG4fiMfTmsPRSUaaxTh44s/LxjcxIP5lqu2UrxCGdY8vDEc5Odu4E5I9dufzFZdtchtcl3/I4tiiHIIO1sgdOcbqzk9ioQdpLt+hrSXqw21uJApMUzIwI/hZSQfzIp8c4tbGOCaQGecbdpGOG65+jGsm+aOC4uY7kBt8ccgUn7wUlW+nUH86gn1NbnVmkiK/Z7QAKRzlcHcQT15z+QrO9tQ9jzqyWm/8AX3ljTUkt9QvwxjMciqVYE4LRjJyf7rKB+K10Fu6vLLIowqbSGHTnpjHT0/Cuf0/H9jRhMrPCjEo7ZJ+Yn8cjGKtW8rqkRgZvJcI3XAAxwD6jpTTskZ1IObZdWZlCnHKZUdupzjNV8ieKVpBmSPPO0EYPX3/Go0uB9nkDhyxcsWAzgjpiq/m7VcZBjLAggde2c/Sl6jUN7bl61mM1ukR3MhAbEjZPPQhvYc8/nVOJGaW/lBVleQABlAYBVAJPoTj8jTLV1W2L7iuGYoyn/lnnj8x2qhBP+/u2yUmU4J5wRtHB9u3qKrokxqGrcSh4iuRBFBKYpneFgihXG2NznH/AcEg+tZNrFm5+0X91aMIwqR4mLgS7mLFvX72eOPmH1qbUTLcagYmjI2oWS3QjaBgHPXqSRz6D8K593vrXWL6W+imM/kKieapAIxt4J6kbR79qajpsdcWlG1y/Jcl9ZsWDeXZ3cwgH8XlhGyCSe2c8HtgdhXUSRLG9zajiFI/Mg2/xDkMPzI/MVy6oswtbWNNokcR7nXIVx90+3Az65rdjma4trGUYD20hglVuCQRtcH1IO0/hRG5z1tGuxkSiR9Ju0HlmK2DQxoTkqshDrjvgcisfStfubDT4beEsIwN6hU3ABjuxnP8AtVo3aRRX+oQxKwW7eFgFOSDvKsT7YAqlaXDQw7OcbmYfus4BYkDP401a+pT1WhvQF0WSFmIa3IePGM9eMH0zWhqCSW7NcGQNFJEDIOAoPOfptOf84rK0eSIX11DIysZYd0agZJO85/LNaeryLb6VMY3UZEmFJ4BGGAx6nJ+taaNNmTvzKI0eYZZ434ivEyCD8qSAZQj1J6fjV3Tb2LyLaTG6UbH2nOCP7vt249jiscMkWhPbyt+8iOUYj5j0x07rn+XrVPStR+2SmVThkjJZVByzDACjnqADgn196nZ2KcHNP+v6ud7qOWugQWjQF0Vk56DqD1x/iaYTIuk3ckrIrfLt+U5O0jbjI+6QQ3vms6W7NxpFlB5i4SR0dvRTt5HfvWnrd/Fd+csOEjFqHUv8rMUbAwO/BU49q07nHyyXLG3X8n+omsW4itbK327JLsh2IOB8oYnnuOhqleTzzAz26uGSNpmGBtCquST3zlhRr980w0hpCrGLd8o6YK44/n+PtVDUjJJaSuXLu0qoGLZOCCfy2gKfoKp9TSjBtR5v61/4YvG6WS6dEaR4Yo3kXaCuU25zz0OP5CpoXtyIMxoz+WF3jLKAqLhcdiM9eozxmliMCGBmTzU8p4UA4GMDbuHrWQJmXT4XbdsETiTJAy4bjpycDH51ew4rm2/rci1BhLk7R5LGbBIOUJAHXqB8ucH61yFxOyOW+UcgYA4yBgfpmuovmxaMJZFSR8yuyNvDrg4IC8bhnnOOMe9cbq0nmbpIkKqWPGc+uMflSbPUwq6dCzptzOJA4VmIIIYnpj3r1LQbgTW0IhL/AGhirRKQFCuCe3cZx07V5HbXSWqsCu8NGVKt0Oa6631a3t2sRPcmWa6dD5g4ABYbic89gM9M8VcGrWZWPpOqlyo9FWa2XeojaCNZBhZCN8bHqF7lfesnxDqktjMiEvLDNymBnA+uPfNULbWIjceW2+SNs7WAyGXOCQGOcdD37jjFWkME0SNBcExHlwy8DJwCo9Kh4f8AlZ5EIqnLmqIu6Sgux5sgK2sS7U5+YjoSM9edtZvijWt1nLDFKGB+UQq5XGSTyOnYY+h9c1TuNYS3tljtY8RoOFBACt3J9c+1crrmpNfW8cR8tYY3Zg4XDuWOfmbqcdvatZRUY2R3YPDSqVvaTWl/uLyXc7qi3K5UKTz0IOcfzqsqYlLyfeYBWbtgHgn86y7a5lS3cM+5cZ4PHoDVu2uWaEsj7unPeudu7PccOW9jr9PSHazuzCRWVdx54x0HuM9B605rgWwCtuZyTjDY4YYI/wA+9UNOniQQ72XjoBk85qW7LmNHmV4nAOcDaWXJz/WiR5zXvWZSup3Csiv8gJPPbPpUcU2yIMcl0+7357Uy+PmOxZUIYZ3A4P5U22Rsgoccgb+wPWoSdzuUo8up0FjqccohE2VVV2PJ1O3vweOMnn1rnvEdqyzF7UqEDblAwcKenseeOO+auzaZcqkm4+WkeAWZsAZ9fT/69QtDcxXps2jQSg+VscfKWbICj88g1dujOeHJGfPTZmw8MZH6nqO49KsW2ty2lyCJJAjK0bBWPKnqMf561CbSZwU4MigZGMn/ACMVFNZOsXJALAMoBznnv6Hiod0dSdOekyHUJW2iSEtkfMMHGfw9ff2qRdkEoZm+SReCe5Ht7j+VDxEFUbhc4UjC88c8/jVQWZ2mKSXfESfLLZyg/wDretS7svmTVjUgVpYOzbAWIzwOMn/69X9Ikhn1K1iumEaRrLszz5jlSVJzxkHAB+lYdjf7ligljQTxttYqT84zncR7jA9se9X5bhorZikSMN6fMRkr8w5z16dcdqNLGM1KSce52+l3Vq9mu0DOPLP8QAYcts44wCeMkcVLtSKO9ttMga5i2Hy5I8KxyuPvHBBBHA6fzrkrbUWtmUsS8fleUcJ14BXG0A5zg8+g+lb2lnOpgFZYCwcSksCPlwzAqPmVhxgEfXNVdM8mtScLv5/11LFrOI7aRrkmJGXGw5zwO/qQe/JrGu/Jg1GFjuUKjIZFBJwxG4j34GK29ZvLLzonht5PM7szYJ57qeh61g38TSFtvyHy/wB4Cc9SCcfh/Kspq2xeHkn70la4++na51LTZoj5iyRzIZf4j0YZzz2NQaPag6lqVrJukheQooBxsJUsB9Opx3waJCqXFpIAojtZVjBUffDD5iT+I/WryRL9ukljLrM6orE4wWUkqfUEcDHcZqeW+opz5I2jt/wS1b2zW88hjkPJBwclSR/nrV3Tp4YbVIZNysgIIJ6LklenbHGenFQrOkkKOFKuxJOex6FSO2MGmOFdhcb0E33SGBCsn8QJHf09DTUbPQ5JT5l7xbScfNtABzkH2/ziqdw0bPHbpuO8Fnxzkeg9M9/b61Qa7kW4nCg4YAhfxI5/KmxS+U8YX7gLKcnpkEkk9ewqdyuW2qNYfLb7ncO4X7xU4/IflisebAMiA8tI0ilRyMjO39PwzVpJxJbwMCo3khskgex+tVEJaGRwoAZyEKtkhRxj8ev5VVuYIy5b3Oce+iSb7bBM8F5abVK7A4YOSX4HUYI655IxVSza4vI5UuhLtWVnWN5yfJXcQY9p6EYHT19Ks+IoViurl7bZCQFuZo0YjcfQ+4C5+u2stroxusqJIjs21wTlpA3DHP8AeyNw/EVcVy6F8yl76/r+rm3LiO1DwgLtkFwhU/KGzuZfptP6+1XNN1C2ubq+jgAO7ZeYOeC42sM+xRT9WrHnDNaESu20MGjCEAqM9D7sP0rM0+5FlqzRou7JEYmH3WD5AGPrj8qWvQUopq73RrAPLrimNG+QEMR2BcN/IfrSwWrvCrROuxuRniqOm3Uh1J52X5HYh1znAUgcfnnPtV3TpXNjCd5X5elCipITk4y0Ln2GMajCwAEYcxqx6ZIDAfXjp35ra1oKNGkidiYXdQ8jn5o8rgr0+ZRwcjp3rOl/eaMYwMSKdwH9454Ix3HXNQXl7KrpaXgWddu4OnG7jn5T37nnp+Va6JW7mLUpyT7FXX2ZTD5UikEJKpBxjgZX8QPzxVjSPLOpQOz/ALqbO9gmCMMMZ9OcHjvWDM0gubZIm8y1H3FGAYm6Y56g++MVdgaaO7MwOx4U2uAnRh2Kn1qLq92dLg+XlTOo0vD3NxFGrOQ2B34J/n0qxJN5l3ZwsmWijZGwM4UA7iffIFYVjqbQSDzd0cYUcg5CEnqD/dJ4GehOK0Vunt2uBFt2yIVZlPOCc9eo5PSqTSOeUW5MkurnzLLT7d1XdGNvmr3yc5/IiluJd1vbspATliq9sDrVW8lSREaL5jEoc54PHGfbjH1xVcXDFMLk7V2kZ7GqbsXGN0mjVjupGtAtwAsSqGDZ28jkgfmMiskzKtqxhwjAbnDdM8jGPof1pJLsMyAEFMZ+YZB79O/pWfPIY7aOPORPhjuwxBBIGD247VSZpThYWa9jmEjGYNI43Z7PjIBPvxgisG/IcFwRtc5GGzx3/Wp73cULRgDB3scdMcfke/0z2rKlukaFlUDdnBUHlP8A63vTR2wXLqhdyPdwlslAwLLnqBWnHrBh1VZ9qSRlHTbMoZQTgg46Z478Vz0cjITuOdikknvSyXCTWrYUhgN4IPU+h/CmpWNrKej9DoH19LdpXtTgsrFNo2hC3UDB+XGfpxWnpmuyrpEEIb5VJbGOvPX8815znex3EADjPr6VaF88CIFclcbSD25/WqjUadyp0Kco8p1o1U7pEyu4k96oG4Lb493ysc49Kw/tIZlVEKrjJyep9auwS8sw+Yt3rKUmzohyw2NNpk8tQMYI+gzWnpzbkCoOF69vwrAd9zIBjkgYPWtyxVYJomTkjJ3Y6jnmku7KnL3To4sCMYVS46Z7DBJyKc8vmQr5YPI+ZmyNxyaqGRyGkK8Kfw9qrT3W5EzJ0GCuc/UimzlUblyc7n2rjGMMDyKtLIYtNgKyHy3LEooOOCBnPTPP4d6wRfOsmW2nYCQrDOTmtuK/CyTSiPCMGUIegJxnAq4pEVVJWVrmlPNJf2xAJdsLjaucgDGCPTHc1Lbs8kAZGlilMJwzcg+WCy7cjJ4LdOD+GKx7e6yEO5fmOxlxwNwrX0m5tyZjPgQDG1SctuVOMHt8xP51drnLUThF6aFqa2uhqVy9skUko/0gQEhomQgkx9sgDJwD6VhiOVkMcdu08cvzxlQTx6p3PHHfpXon2OadoooQHu7RdyFh8jK5aN0PqAOc/SsuDQrSRNQV454LmJBGix53xP8AwlWBOAwblcHgnnis2rHJSxsUve8v6/rzR57c/OEhVdkhOSX4YA9OSeBUMkYilEbuhK/xo4ZCMkbge4rodcjjtRJZyXwubW3nLLB5mCxzhlLgZyoCg5H071ysK7ZTO0SsI3DFWbjaeOcc88Vm0ezRnzxv0Irm2S1uLK9nnjKys8Xlqx8yPuvmegY8DnkHtkV0VkYplCTJtR4mjYrk7iQR6jGARxnsK50ujxyK8YMfZW7c5GPXFaemzRAKbkv5bE7thwSPqevOBUlVU2tS7GFNpCs/LKh+YNwWHT64x/MVWsHtlu5nfiUJxIOXCdOh4yMVHbzuybQobaQ4PHAx0BPOOefpVe5V1mErLMkgc7VVflZG4YdenQ4HNK/UyaVnFs6ACNrJJEnbzFfYYD1Ixywyen+NT3jotvLIwwkYLEk8lfrWFpc6pd+UzhjKokEJU7hjg5B9ePwo1WUyW7RiRcLGS4HIOT/k/lUvY5ZJ81rluwcy2X2aUFZHzISeDljlvyOBVuzu3aNFyBMSTI3cMODj8f51QguQHi3LvZQRuPUqwwH/ADxx61NG227MwBwyAMMdMADJ9OOtFuxjJ3ujQS5eG7aQkfZ5wN3I+RxxkD3AA+o96uR3kioHgwXjzgmMHaex+ozWF9uUSyLlWcMCSDnr0/z7Gp0kP2dni3AAFmzkhj2HtVR30OecE1qhksxW4WV2y8gKuzf3s5BP60CXzIWcMV8xguCeT6j9DxWTBeC8jaTqMbNhHQHqfqcflTxI6h4gWIkGHYDJ4PXb6/kalK5s01obzSt820YZclkBGRziqsMxdYstMJ3ZmKgAIB6A+veoLy5RbbE/yXDgE7X3JMOzAj04BBwc1Tgum+zyJIvllwVhRjjLjkAk96u1nYxTvG5BqN0pNzdM433DM+WUsGULswfQ8H2/OuVvEktk8xH3NAy+dEDkngdD67QD+VdHBdi3mikMYf8Ad+ThZNpwcjrgjqufeudiiliurmRWLKDyzKF29gW9B259qHG6LhJRdnsbkVwq2h+4TGUfcrZCbhkZ9sflyKyr+5KXEKsQryny1ZRjaNwxuI7gjOeaju2EKIUzFEAWcYzgfxDHcdxVd4UnmldflAAVChyBxyPrjmhp9Bwa2ZZFy1tZxXsu7y3b94Qe6kEtj6Z+oNXY53hjRIhGyYBU7scHn+tZU16qRwxciKOMfKpwdwIXr6nn8qhuL+3spmtpJwrRfKBgHjHH6YocUluZqTctUd5K6RSL5mWGRvj+6MDkn6ZwMVTmWOWZpN4CRhXIJJ5B7ZPaq+oO0sz3Ku0Q3FVGc7h15P6j60z7QVmQMhI2AlcYyB0+tPqNLS5JfSLHLas6BicEgDqOoz9f0pLZVgnfcWcORGDjJHXCk/U4zWTcNPcXoiikEbOWbeDxgDOSD6/rT47ie3MQuclmIJbJ+ucVLZtGN1ZG5MDJGzBCCDtZc4PPB/8A1U+C7GNtww34AXJO047euaqQ3aMWUk/NgE9MH19zUqbJoWymJFyPn6sKES9NGWIrgjzVYlxyTnqTUokxbsMDep45rIt8QyPGoYAgttPYe1WJZ5PsyuCAmMHI71SCyvoXWCTQBlYrIAeGH8jWVNc7W8oJmM4LEjpg9fpVlbryo43l2K4x8p/w7/Sql0gkuS+woS2dnb8vSm12NKfZ7Db2L9w7ZbkkAkYye+PeuentUTEm0hgfl2np9R6V1Nw7SwDK9Plx6+9c9r7FEYxqQFPc/p+NVdbm9OTfumXcAtG7Ej147mqHmqSRzjgkVa81SFV1bb9fasgcTzMMrk42j+dDN4dUOnm2um2QZ5HXoKnAEo4IcEZAHWqCW8E7bgJOOSSOB61dS3jjcOBg/d+oNBUmltuXoFZSGyq44weRircaqJSWxvHXJwQPpUduiLuIJLYPHp65qzEV+X5ScjnaKqxnGbuXLaMud33RnjPOa3bZkiQONpP8WOAKxrbhN6naMkjPP0zViK4YBkICgnI5796mxq5tmmLuUJJGFVYOC46hvQCsy4uD5kmeATkgcDOKlmk4+QMUCgsOn51k6lcZ/ebQMMFPOeOhFDRrRkm9DZ08+dcIDnJBPHIrai/eMHU7V3BeG/r+dctbzbLbdDJ8y/N06Z/+tW5a3KiEKThigbr1wen1xk1cTOre9zTtnto5mkkcSQz4UoRlk6kf8C46/X1ql/bcmm6pAF2zRpKjzIO/Q7MnoSAeaq3s8Rt5N2Tz5q8e+Dn/AArj4dRT+2Fed5I4VIyQcHrgkZ4/ChyaNcPQVW7lqj33/hMLMWyvNKRqMIMaFWyrBwGVCOvQ43AcFfwqPUfE0NzDsOY7mIr8/CSl+7YGAMfMATnvkV5f9vtp1LQS/aobZsyLs2sEHAYhc9Ocnt171R1HWY2m815kZ8BMqcs3ByWpXS1ZyQymnJ+6nc6u9vo3URiTPyAL8uN23pz+J/OsZbzbPJGVAZ1IZTwcev5jnHNUtNvJGZY7dWeROigZb8PTrU2tFmlWZVMUkeSdvOcjlQfxB/Co3OuVJUnysmuLtkCxEFChIO4cipftCRWMr/NHcRgFjMScuMjAx06jj2rFSYvAC5DHA5z146/59KdDNIN6qVZEOVJ6v7+mBSa0E0rWOnju/NjQqmPlwMDH44oubpJECXDjaAEKsvysD3NVbB5JY97FsMeCRnd26+n+e1QTKpLDftjHJyuT9KlqxyStdlPWpylzbPuLFHOyTeQyHoysem3jjNPfVIRd7i+WbCNnoTkfnWdqceLk28BzEcbt+QM4OMjryAf++R61hmY20g+0ExRlgI5d33CexP8AI/gfWspXM9Dv5ZRNapANyYU4lTIK8YGPwP41Np96s8bW8oPmIcSjPr3B9Djg/wBa559QMeIvnmVjhXzh04/Ufrn1qxDdZeOdm3mRCu9QMOBjCn3zWq3OZ7aGmbv7IUuA2TGGygPXPY+g96syXB/s8tcKkaldygHgKfSubvZsbsKDuOT/APW96tXMsskMW9liDYbCuGBK9Bjt0xj2prsKoldMtC7jhtibhJIlxsPkrkgnheM84Yj8M1q2bvbRTebG7IFMCE8lGAGCc/rjnFcxGJLksZBkkEyLxgj1+mAePwrQsPMS2nBdjNKuVzklMEfnkY69hiqjqZVPUv8AlxvFmSURI0mRJuCxrxyWzyewqhq9wscjJdQyBMKrYfIGeRjOeO456VHfsT5SFHEO3KSFw28nGSPYYxisnU7xYIW3CSRAM4GAXA+vXn/JpyVkZxk27lqctPYsTLHDkoDNI37sJvC7jj33dMkc1FLG9ppUdzNsEU8jxAoxcNtxuY8Y7jj6HoaoXNxbvoc8kMkfn2+zcoJG5Mguqg9TnBCnFVjcRXMVxFZPcM5lKAsoVGXj5hjkMOQT6HFOy36kczbt0uWoiPsrSxHf8hOE9uR7H8KiDGEpC00axNjEiKVUL1HUD3xkeo9KjhkltDHbrgwR5KqRwxJ5OabqF7G2JJkLI+YljI+99APelbQ0U3fYq6nOjyXUEZ3PzKOPukcrn2zknFTC5tZQGuVQzYAfzM7gRxg4446VirIwjmmVjLdzsR8x+8P+WePbANXLWzgmt43vDE1wVActKwJI47D2qE9bBNrdncXd0RCcIrKHAXa20nAAJwR7VVE3mSgBZU+VtzHB6DpnNaT28L+UAvI+bIXpj1qCYRlEQK77QQNuCFHPGabWtylNWsiOFI7mZ5AVwEOO34fpTLySHOCXdgvQc8+vt24pLBIzG7FwWDDp/hT77cqBI8ZJJCnAJyKnoXGVpWKltK9vL5JKyyN83yvlcdc57VfeZLhVeSMl+hBOVH0Hf8apXIMc4y0QEjbQFXABAx6596fNKY0zNujx85YHMbe/t75FFrFynzWbHSBFnDRxqpk6FQOR2HFWxcN9iIQHzGBUAHH+fpVK5l/0dXQqzdQw74p9rKjqAx2hm6A4ovYa2TJBO0jM2GU4OQqkjP8AOpoJl5AOVxj3Xj9KdmNGKqQwYnocZ/Gqtw0EyMN2HU7lwcMP8/lTuVzJl83TrFHJGSJAwIbPINZ2sp9picMgAUE8cZNRxXjAeSy7ZQNyuv8AEMjoOefUUy6uBOgTOBkgkdf/AK1NPQnaV0YTRNJHvIBfOSM1nzW5dsFWYbuSPStvywLaSJVdQCRwO3sfpiq8yRCNmAY/gf8APWqSNY1WY8cS4MQUGPBHJ6cdv0qSCNhOpkJ2Jj5T3NWRHIjLuGQTnaOuKsPAWAIBB6/X2PpTt3NVVuK9wIGdRF5mQeD6+tTWxkCDeAXUnPqDTYoUIbOEwOzcVIhXZgHCrgBs8mkylNLQuQKoHytjI6+nHI/nSzSvbhSrFZASh7goRzz75qGMkMqhUOem7tS3bAR4bcXDKAex9aSJlV1sKl0VUMzjoV44yMfrVO5uchVVgsRcAhlz6jio7gqN4Em4k8KQcrjvWbcXCyOImOQzZAB79KclpYunPW5q2d0RPCW4EgCt7EACrtzqIjbamFCjJ9TzXPzXTRojs6u8bdQeCO5zjkU3W2RTb3pDPbqoZ1RtobHT8ScChOyOtNSabOgtb5HBMjb8k/KufTPX61hyabc3l1NLbNGyr8wDDPArJg1dZZbhVjEUPzOiqSSg6hc9/rW54Q1MRatFGW3JOrLyOpx0qZPmjc6oynSTcNzM0u7u7TVHtrnzII7hWgkRAVDKw5zj8DUFxcSWeoTRS8tExQ5xkiu78R6FdzW1vqNtDuiRfl4/iB7f/XrgPFC3KX0d3MiCOdF2smeSBgg/7QxyK5ueUUbYTFxqSu9+vqjX0jWGE7AyKu8FQT3B68flXRRXazsnnENtPIDEAn3x/SvMFuMEHkgHPBwa6Ky1WIxuF3kswDBTyB6//Xq6c7hjYxkuaJ0NpIYZZAQoB59cev51at5DOFMC/wCrClmHXHr/ACrG02VnmkW4fKqwXzD/ABDjr7itVSiz/IjCP+Hvj2zW1mzynVR0NjdJjLMqLngLnAp1zOpikjyodh95eorLhcDaZSFUHGevHsKS4vSzsCcBT1x1Hrik0cU5JyKt1CIgVkwirySOSffPcnFV54rZrhQMkKhJJ/lT7+8DtEkYOWbAA5OfaqTzK8yruKsN3JyOf8eaTWuhm5uxZLL/AALkZ+XnFI0uyeGSPzFxuDDPByP0Pf8ASq6yMxJc7gvy49f61DcKSVKZVm4UMRj2Ipu+6MXJPRm0s6PJCHBYHLY7n0/nUNy7MsyAM/XcxPRcZJx35qtBOjT3KTSQpMiL5YXcS/IBxyR6nr+XFQ307MwjO8kKX4OM+36c+tWkZOqnoW/OnMlupDhmbrsB8yM5G4Dvzity4uLpYEUxgqP9ZGMMeOhbuD+nT0rjJJ3vLh4o5Gt7pCAJImBZAOcgdjxgjoRnpVu/8Q20+d3mJeouZImI2q3ZkIOduACM+4OKuKSTZhOcnJJK50HnB9PU3VwnysBEX5cL2YAdhkjFZN5P56vG7ho1OCzLk8c9OoGR1qGHW5VSA5BiaP5o4QVKIRjc57j1Hoe1VbjUQboi4YpGAfmAyG4wACOgpyS6ERlJXuV9TlaaObzGMc00ZxJkHoPyI46GorG6aJZJ4nJ0/wAx22MMEdCcd9vIz6daqX8sv2edUMs28EFRGV29COvXjBz71T0e/wDMtYZAUwSisZOCCBjp+Bx/9as3bmNE24nWaxrV1eI8l3JDDCQHSJFPlouAPkznaOM4HU9qyZp4oogokbzSmxA4x5QIOc+p6fnj1rLmmjuLkXCNBFiQCJHbA3HPzFegHHXtUAjZrNJrwMHkbndwMH/Iocm3cqEUlbYvkP8AZLR4oz5yKJEXjPQEr+P8wK1TIr4aIAxkAqR3FczbXapcYfdGEXchzw57kD+naoZNSu0dgJJAM5AUcDPOKi6QSTPZLm8U+aIpNpkTa2P4RjLfTP8AU1XRS1nFIvBIwyqMZ7CqcsqTOkcTFi2c7QcDv19PapvtCW8KrI+9SSQFBO7Jxx6c56/hRK7dyotLQspGsKqDhY3QF2IxtOOeKp3F2kl3GWVlhWTlDkbh/SrDyC75QNvjG9UjGVAHUnPUis64Ym6QRAZz29MUSWlxxd3qaEz5j+Vs4O8Mw6E8fqKqmWWFkZbcTopzsbIOfY+n+FTRN5p2LkjByDwfb+fSmAu4dXDggbAcjjPt1NVYcZ9yhh1gbGYpCD05RvqP60WMziUpIcPtyFB4x6g96dAys7o7BSTj/wCvU8KESEKh3n7vGDj2qbGrna46W4eNghbC45GDx+NQrcNOnyKjqBjG3p/hTp5PODCRDnjBAzRZoLbeI5B1xjp+lNWY1Oy13Kd7I8ZWNV2uCDGT2bHHT64/GpRGTGZlD7JORu65zzmjyV3u8gBYnP4f5xU20xZjZyIiA/sDjk4/I/XNOKRUptJWIsEkGRmG5QMZ7g4xSCIr8qkKOeQOo7iooblZozswJExkYzx160W8zSyFVztHPy980+ZECyQhGwGBVjvB9+hFTRptkCqBjGCfrUV4qCAlSxkGOOmPXP6U+JjthbzBng4AyMGhu5UXoRmJY5GDHIUnLeopXYRqkiDjjOOuKmn+V1JfBLfICB/nvVRRi0CLyigjjqT65qbFKZd/1irIwUHGevTvWbqt5t6yDlwQPX2pZSwVCODwcsece1UL5o2dUxuYNuHHHWqBPXUvG8mimXa0biPAIkTcCAd2PpmsHU5JI5nkWJwmDJI+7p6H8/ate5tzFBas7RRmQFvLdiCPTP1/SsG/VUvhI8KvbS4Ij3nbjByM/nWliIVFe6GzNOksSyKIZjtRkmYoBkA87ug5zk9q0E0lJIr23vL+1SQKgG196jaDjG37xPT5cjnNc3cXMAg+zSKEaORv3kkjEkNyFI/2efrmqenarNY6ta6j5MV2bZhshu0MkZA6KR6fTFZyaWm51KrPl912sSzRSWd08cy4dDtIz1rrNEKRy2kkKiNgGO1upGMnnvgCsbVfGN3r2om716CC6UKyRwxIIRCmPlRCAcKvYHP1yc0ywvUR4WglJPKtE5zjIxjdx1/+tSpxWqR1xxUnH3lZ/ej2/wAO+L47rTRaSWvmRxK+fLBcxgZJLgDpjJz6A56Vw3jHU7BpL0WCGawyom3AbHJH3lJ6P1xjk4Ncnbaq1kyBWVCSr78kGNuhz/s9KW7tZL+5ggF5p6Y+873SJCBnqWJweSff2oqRk0kuhFKlQpVHVva/9XMi9hWCcCJ1eF13o2RyuccjseOhqW1kjg8xwzCVejL0Pp9af4na7tBbafc30N3FbxK0TQzLMibuoVlzx7Z7Cs2SOQQQu7xv5ilwqyDcmDjDeh7464rGMVFuyN5YpTjZvc6vRL1vtCLOHDnqRjBYnOQf6da6WS8lLCR8YU9xjr3x615xIJrYYLBnB3SRMc5A9a2vtVxcWxjRHhWQfKftBOPwINbRlbQ4qnvO6Oqmuz5sbwBQvWQt/CPb361Y1Ke3aSFYGhkIi3O0Ewk+btuIOBx261zi3gjAZi2PLAcAdv73vj+VRT3QiBZyRnGNpAyD1Ofy4ptnHKTurGm84W5jwWVwwVcNgd+h+lVb+TMjShpHYBjnkk9M8965q9kaS6Vgk8pOSiRyYZGPRlwOoPp1ptlrswMv2jbOrDMpI6DoGB69TyPWo3M5c0Xc6azu2eCJEAYEFiwXnOaNRneC4jAkiVQm+Rd/VMDHXofas/8AtSG3iMBlkid9qtLGRlGznAHdSOPY+vanfXE95cT21vPvhKGMsFVyxHPUDuffIxWijpY53UvLsjorZrY2qSJIyyySc7VyYxjrj3GfbtUKahbSxeZM4gt3ciN5csTg/wB1eSe349q56C+80xmRIlEYCOmWG9sfNk/wgDnj0PrUTNZvFxeyGVMF2RMqoDD5Qe+e2PUVUV2M29Xds6i+vLEXIeK2eNpAqA7NxVjgEqByMkcA5Irn9TuTeXOx4hHIshXy4sAgdGAJzzx3yM/WhFF6nlk7toDzZQjZ2AJHrWfPeSWtyskarIsXyBT8yheuCPf+lOV7ajhyxem5tLq9zcbjDcGBkQOHIPKL8p45PJ4KnpUMV9FDa7W2vEMxqjOW2d/lGPujrzWBJrT/AGtprS4MYU72b7pc4xhgeD1PGKkl1BJp/Nljt4I5SFRFJG1ccHJ6/wD66V/Mz5ltbQnvr3BntleWRpXDjLblAwQQCPYD2rNt78zStIhWKU8IgGVUHrz/AJxVJryLz7jnzPMAXdyCe5x6A/Sls1XyJJppRhDtKIwzgdDg9veofvB7RR2OmhjjKK5kWMwwjAbgvyeV9R71JqF8kkYSeby0I3bDgGT0Oa52GcuwkuXJfAAUY+TJ4/CnTakspMjEsgKgqGwrY6KPbvRpayRXtdbtmrqUsEsS4lDMTmOKGM7UI93OSP8A6+KZDqN1bxLEpYBfRQf1xWC1wyEyxkrLLy3QD/61NW/lVQPlGBjgA0tjKVVdT2x5D9rRzKyJGMEEn5ixwRx2wDV29v5Z7Y29qiHJ6YIUDv7E9Kx8SXFwFZVJQksV7joBita1VWhjjby4x0yxzt568UkmdiklruybQLk6aLhLlVk8wLnaeQeeORjHI4qOaWKS+/0ZJNoXDE4PXvjj8KkUiNnIRidzYfA54wcDtxTYZlt4V3rG3nMxXzc/ul6ZYjr+NVfS3YLNyclux9sgvLlWEg8wghAQR9OT79TRchxdYkJ85sKw3dDjjGeKsJqLJJb5laSF/kLhFVCgwFAZew64zxxUWqXjO01tZW8TLERuk7yAc8HdyB19+tPlVtxc0uZaGZKgFxk84Jy3qf8ACpZZHNyVk4dQMEDke1VC7yKcygkfMCMfn9farEjRRwFiWGf9k/N+NZG99SQTCOVGVSDnhh6/55qBmBYhmByfm560xJDKdwcOM5UD+ZrPvsxzYRC27heuAfei9lcaNdpQiKHI5+UZqcMJEYuzdCAxXgAcViybjaLvK7txYY5wR61Mro8Q/eZDDnb0H/16d3fUrRrcitbeMXbywrsIbhVJwT0zVxHdZTv4Gc7UAHPas6C5EGpFCMI4yue/+eKvXUhWdHUKV+6T3yelCREnqF3MERxk5PykA9qWInYrheVx05zVDUn82cOF28cheh9AKlWbzHZIyVwcgkAEj/DrTsHPYvXNwLhWbONvTaO9ZtvMwmZZGyc9MYz7inwOQSpIkAHHPFZtz8l/vdmAdeBjuKVxprY0kYhRvXcBgYJ6+2e1ZGryMiGSJMiN1dVDnnBztyOe2M1bMqswCSLuI55zz6cVEzIX2b1+bg5PSqfYSn1KjXQmuUuoVaAs2dpfdt5zil1aSRuMs0LFmREI+U9+nTvVG2YSxTxhpBHGSHwoPfnr+eKq+bsuIHSaQJgkmM7ScD+fP61UZWWpTgr6dDH1GQPAGlR/tO4KXGNpAz1HXPT8M1Uv7a6026aG8haCVWKkN0yOuD0P4VrXdpK98oQbjdHKovOWHbH09fesSdZRbLHI7SCM/Im4sqZ64X3PX6UnHuYzqtPQZ9scLs52E7se+MZoF5uIG8qvfHaqCuwOGVSc4BY4wf8APrUk8CmWb/SLaNlUvtBJUnP3VIyPpkj/ABFC6MHjpRNB9SZjlgjtgrlhmq4u2C7c5TrjtWapeVjlhnBYlmAz+fU0nmHp2qXC+of2hJm9ZalDbW8iNarM7ggSOxGw9mGO49+tWba4ZYizqCCTk5Gc49/rXNpLg5NXLS5KuAGGD2ai3Q0pYtX16nVWJYttIVnI2YJ4A6DHqK1Lm48qAIhQbeMDPBNcxZXab1DHaQpJOPmU+3rVuS7LSG5lAkjikXchOQQOg46j6VWysjq9tFu9zXuLne0m0snlgbQnY465NVRexy3VvGpyoYKVIzuz/T1qidQQrKdyqDzjkAg/5/SqUE4MjAOiKWAMj/dXPfip6kSqxsbkE8VrKslyBJChLOsUnls49EYg7SfXBqG3aKS1kuoIGWRSSQ48zyV4wTxj5iQueDWNqE8YVT5lvOTxiNiSvPUjGORwKbqt3b/Z1tViK6gkvzyo+Y2QgELjsynjPQ/hWkY2RxVa6bH3N9HIjKpk8wnJVDhEwBhgTzn1HT6VY0/UTZWwdBi6BOEcfIOBknnvWHPJDGqTRyl7hnJeMrlQB0JOeST29O9N+2l7gTSKPMyDkcYx0oS11MHWRv3eqNqTJb36x2rw25XbBGczsCWUMOgIDYz6LzzzUdlPbQmITSnyHJ8ySFCzjA6gEgHBxWE1xskZvNd3k4dj1wcZAJ79alur1ZGJRduRhVPPlr6dOap92QqttFojWOquoItB5UaqG+diDIRn5z359ORxVUXXlRy5Ik3rlnGR78Z96ouSLQSSbF3ECME5bA6nHp9ahJIjDuc7z93vgdPw/wAKGrC9r2HXEhjkChg2087ehNOmuwyKqJhVXHPJJ9aqE559aT61OxDmx6ng881LF/eJGf51ByAaAcEUrC5jT2M0EkxngjKj5kZ/3h5A4Hfrn6CqsrMGbJTGeCo4P09KjPlCBCGk8/cdylQFC8YIOc5znjHpTAeDg02kLmfUk3nkjqfentvjO1l2kdnwDUI7c0fgD74pWJbPojT1Rd0sYIZgqc9z65/pU8TRRxMFZOpPvkCqUU4WIqMFc/d7Y/yar3lwIphsBJY9+ee9DnZHqxhdmvKVZY9mEK9Oc5qtI8ZjOZNuOqc8g+3fgVGJAxV2+Xav3c9T9KozIZHYR/qMjn09aV7DXqXo5JLiGdmlH7t/MjLgkL2OAowODjnis7c4ndnIYMcEgYXkZ6VPZyiGT7POqyZHzKzbFXv976evGaknurcL5VhAGWQ5YycsVBzgdOOBnjJoaurtjUrPYdo1tGs8DXCiW2L4ZC2N4z0yP6VNqTxiMrG7qq8QLj5sE8e3HrVWO6d7gzBYg25mCoNqgY7Dt/8AWptxbu8k2A0ko+7g5wpHDfWrUFy2iSpXneTKtvPIjSYY4zz0qU75Udo5Ykx1ZnGR7D1+lQ6nFcI0BFobWKQLEZ2kJEsmM9+F4Gcc96zIVYozxBI4zuclvujvnn+L6d6nk5NGbNqaumaEbz4PnbQcE/KPlI9R60quVGVChGGcA849Pp3rOnmkJWWaV3hT92qyYBBxnn2p9vOFwGY8jgY71LBSdrlDxRJLFFDLA8kZWVQzHjeCOfw+taSXRePAJAkQjg9z2/OqPiHdcxjy9skiLvxzjP8Ad+vaotKune22EjBHQgHJx39Ki+tjRK8EzYlUXaLHHcIjn70z8BBj09f61naXJNDJ5dwVVAQivJ8uCM8/59qS/uMOI8IsZO0ybctn0x/nrVPUbwzRkqSWxlVI+6R2qm1uZqMnp0ZsWt2jXEke90UfNv2789eFA6n2rP1Z5WiaRWO5RuK4yCBzjH6/hWTYzzXA2SFA2dwAPPv9OtasVwoZfMLA8AFSNpHfdnufWhaltcjuM067MsLPg+coAwVAH4+5zUK38aXQW5cbT2wAP1/KqUrGxvJLdQQrkyRckDYeh/DkVG90xnVmjgY4KAFOmepHPXvzmgbtq1sW7O5CXd474VJG3e2D1/HFQXF1LM8bOiL9mjWFVVQMKMnJHfO48+tZktz9mmyoXDqFKdmHf6GknuYwFkj3lernqVOf5elCdlYOZJ3Zo6jNu0/7RHhZo8SIy/wsMfNzWAupTpCYUWB1kwzO8YZx7BjyO/A9auxXSbWWUxrE/Vecj1b/AOtWNIMrIVdI/mwFZuemcgen+IrRSe6OKu4lnWtSF4gij0+3t7WNmMMcakmLdg4Ln5mHBIDE9TWTiIxLtJEgzu3Hg9MY/WrdxqE9ySspWNVXYEiQRjHofx5/Os8+1VJ31PPA04OyqyqxCt1APWhNm1t+7P8ADj+tOmEI2eQ0jZUb96gYbuBgnI9+KVuor9BnGB1qSJwBgrnPf0qIUpBADYOD0NIadiw0wO3P3hxuzzipZLn5fKjcmIjnI4qmGHygjgdcdTSH9PeixftJFsXLLhkDbMYyfXHNRLMVIKOQQcgjjBqHJxtycZzikoE5ye5KsmGyQDznBHBpskhd2bCruOSFGB+ApE2lvnLY9utIcZO0EDtk0dCb3JGlIbKkZ9cCo80lFDdwFzSjgdefSm0DrQA88HPJ+p5p6OjMgm3CMHnbyce2ah70oNO4rGjb6bdNaHUPsoNgrbQ87BFY88DkEnjtVHdtJxtznqOfyppJb7xJoobXQSXcM9epNLmko7Uhi0ufSkpaAFHuetKOlJ245pfm9vyoEe5mdG39Seq4wAPaqpH2iRgdyjBZR6H0FVWEkKEO+W9MVFbSFHzICoPP4Ad6hpvc9mNre6y+k7qSRwAAAfU9xirNk5dSEZlYg9Dg9aowSr5bygR5kJ3JnPT+lR6dOouzFLcQpGw3+bMDtCfQck5HT6UJWZEtmaUTjyJFJ3F2K5wCR+P4fzquWjRt0bB5Fz84B69vw96iNyscTtFkoxO3eoViAeuOwP8Ak1Vs5ZsvKsBeFBhtjZB9MnoOnFHWyEno2WppJIXhVxtR2LZbgqCMdPrmrE9zIwt5wzJDAfmI68gjAPfnH0qjC0VybQ3pYQASKc9WJyQQ2OeQKgnm+0M32iSMW4TakYOMD046nPc1rtsQtXr/AF/wS/Z3VtBcKlxam8jaMxr5rEFHPQoefyIxWNLqI8mKBo7eYQpgs4YNv78g44/KmrK9mGV1cuB8rl+jHvj1x9KbqMtwEgnkUhJUJRn4JweR+PFQ22i0oqXr5jZZHFqkiyL5KfMAo6k9eTnBPrSfaPMXe0YTB4G4nA+vrUNvcC4ZYt5YP8xVRjaB79OnNQwSm3lxLASEGCko6jHBP4c1k22joVl6mh9rlcQyBCFDHPHPr/n6Vl6fdsslzCZchJDy4yTzkfSrcsgnhZnuQWU5RQowoPXb2A9vasm81RJ7lPLgjgEUexmTgyc8FvftRawKSvax06q9xEAkL5I3AAk7QOQ2fr3PHWsW+vIluXdEVUCBiZuV39x8vXNSQ3lwsJlDtGmdjZk2M3GMdcn+VU9SjiHnRQ7XDlXQq2UyO3vzn86tK6Ib5WyOGZllMqGMtIxYbcL5Xf8AD0o+0SFeFkaMnKbQeCPfFZclzne+wq0vKnzABkHnP+HFNM8zJ59sZIfLwNyFhuPr6ZqmrGftyS/1KW5kjm6mHI3d9pPc/WhrlpPLmkUgBhnArNup98Y3DL5zuz1pvmExH5vm96nch1rOyNe7aO4hLIH81ew6Lz0/LvWcszRE4DEEHcMdfWoVum2MueGGGHrUDuRjnnoRRYzlX7Gtb2F/LaLdfY5zApA81hhGznHJ4/8A1VQ1NT5+47Ax+8FdW5/A1UDev4U3J6dqqyOeVRyVmbWn+GNZ1HTZb+0sZJLSJgryllUAk9OSKyjA4d1OwFOuXX/HmoaKptGOo5yWbJxnpwB/Sm0UtIYlLU0FrcXCSvBBLKkS75GRCwRfU46D3NQ07NbiumFFFLxt6c565oGNpaSikAoox9KSigApaMUUAGTjGeKKKKACiiigBaKSigBaWkFFIQtLSUvamAtKevSkxTsj0/SmiT2e7Hk6fFPH8s32jG4dcCsK6uZvtEnznt+vWiirqbpHp0N38zRaRhE7fLlZWUfKOlY0zFdQCg5VU4B5H69vaiis6nQ0pGwiibQjPIN0qbQp7AFiDx06AVgXhKWttsJXczuQDwWUgA49QKKKmey9P1FR+Jrz/Q2XJj023dWYMACDnplTn+dZ1/czLpVmyvhmO0kAcgGiiqnpsKkrtX7/AOY23uZuH8xt5Z8t34XjmszTrie5URXE0kqG4RcO5PHPH0ooqYt+6FRJN2NBkWCS4WNVC7ygyM4XJ4GelFyiyQTSvkyKgw2T2OB+lFFD2aCm3dMzJiYpNicKFDAdeSBn+dUNQY/aIzwCy4OAB60UVn1aNZ7IbZSuqNhiNvT2ra1nEWhR+WqofOiIIUAjMZJweoyaKK0hszGs9jlAzJKNpPEo4+vWrup3t1M8olnkdVbYoZsgAMQAPoAB9KKK0WxxS+IyDyrZ9aRug+lFFSiWMHUCrGof8fUmAoAIACgAYAx2oopr4WR1/ryKtOxRRS6DEpKKKQCikoopgSwzywFmgleNmUqSjEZB6g47VGaKKYrEtwAGQgAZQE4+lQ0UU5/EKOwtAooqChKKKKACiiigBaKKKYBRRRQAUtFFIAoH3gKKKBCjpTj0FFFCAUf1pR0ooqkI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerative nodules on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. p.145.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28658=[""].join("\n");
var outline_f27_63_28658=null;
var title_f27_63_28659="Word catheter placement for treatment of Bartholin cysts and abscesses";
var content_f27_63_28659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Word catheter placement for treatment of Bartholin cysts and abscesses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28659/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28659/contributors\">",
"     Katherine T Chen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28659/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28659/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28659/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28659/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/63/28659/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two Bartholin glands secrete mucus to provide moisture for the vulva; they are the homologue of the bulbourethral glands in the male. These glands are located bilaterally in the vulvovaginal area at approximately the four and eight o'clock positions on the posterolateral aspect of the vaginal orifice. Each gland is approximately 0.5 cm in size and drains into a narrow duct 2.5 cm long. The ducts emerge onto the vestibule, one at each side of the vaginal orifice, just below the hymnal ring (",
"    <a class=\"graphic graphic_figure graphicRef66162 \" href=\"UTD.htm?17/44/18126\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Perineal inflammation or trauma can obstruct the orifice of a Bartholin gland duct, thereby leading to cystic dilation of the duct proximal to the obstruction. Intervention is usually not necessary because most cases are asymptomatic. However, some Bartholin cysts are disfiguring, cause discomfort, or become infected (Bartholin abscesses) and require treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=see_link\">",
"     \"Disorders of Bartholin gland\"",
"    </a>",
"    .) General principles of vulvar abscesses are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31464?source=see_link\">",
"     \"Vulvar abscess\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartholin cysts average from 1 to 3 cm in size and are usually asymptomatic. Larger cysts may be associated with vulvar pain, discomfort during intercourse, or difficulty sitting or ambulating. Cysts are diagnosed upon finding a soft, painless mass in the labia or lower vestibular area by a routine pelvic examination or by the woman, herself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Bartholin abscess appears as a large, tender, soft or fluctuant mass in the labia or lower vestibular area, occasionally with erythema, edema, and pointing. Women usually present with such severe pain and swelling that they are unable to walk, sit, or have intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis of vulvovaginal masses is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef68201 \" href=\"UTD.htm?24/53/25435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PLACEMENT OF A WORD CATHETER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a Word catheter into the cyst or abscess allows the contents to drain and, over time, to form around the catheter a fistulous tract from the dilated duct or abscess to the vestibule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Supplies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assemble the following supplies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28659/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterile gloves.",
"     </li>",
"     <li>",
"      Sterilizing solution, such as povidone-iodine swab sticks, to prepare the surgical site.",
"     </li>",
"     <li>",
"      Local anesthetic, such as 1 or 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      . Oral or intravenous sedatives or analgesics may also be given if necessary.",
"     </li>",
"     <li>",
"      25 or 30 gauge needle and 3 mL syringe to inject the local anesthetic.",
"     </li>",
"     <li>",
"      Small forceps, which will be used to hold the cyst or abscess wall.",
"     </li>",
"     <li>",
"      Scalpel with a number 11 blade for performing a stab incision.",
"     </li>",
"     <li>",
"      Microbiologic testing supplies &mdash; culturette for sending sample of abscess contents for microbiologic identification and nucleic acid amplification of gonorrhea and chlamydia test kit.",
"     </li>",
"     <li>",
"      Hemostat to break up loculations.",
"     </li>",
"     <li>",
"      Word catheter. This is a balloon-tipped device that is placed into the cyst or abscess cavity. It can be obtained from Teleflex Medical (2417 Weck Drive, Research Triangle Park, NC 27709, telephone 1-800-553-5214) or Cooper Surgical (95 Corporate Drive, Trumbull, CT 06611, telephone 1-800-243-2974) (",
"      <a class=\"graphic graphic_picture graphicRef65445 \" href=\"UTD.htm?16/46/17134\">",
"       picture 1",
"      </a>",
"      ). Test the catheter to confirm there are no leaks when the balloon is filled.",
"     </li>",
"     <li>",
"      A small syringe containing 3 mL saline or water and attached to a small gauge needle, for inflating the catheter balloon.",
"     </li>",
"     <li>",
"      Gauze pads to control bleeding and effluents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following steps are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28659/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain informed consent. Complications and possible outcomes of the procedure include recurrence of the cyst, and scarring leading to infection, bleeding, and dyspareunia or distortion of anatomy.",
"     </li>",
"     <li>",
"      Ensure that the patient does not have any allergies or hypersensitivity reactions to any agents that will be administered (eg, latex, iodine, amide type anesthetics)",
"     </li>",
"     <li>",
"      Prepare the area of the cyst or abscess with sterilizing solution.",
"     </li>",
"     <li>",
"      Inject 1 to 3 mL of local anesthetic to infiltrate the site planned for the stab incision. This site is usually at or behind the hymnal ring.",
"     </li>",
"     <li>",
"      Hold the cyst or abscess wall with small forceps to maintain traction and prevent collapse of the cyst wall after puncture.",
"     </li>",
"     <li>",
"      Incise the cyst or abscess with a 5 mm stab incision, 1.5 cm deep, in the introitus at or behind the hymnal ring to prevent vulvar scarring. If the incision is too large, the catheter will fall out.",
"     </li>",
"     <li>",
"      Drain the cyst or abscess contents completely by breaking up loculations with the hemostat. Culture abscess contents with a culturette and send for microbiologic identification.",
"     </li>",
"     <li>",
"      Place the Word catheter through the incision, as deep as possible. Make sure the catheter is in the duct cavity. Holding onto the cyst wall with forceps helps to prevent creation of a false passage separate from the cavity.",
"     </li>",
"     <li>",
"      Inflate the balloon of the Word catheter with 2 to 3 mL of saline or water injected into the catheter hub with a needle and syringe.",
"     </li>",
"     <li>",
"      Tuck the end of the Word catheter into vagina to minimize discomfort (",
"      <a class=\"graphic graphic_figure graphicRef59709 \" href=\"UTD.htm?7/27/7600\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Empiric broad spectrum antibiotics may be given if patient is at risk of complicated infection. One antibiotic regimen we use is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"       cefixime",
"      </a>",
"      (400 mg daily for one week) to cover streptococcal species and Escherichia coli and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (300 mg four times per day for seven days) to cover staphylococcal species, including community-associated methicillin-resistant Staphylococcus aureus and Bacteroides species. The regimen may have to be modified based upon culture results (eg, if chlamydia is present, administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      [1 g orally as a single dose] or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      [100 mg twice daily for seven days]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should wear a peripad to absorb discharge.",
"     </li>",
"     <li>",
"      She should maintain pelvic rest (ie, nothing in the vagina) while the Word catheter is in place. She should call to be examined if she experiences increasing swelling, pain, vaginal discharge, or fever.",
"     </li>",
"     <li>",
"      She may use sitz baths and mild analgesics to treat pain, if present during the first postoperative day or two.",
"     </li>",
"     <li>",
"      The catheter is left in place for at least four weeks to promote formation of an epithelialized tract for permanent drainage of glandular secretions. Epithelialization may take six weeks.",
"     </li>",
"     <li>",
"      In patients with a balloon catheter in place who have persistent discomfort despite analgesics, we remove 0.5 to 1 mL of fluid from the balloon.",
"     </li>",
"     <li>",
"      When the tract appears well epithelialized, remove the catheter by deflating the balloon in the office.",
"     </li>",
"     <li>",
"      If recurrent cysts occur, then marsupialization or excision can be performed, usually in an operating room or ambulatory surgical facility. Marsupialization refers to a procedure whereby a large (1.5 to 3 cm) incision is made over the center of the cyst and then the inside edges of the cyst are everted and sewn with interrupted stitches to the vestibular mucosa (",
"      <a class=\"graphic graphic_figure graphicRef60294 \" href=\"UTD.htm?5/58/6051\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the catheter falls out before the tract is epithelialized and the cyst or abscess remains, the patient may need a repeat word catheter placement or another procedure, such as marsupialization or excision. If the problem has resolved, the patient can be followed for complete resolution and no recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/2/12322?source=see_link\">",
"       \"Patient information: Bartholin&rsquo;s gland cyst (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placement of a Word catheter into the Bartholin cyst or abscess allows the contents to drain and, over time, to form around the catheter a fistulous tract from the dilated duct to the vestibule.",
"     </li>",
"     <li>",
"      The cyst or abscess is incised with a 5 mm stab incision, 1.5 cm deep, in the introitus at or behind the hymnal ring. Loculations are broken down and a Word catheter is placed in the cavity, its balloon is inflated with 2 to 3 mL of saline or water, and the end tucked into vagina. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The catheter is left in place for at least four weeks to promote formation of an epithelialized tract for permanent drainage of glandular secretions. Epithelialization may take six weeks. When the tract appears well epithelialized, the catheter is removed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28659/abstract/1\">",
"      Hill DA, Lense JJ. Office management of Bartholin gland cysts and abscesses. Am Fam Physician 1998; 57:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28659/abstract/2\">",
"      Omole F, Simmons BJ, Hacker Y. Management of Bartholin's duct cyst and gland abscess. Am Fam Physician 2003; 68:135.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3259 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28659=[""].join("\n");
var outline_f27_63_28659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PLACEMENT OF A WORD CATHETER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Supplies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/44/18126\" title=\"figure 1\">",
"      Location Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/27/7600\" title=\"figure 2\">",
"      Placement of word catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/58/6051\" title=\"figure 3\">",
"      Marsupialization Bartholin cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3259|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/46/17134\" title=\"picture 1\">",
"      Word catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/53/25435\" title=\"table 1\">",
"      Diagnosis of vulvovaginal mass",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/2/12322?source=related_link\">",
"      Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31464?source=related_link\">",
"      Vulvar abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_63_28660="Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information";
var content_f27_63_28660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=see_link\">",
"    see \"Cromolyn sodium (systemic therapy and oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=see_link\">",
"    see \"Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrocrom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nalcrom&reg;;",
"     </li>",
"     <li>",
"      Nu-Cromolyn;",
"     </li>",
"     <li>",
"      PMS-Sodium Cromoglycate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10576207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Inhalation, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10576383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=see_link\">",
"      see \"Cromolyn sodium (systemic therapy and oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation, nebulization solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic control of asthma: Children &ge;2 years and Adults: Initial: 20 mg 4 times/day; usual dose: 20 mg 3-4 times/day;",
"     <b>",
"      Note:",
"     </b>",
"     Once control is achieved, taper frequency to the lowest effective dose (ie, 4 times/day to 3 times/day to twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevention of allergen- or exercise-induced bronchospasm: Children &ge;2 years and Adults: Single dose of 20 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Administer 10-15 minutes prior to exercise or allergen exposure but no longer than 1 hour before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NIH Asthma Guidelines (NAEPP, 2007): Children &ge;2 years and Adults: 20 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Systemic mastocytosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates and Preterm Infants: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;2 years: Not recommended; reserve use for patients with severe disease in whom potential benefits outweigh risks; 20 mg/kg/day in 4 divided doses; may increase in patients 6 months to 2 years of age if benefits not seen after 2-3 weeks; do not exceed 30 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-12 years: 100 mg 4 times/day; not to exceed 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 years and Adults: 200 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Food allergy and inflammatory bowel disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;2 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-12 years: Initial dose: 100 mg 4 times/day; may double the dose if effect is not satisfactory within 2-3 weeks; not to exceed 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 years and Adults: Initial dose: 200 mg 4 times/day; may double the dose if effect is not satisfactory within 2-3 weeks; up to 400 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Once desired effect is achieved, dose may be tapered to lowest effective dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as sodium: 20 mg/2 mL (60s, 120s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium [concentrate, preservative free]: 100 mg/5 mL (96s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrocrom&reg;: 100 mg/5 mL (96s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8012090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10576444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral concentrate: Open ampul and squeeze contents into glass of water; stir well; administer at least 30 minutes before meals and at bedtime; do not mix with juice, milk, or food",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8012177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nebulizer solution is",
"     <b>",
"      compatible",
"     </b>",
"     with metaproterenol sulfate, isoproterenol hydrochloride, 0.25% isoetharine hydrochloride, epinephrine hydrochloride, terbutaline sulfate, and 20% acetylcysteine solution for at least 1 hour after their admixture.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10576304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from direct light and heat; nebulization solution is compatible with beta-agonists, anticholinergic solutions, acetylcysteine, and NS; incompatible with alkaline solutions and calcium and magnesium salts; store oral concentrate ampuls in foil pouch until ready for use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10576224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: Prophylactic agent used for long-term (chronic) control of persistent asthma;",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm; also used for the prevention of allergen- or exercise-induced bronchospasm (",
"     <b>",
"      Note:",
"     </b>",
"     Cromolyn is not as effective as inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists for exercise-induced bronchospasm; NAEPP, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Systemic: Mastocytosis, food allergy, and treatment of inflammatory bowel disease",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8012119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angioedema, chest pain, edema, flushing, palpitation, premature ventricular contractions, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, behavior changes, convulsions, depression, dizziness, fatigue, hallucinations, headache, irritability, insomnia, lethargy, migraine, nervousness, hypoesthesia, postprandial lightheadedness, psychosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, photosensitivity, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, dysphagia, esophagospasm, flatulence, glossitis, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia, pancytopenia, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver function test abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, leg weakness, leg stiffness, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10576244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cromolyn or any component; primary treatment of status asthmaticus",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10576246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease dose in patients with renal and hepatic impairment; use with caution when tapering the dose or withdrawing the drug since symptoms may reoccur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral cromolyn increased mortality in neonatal rats when administered at ~9 times the maximum recommended daily dose for infants, but not at ~3 times the maximum recommended daily dose; use of oral cromolyn in infants and children &lt;2 years is not recommended and should be reserved for patients with severe mastocytosis in whom potential benefits clearly outweigh the risks.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10576245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cromolyn is a prophylactic drug with no benefit for acute situations; rare but severe anaphylactic reactions can occur; discontinue if eosinophilic pneumonia occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8012109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8012110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. No data available on whether cromolyn crosses the placenta or clinical effects on the fetus. Available evidence suggests safe use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10576445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asthma: Periodic pulmonary function tests; signs and symptoms of disease state when tapering dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10576305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents the mast cell release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis by inhibiting degranulation after contact with antigens",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10576306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not effective for immediate relief of symptoms in acute asthmatic attacks; must be used at regular intervals for 2-4 weeks to be effective;",
"     <b>",
"      Note:",
"     </b>",
"     Therapeutic response may occur within 2 weeks; however, a trial of 4-6 weeks may be needed to determine maximum benefits.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10576324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Oral: 0.5% to 2%",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Inhalation: ~8% reaches lungs upon inhalation; well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 80-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Within 15 minutes after inhalation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Equally excreted unchanged in urine and feces (via bile); small amounts after inhalation are exhaled",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10576446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=see_link\">",
"      see \"Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth. Cromolyn is not effective for the immediate relief of symptoms in acute asthmatic attacks; must be used at regular intervals for 2-4 weeks to be effective for asthma control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10576447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The 2007 Expert Panel Report of the National Asthma Education and Prevention Program (NAEPP, 2007) does not recommend cromolyn for initial treatment of persistent asthma in children; inhaled corticosteroids are the preferred agents; cromolyn is considered an alternative medication for the treatment of mild persistent asthma in children. Reserve systemic use in children &lt;2 years of age for severe disease; avoid systemic use in premature infants.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15957 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-6A52161855-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28660=[""].join("\n");
var outline_f27_63_28660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012087\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012088\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576207\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576383\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012240\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576444\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012177\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576304\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576224\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012119\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576244\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576246\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576245\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299102\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012170\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012109\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012110\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576445\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576305\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576306\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576324\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576446\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576447\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15957\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15957|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/27/23987?source=related_link\">",
"      Cromolyn sodium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/12/197?source=related_link\">",
"      Cromolyn sodium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=related_link\">",
"      Cromolyn sodium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/46/17124?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_63_28661="Child injury statement A";
var content_f27_63_28661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Child injury statement, page 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 637px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hospitals and or states may have specific forms for reporting child abuse and or neglect. The form used by Texas Children's Hospital is shown as an example. When child abuse is reported by a physician, a copy of the written report should be filed in the patient's medical record.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28661=[""].join("\n");
var outline_f27_63_28661=null;
var title_f27_63_28662="Eculizumab: Drug information";
var content_f27_63_28662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eculizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/31/16885?source=see_link\">",
"    see \"Eculizumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4426547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soliris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10205364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Soliris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4426550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Monoclonal Antibody, Complement Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4426649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. Treatment should be administered at the recommended time interval although administration may be varied by &plusmn;2 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Atypical hemolytic uremic syndrome (aHUS):",
"     </b>",
"     I.V.: Induction: 900 mg weekly for 4 doses; Maintenance: 1200 mg at week 5, then 1200 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Supplemental dosing for patients receiving plasmapheresis or plasma exchange:",
"     </i>",
"     If most recent dose was &ge;600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Supplemental dosing for patients receiving fresh frozen plasma infusion:",
"     </i>",
"     If most recent dose was &ge;300 mg, administer 300 mg within 60 minutes prior to each 1 unit of fresh frozen plasma infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Paroxysmal nocturnal hemoglobinuria (PNH):",
"     </b>",
"     I.V.: 600 mg weekly for 4 doses, followed by 900 mg 1 week later; then 900 mg every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13259673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. Treatment should be administered at the recommended time interval although administration may be varied by &plusmn;2 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Atypical hemolytic uremic syndrome (aHUS):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 5 kg to &lt;10 kg: Induction: 300 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 10 kg to &lt;20 kg: Induction: 600 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 20 kg to &lt;30 kg: Induction: 600 mg weekly for 2 doses; Maintenance: 600 mg at week 3, then 600 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 30 kg to &lt;40 kg: Induction: 600 mg weekly for 2 doses; Maintenance: 900 mg at week 3, then 900 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;40 kg: Induction: 900 mg weekly for 4 doses; Maintenance: 1200 mg at week 5, then 1200 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Supplemental dosing for patients receiving plasmapheresis or plasma exchange:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If most recent dose was &ge;600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Supplemental dosing for patients receiving fresh frozen plasma infusion:",
"     </i>",
"     If most recent dose was &ge;300 mg, administer 300 mg within 60 minutes prior to each 1 unit of fresh frozen plasma infusion",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4426650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4426651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is recommended in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4426652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not studied in hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4426659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soliris&reg;: 10 mg/mL (30 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4426548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients and providers must enroll with Soliris&reg; OneSource&trade; (1-888-765-4747) program prior to treatment initiation.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089130.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089130.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4426653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Allow to reach room temperature prior to administration. Infuse over 35 minutes. Decrease infusion rate or discontinue for infusion reactions; do not exceed a maximum 2-hour duration of infusion. Monitor for at least 1 hour following completion of infusion (for signs/symptoms of infusion reaction).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4426641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, sodium chloride 0.9%, sodium chloride 0.45%, Ringer&rsquo;s injection",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4426551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for the treatment of hemolytic uremic syndrome related to Shiga toxin",
"     <i>",
"      E. coli",
"     </i>",
"     (STEC-HUS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4426632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (aHUS: 35%), tachycardia (aHUS: children 21%), peripheral edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (30% to 44%; serious: 2%), insomnia (14%), fatigue (11% to 12%), fever (2% to 11%; children 47%), vertigo (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (32%), vomiting (21% to 22%), nausea (16% to 19%), abdominal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (24%; serious: 2%), leukopenia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (19%), limb pain (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Respiratory tract infection (7% to 35%), cough (12% to 26%), nasopharyngitis (23%), nasal congestion (aHUS: children 21%), pharyngolaryngeal pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes infections (7%), flu-like syndrome (5%), viral infection (serious: 2%), meningococcal infection (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal distention, anxiety, arthralgia,  cholangitis, dizziness, endometritis, hematoma (mild), infusion reaction, pyelonephritis, renal impairment, taste alteration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4426627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unresolved serious",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     infection; patients not currently vaccinated against",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     (unless risks of treatment delay outweigh risk of meningococcal infection)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4426628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections: In addition to meningitis, the risk of other infections, especially encapsulated bacteria (eg,",
"     <i>",
"      Streptococcus pneumoniae, H. influenzae",
"     </i>",
"     ) is increased with eculizumab treatment (because eculizumab blocks terminal complement activation). Children should receive vaccination for prevention of",
"     <i>",
"      S. pneumoniae, H. influenzae",
"     </i>",
"     according to current ACIP guidelines. Use with caution when administering to a patient with a systemic infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion reactions: Infusion reactions, including anaphylaxis or hypersensitivity, may occur; interrupt infusion for severe reaction. Continue monitoring for 1 hour after completion of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Meningococcal infection:",
"     <b>",
"      [U.S. Boxed Warning]: Meningococcal",
"     </b>",
"     <b>",
"      <i>",
"       (Neisseria meningitides)",
"      </i>",
"     </b>",
"     <b>",
"      infections have occurred in patients receiving eculizumab; may be fatal or life-threatening if not detected and treated promptly. Monitor for early signs of meningococcal infection; evaluate and treat promptly if suspected. Follow current meningococcal immunization recommendations for patients with complement deficiencies. Vaccinate with meningococcal vaccine at least 2 weeks prior to initiation of treatment;",
"     </b>",
"     revaccinate according to current guidelines. Polyvalent meningococcal vaccines are recommended. If urgent treatment is necessary in an unvaccinated patient, administer meningococcal vaccine as soon as possible. Although the risk/benefits of prophylactic meningococcal antibiotic therapy have not been determined, prophylactic antibiotics were administered in clinical studies until at least 2 weeks after vaccination. Meningococcal infections developed in some patients despite vaccination. Discontinue eculizumab during the treatment of serious meningococcal infections.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulation: In clinical trials, anticoagulant therapy was continued in patients who were receiving these agents (due to history of or risk for thromboembolism) prior to initiation of eculizumab. The effect of anticoagulant therapy withdrawal is unknown. Treatment with eculizumab should not alter anticoagulation management.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation in aHUS: Monitor patients for at least 12 weeks after treatment discontinuation for signs/symptoms of thrombotic microangiopathy (TMA) complications (angina, dyspnea, mental status changes, seizure, serum creatinine elevation, serum LDH elevation, thrombocytopenia, or thrombosis). If TMA complications occur after stopping eculizumab, consider reinitiation of treatment, plasmapheresis, plasma exchange, fresh frozen plasma infusion, and/or appropriate organ-specific measures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation in PNH: Patients with PNH who discontinue eculizumab treatment may be at increased risk for serious hemolysis; monitor closely for at least 8 weeks after treatment discontinuation. Consider RBC transfusion, exchange transfusion, anticoagulation, corticoids or reinitiation of eculizumab for serious hemolysis after discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Patients should be up to date with all immunizations before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Access is restricted through a REMS program.  Prescribers must be enrolled in the program; enrollment information is available at 1-888-765-4747.",
"     </b>",
"     Counsel patients on the risk of meningococcal infection; ensure patients are vaccinated and provide educational materials.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4426622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4426623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated fetal abnormalities. Eculizumab is a recombinant IgG molecule with IgG2 and IgG4 sequences; human IgG is known to cross the placenta, however IgG2 may have reduced placental transfer compared to other IgG subclasses. There are no adequate and well-controlled studies in pregnant women. Pregnant women with PNH and their fetuses have high rates of morbidity and mortality during pregnancy and the postpartum period. Limited information is available related to use during pregnancy.  Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4426625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4426626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if eculizumab is excreted in human milk. However, human IgG is excreted in breast milk, and therefore, eculizumab may also be excreted in milk. Although antibodies in human milk do not enter neonatal or infant circulation in substantial amounts, the risks to the infant from gastrointestinal or limited systemic exposure are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Soliris Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (30 mL): $6830.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4426656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of infusion reaction (during infusion and for 1 hour after infusion complete); CBC with differential, lactic dehydrogenase (LDH), serum creatinine, AST, urinalysis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serum LDH levels greater than pretreatment level along with: &gt;25% decrease in PNH clone size in &le;1 week, or hemoglobin level &lt;5 g/dL, or a hemoglobin decrease of &gt;4 g/dL in &le;1 week, or 50% increase in serum creatinine, or angina, mental status change, or thrombosis is indicative of serious hemolysis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     After discontinuation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     aHUS: Signs/symptoms of thrombotic microangiopathy (TMA) complications (monitor for at least 12 weeks after treatment discontinuation), including angina, dyspnea, mental status changes, seizure, serum creatinine elevation, serum LDH elevation, thrombocytopenia, or thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     PNH: Signs and symptoms of intravascular hemolysis (monitor for at least 8 weeks after discontinuation), including serum LDH, hemoglobin, serum creatinine; signs of angina, mental status change, or thrombosis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Solirus (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, HK, IE, IL, IT, KP, NL, NO, NZ, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4426642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Terminal complement-mediated intravascular hemolysis is a key clinical feature of paroxysmal nocturnal hemoglobinuria (PNH); blocking the formation of membrane attack complex (MAC) results in stabilization of hemoglobin and a reduction in the need for RBC transfusions. Impairment of complement activity regulation leads to uncontrolled complement activation in atypical hemolytic uremic syndrome (aHUS). Eculizumab is a humanized monoclonal IgG antibody that binds to complement protein C5, preventing cleavage into C5a and C5b. Blocking the formation of C5b inhibits the subsequent formation of terminal complex C5b-9 or MAC.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4426644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: PNH: Reduced hemolysis: &le;1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: PNH: 7.7 L; aHUS: 6.14 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: PNH: ~11 days (range: ~8-15 days); aHUS: ~12 days (during plasma exchange the half-life is reduced to 1.26 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brodsky RA, &ldquo;How I Treat Paroxysmal Nocturnal Hemoglobinuria,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(26):6522-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/19372253/pubmed\" id=\"19372253\" target=\"_blank\">",
"        19372253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodsky RA, Young NS, Antonioli E, et al, &ldquo;Multicenter Phase 3 Study of the Complement Inhibitor Eculizumab for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(4):1840-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/18055865/pubmed\" id=\"18055865\" target=\"_blank\">",
"        18055865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-7):1-21. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf%20\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Use of Meningococcal Conjugate Vaccines &ndash; Advisory Committee on Immunization Practices, 2010,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(3):72-6. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/21270745/pubmed\" id=\"21270745\" target=\"_blank\">",
"        21270745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Danilov AV, Smith H, Craigo S, et al, &ldquo;Paroxysmal Nocturnal Hemoglobinuria (PNH) and Pregnancy in the Era of Eculizumab,&rdquo;",
"      <i>",
"       Leukemia Res",
"      </i>",
"      , 2009, 33(6):e4-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/18952283/pubmed\" id=\"18952283\" target=\"_blank\">",
"        18952283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill A, Hillmen P, Richards SJ, et al, &ldquo;Sustained Response and Long-Term Safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(7):2559-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/15985537/pubmed\" id=\"15985537\" target=\"_blank\">",
"        15985537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillmen P, Hall C, Marsh JC, et al, &ldquo;Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients With Paroxysmal Nocturnal Hemoglobinuria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(6):552-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/14762182/pubmed\" id=\"14762182\" target=\"_blank\">",
"        14762182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillmen P, Muus P, Duhrsen U, et al, &ldquo;Effect of Complement Inhibitor Eculizumab on Thromboembolism in Patients With Paroxysmal Nocturnal Hemoglobinuria,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(12):4123-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/17702897/pubmed\" id=\"17702897\" target=\"_blank\">",
"        17702897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillmen P, Young NS, Schubert J, et al, &ldquo;The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(12):1233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/16990386/pubmed\" id=\"16990386\" target=\"_blank\">",
"        16990386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malek A, Sager R, Kuhn P, et al. &ldquo;Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy,&rdquo;",
"      <i>",
"       Am J Reprod Immunol",
"      </i>",
"      , 1996, 36(5):248-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/8955500/pubmed\" id=\"8955500\" target=\"_blank\">",
"        8955500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitcher-Wilmott RW, Hindocha P, and Wood CB, &ldquo;The Placental Transfer of IgG Subclasses in Human Pregnancy,&rdquo;",
"      <i>",
"       Clin Exp Immunol",
"      </i>",
"      , 1980, 41(2):303-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/7438556/pubmed\" id=\"7438556\" target=\"_blank\">",
"        7438556",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor CM, Machin S, Wigmore SJ, et al, &ldquo;Clinical Practice Guidelines for the Management of Atypical Haemolytic Uraemic Syndrome in the United Kingdom,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2010, 148(1):37-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/63/28662/abstract-text/19821824/pubmed\" id=\"19821824\" target=\"_blank\">",
"        19821824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8836 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28662=[""].join("\n");
var outline_f27_63_28662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708724\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426547\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205364\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426550\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426649\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13259673\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426650\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426651\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426652\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426659\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426548\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233712\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874616\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426653\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426641\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426551\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426632\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426627\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426628\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299250\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220068\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426622\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426623\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426625\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426626\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324130\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426656\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038892\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426642\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426644\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/31/16885?source=related_link\">",
"      Eculizumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_63_28663="Therapeutic use of dofetilide";
var content_f27_63_28663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use of dofetilide",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28663/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28663/contributors\">",
"     Raymond L Woosley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28663/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28663/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/63/28663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is a class III antiarrhythmic agent (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) available for use in the United States and other countries for the acute termination of atrial fibrillation or flutter as well as prevention of atrial fibrillation or flutter recurrence. Dofetilide has also been used in an off-label manner to treat paroxysmal supraventricular tachycardias. Some investigators have studied the efficacy of dofetilide in the treatment of life-threatening ventricular arrhythmias, although the drug is not approved for this indication. In contrast to some other antiarrhythmic medications, dofetilide appears to be hemodynamically safe for use in patients with heart failure or a prior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of a relatively high risk of torsades de pointes as an adverse effect of dofetilide, it has a formal risk evaluation and mitigation program that requires training and certification of treatment sites. (See",
"    <a class=\"local\" href=\"#H453858352\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The basic pharmacologic properties of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , its clinical uses, and its safety profile are discussed in detail here. Alternative treatment approaches for supraventricular and ventricular arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H21#H21\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is a class III antiarrhythmic agent that blocks the delayed rectifier cardiac potassium channel and prolongs repolarization (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ). Dofetilide has relative selectivity for blocking the rapidly-activating component of the delayed rectifier potassium current (IKr) at concentrations of 10 to 30",
"    <span class=\"nowrap\">",
"     nanomole/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. At these concentrations, it does not block the slow component of the delayed rectifier potassium current (IKs) or the inward rectifier (IKi) and does not affect sodium or calcium currents.",
"   </p>",
"   <p>",
"    As a result of its electrophysiologic action,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    has a selective effect on the QT interval of the surface ECG. In clinical electrophysiologic studies, it prolongs the QT interval with little, if any, effect on QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/4\">",
"     4",
"    </a>",
"    ]. Purkinje fibers from female dogs are more sensitive to dofetilide than fibers from male dogs, which is consistent with the threefold greater incidence of torsades de pointes in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like other class III agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    exhibits reverse use dependency (greater prolongation of repolarization and the refractory period during slower heart rates). The drug prolongs the effective refractory period of atrial and ventricular myocardium and accessory pathways, but it has no effect on conduction parameters, sinus cycle length, or sinus node recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    that have been used in clinical trials range from 125 to 500 mcg twice daily. Peak plasma concentrations are seen two to three hours after oral dosing when fasting. Dofetilide is completely absorbed after oral administration, and bioavailability ranges from 75 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/8\">",
"     8",
"    </a>",
"    ]. Elimination is predominantly renal (80 percent), with only 20 percent hepatic conversion to inactive metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/9\">",
"     9",
"    </a>",
"    ]. The elimination half-life is approximately ten hours after intravenous or oral administration. Clearance has been estimated to be 0.35",
"    <span class=\"nowrap\">",
"     L/hr/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    , like most other potassium channel blockers, is metabolized predominantly by the CYP3A4 family of enzymes predominantly in the liver and GI tract. This means that it is likely to interact with drugs that inhibit CYP3A4, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , resulting in higher and potentially toxic levels of dofetilide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a very linear relationship between the dose administered, plasma concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , and its effect on the QT interval after both oral and intravenous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/10\">",
"     10",
"    </a>",
"    ]. This observation indicates that it is unlikely that there are important effects of the metabolites on potassium channels and supports earlier work examining the activities of the metabolites in vitro.",
"   </p>",
"   <p>",
"    Although some safety and efficacy trials with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    have been performed, dofetilide is not available for intravenous administration in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/12-16\">",
"     12-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DRUG APPROVAL AND RESTRICTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration (FDA) approved the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    for the reversion of atrial fibrillation and atrial flutter to normal sinus rhythm and for maintenance of normal sinus rhythm in symptomatic patients. Several other countries worldwide have also approved its use; however, widespread approval and usage have been somewhat limited due to safety concerns. Because of the risk of torsades de pointes, the FDA approval for dofetilide was contingent upon the following restrictions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is available only to hospitals and prescribers that have received education in the proper dosing and treatment initiation of dofetilide.",
"     </li>",
"     <li>",
"      Patients must be",
"      <strong>",
"       hospitalized",
"      </strong>",
"      for a minimum of three days for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      initiation at a facility that can provide dosing based on estimated creatinine clearance, cardiac monitoring, and cardiac resuscitation. The majority of episodes of torsades de pointes have occurred within the three-day period of initial dosing and at the time of peak increase in the QT interval [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/17\">",
"       17",
"      </a>",
"      ]. However, late occurrence is possible and has been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    was developed for the treatment of atrial fibrillation and atrial flutter but has been evaluated in small studies in patients with other supraventricular arrhythmias and ventricular tachycardia. Dofetilide may be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in treatment and prevention of supraventricular arrhythmias, but it has never been directly compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , which is generally considered the most effective drug for treatment of supraventricular arrhythmias. In an effort to optimize efficacy and safety, the initiation of dofetilide should occur in a controlled fashion according to the FDA-recommended protocol (",
"    <a class=\"graphic graphic_figure graphicRef64845 \" href=\"UTD.htm?12/34/12839\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral dofetilide for atrial arrhythmia termination and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    has been evaluated for the reversion of atrial fibrillation (AF) or atrial flutter to normal sinus rhythm and for the prevention of recurrent AF or atrial flutter.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To evaluate the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      in termination of atrial arrhythmias, the SAFIRE-D study randomly assigned 325 patients with AF (n = 277) or atrial flutter (n = 48) to 125, 250, and 500 mcg of dofetilide twice daily or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/18\">",
"       18",
"      </a>",
"      ]. Overall conversion rates were 6, 10, and 30 percent, respectively, versus 1.2 percent for placebo. At a dose of 500 mcg twice daily, the conversion rates for AF and atrial flutter were 22 and 67 percent, respectively. For those patients who responded to dofetilide, conversion to sinus rhythm occurred within 24 hours in 70 percent and within 36 hours in 91 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The SAFIRE-D trial also evaluated the long-term efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      for maintenance of sinus rhythm in 204 patients with AF who were successfully cardioverted electrically or pharmacologically with dofetilide and maintained on a dofetilide dose of 125, 250, or 500 mcg twice daily or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/18\">",
"       18",
"      </a>",
"      ]. The probability of remaining in sinus rhythm at one year was 40, 37, and 58 percent versus 25 percent for placebo. The all-cause mortality was the same in the four groups. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      (500 mcg twice daily) was compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      (150 mg three times daily) and placebo for the prevention of recurrent paroxysmal supraventricular tachycardia (PSVT) in a trial of 122 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/19\">",
"       19",
"      </a>",
"      ]. After six months of therapy, freedom from episodes of PSVT was the same with dofetilide and propafenone (50 and 54 versus 6 percent for placebo); the median number of episodes of PSVT in those with recurrences was also the same with these two agents (1 and 0.5 versus 5 for placebo). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the acute management of tachyarrhythmias\", section on 'Paroxysmal supraventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    reduces the incidence of sustained ventricular tachyarrhythmias during acute myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/20\">",
"     20",
"    </a>",
"    ]. However, comprehensive studies of dofetilide in patients with life-threatening ventricular tachyarrhythmias are limited.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    (500 mcg twice daily) was compared to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (160 mg twice daily) in a randomized, crossover comparative trial of 135 patients with ischemic heart disease and ventricular tachycardia (VT) induced during electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients underwent repeat electrophysiologic testing after three to five days of therapy and then crossed over to the alternate drug. The response rate was the same with dofetilide and sotalol (36 versus 34 percent), but only 18 percent responded to both drugs. Drug-related adverse effects were significantly less frequent with dofetilide.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    has also been evaluated patients with an ICD, yielding mixed results. Among one cohort of 174 patients with an implantable cardioverter-defibrillator (ICD), dofetilide did not reduce the incidence of ICD interventions for ventricular tachycardia or ventricular fibrillation (VF) compared with placebo; however, the incidence of pause-dependent torsades de pointes was significantly higher with dofetilide (17 versus 6 percent for placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in a smaller cohort of 30 patients with ICDs for secondary prevention who were treated with dofetilide and followed for an average of 32 months, dofetilide led to significant reductions in VT and VF as well as ICD therapies delivered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pending the completion of additional prospective studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , we do not suggest its routine use as a first-line antiarrhythmic drug for the treatment of ventricular tachyarrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both animal and human studies have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    does not have a negative inotropic effect on left ventricular contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a clinical study of patients with class II or III heart failure, intravenous dofetilide (8",
"    <span class=\"nowrap\">",
"     mcg/kg),",
"    </span>",
"    which is not available in all countries, did not alter left ventricular contractility or ventricular volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, because of the limited number of antiarrhythmic medications available for use in patients with heart failure or reduced left ventricular systolic function, there is interest in developing additional antiarrhythmic medications for use in this population. Despite this potential interest, there remains limited data with mixed outcomes regarding the safety and efficacy of dofetilide use in such patients.",
"   </p>",
"   <p>",
"    The DIAMOND-CHF trial evaluated the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    compared to placebo in 1518 patients with symptomatic heart failure and left ventricular dysfunction (left ventricular ejection fraction &le;35 percent), including 391 with AF at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/17\">",
"     17",
"    </a>",
"    ]. After one month of therapy, 12 percent of patients with AF at baseline had sinus rhythm restored compared to only 1 percent receiving placebo. After a mean follow-up of 18 months, there was no overall difference in mortality between the two groups (41 versus 42 percent). In a subsequent analysis, a difference in mortality was noted according to baseline corrected QT (QTc) interval [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/26\">",
"     26",
"    </a>",
"    ]. In those with a QTc interval &lt;429 msec, dofetilide was associated with a significant reduction in mortality (risk ratio 0.4, 95% CI 0.3 to 0.8), while it tended to increase mortality in those with a QTc interval &gt;479 msec (risk ratio 1.3, 95% CI 0.8 to 1.9). In these same patients, the incidence of torsades de pointes was 3.3 percent; three-quarters of these episodes occurred within the first three days while the patient was in the hospital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Postmyocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    has been evaluated and appears safe for use in patients with a history of myocardial infarction (MI). The DIAMOND-MI trial enrolled 1510 patients with an acute Ml and a left ventricular ejection fraction &le;35 percent. Patients were randomly assigned to dofetilide (500 mcg twice per day) or placebo within seven days of the MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/27\">",
"     27",
"    </a>",
"    ]. The one year mortality was 31 percent, and the incidence of arrhythmic deaths was 17 percent. Total mortality, cardiac mortality, arrhythmic mortality, and the combined end point of cardiac death and resuscitation were the same in both groups. In addition, there was evidence of antiarrhythmic efficacy of dofetilide. Among patients receiving dofetilide, there was a lower incidence of new atrial fibrillation and a higher rate of conversion of atrial fibrillation to sinus rhythm (42.4 versus 12.5 percent for placebo).",
"   </p>",
"   <p>",
"    Torsades de pointes developed in 0.9 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , most of which occurred within the first four days of treatment. However, the patients in this trial were scrutinized carefully to exclude those with known risk factors for torsade, which may explain why the incidence of torsade was lower than in some other studies noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9796647\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern about the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , which like other class III antiarrhythmic agents (",
"    <a class=\"graphic graphic_figure graphicRef64845 \" href=\"UTD.htm?12/34/12839\">",
"     figure 1",
"    </a>",
"    ) is associated with a risk of torsades de pointes. Torsades de pointes has been reported in up to 3 percent of patients receiving dofetilide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. In a pooled analysis from the dofetilide treated patients in the DIAMOND-HF and DIAMOND-MI trials (where the incidence of torsades de pointes was 2.1 percent), the risk of torsades de pointes was greater in women than in men (OR 2.2), and in patients with NYHA class III or IV heart failure (OR 3.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/29\">",
"     29",
"    </a>",
"    ]. Despite the increased risk of torsade de pointes, a pooled analysis of 1346 patients receiving dofetilide and 677 treated with placebo in randomized clinical trials did not show an increase in mortality with dofetilide use (adjusted hazard ratio 1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because excessive QT prolongation is assumed to be a critical component of torsades de pointes, orally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    has been used to shorten",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    -induced QT prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/31\">",
"     31",
"    </a>",
"    ]. This is based on the untested assumption that this would reduce the risk of torsades de pointes without interfering with its antiarrhythmic efficacy. Magnesium has been found to reduce QT prolongation and not interfere with the efficacy of a similar drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28663/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453858352\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QT prolonging effects and the risk of torsades de pointes can be increased by coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , drugs that also prolong the QT, or drugs that interfere with its renal elimination (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , verapamil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , alone or in combination with sulfamethoxazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    , megestrol, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lack of an increase in mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    in the DIAMOND trials is reassuring. However, because strict entry criteria remove high-risk individuals and because drug-induced torsade de pointes is relatively rare and can be treated if it occurs in a monitored setting, the impact of this complication may not be seen in analyses limited to overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H678448\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is a class III antiarrhythmic agent (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 1",
"      </a>",
"      ) that blocks the delayed rectifier cardiac potassium channel and prolongs repolarization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Electrophysiologic action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is effective in reversion of atrial fibrillation and atrial flutter to sinus rhythm and prevention of recurrence of atrial fibrillation and atrial flutter. Dofetilide is at least as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      in treatment and prevention of supraventricular arrhythmias, but has never been directly compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , which is generally considered the most effective drug for treatment of supraventricular arrhythmias. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Oral dofetilide for atrial arrhythmia termination and prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are candidates for other antiarrhythmic drugs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , etc), we do not suggest the routine use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      as a first-line antiarrhythmic drug for the treatment of ventricular tachyarrhythmias. This is based on the lack of prospective efficacy data showing improvement in outcomes over other medications when dofetilide is used for the treatment of ventricular tachyarrhythmias. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Ventricular tachyarrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      is approved by the United States Food and Drug Administration (FDA) and several countries worldwide. Its use in the US is contingent upon the following restrictions: (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Drug approval and restrictions'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is available only to hospitals and prescribers with prior education in dosing and treatment initiation.",
"     </li>",
"     <li>",
"      Patients must be hospitalized for a minimum of three days for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      initiation to monitor creatinine clearance, QT interval, and cardiac rhythm (",
"      <a class=\"graphic graphic_figure graphicRef64845 \" href=\"UTD.htm?12/34/12839\">",
"       figure 1",
"      </a>",
"      ). Most episodes of torsades de pointes occur within this three day period, the time of peak increase in the QT interval, but rarely torsades de pointes can occur later.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is contraindicated in patients with congenital long QT syndrome, severe renal insufficiency (CCr &lt;20",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      known hypersensitivity, and in patients taking drugs known to slow its renal elimination (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      , alone or in combination with sulfamethoxazole,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , alone or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      , megestrol, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      appears to be safe for use in patients with a history of heart failure or prior myocardial infarction. In patients with heart failure, however, there is a suggestion of increased mortality in patients with a baseline corrected QT (QTc) interval &gt;479 msec. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Heart failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Postmyocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Like other class III antiarrhythmic agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      is associated with dose-dependent prolongation of the QT interval and a risk of torsades de pointes, which has been reported in up to 3 percent of patients receiving dofetilide. (See",
"      <a class=\"local\" href=\"#H9796647\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/1\">",
"      Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000; 102:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/2\">",
"      Carmeliet E. Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993; 7 Suppl 3:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/3\">",
"      Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996; 94:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/4\">",
"      D&eacute;molis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/5\">",
"      Abi-Gerges N, Small BG, Lawrence CL, et al. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol 2004; 142:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/6\">",
"      Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992; 69:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/7\">",
"      Cobbe SM, Campbell RW, Camm AJ, et al. Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart 2001; 86:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/8\">",
"      Smith DA, Rasmussen HS, Stopher DA, Walker DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 1992; 22:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/9\">",
"      Rasmussen HS, Allen MJ, Blackburn KJ, et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992; 20 Suppl 2:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/10\">",
"      Le Coz F, Funck-Brentano C, Morell T, et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995; 57:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/11\">",
"      Walker DK, Alabaster CT, Congrave GS, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos 1996; 24:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/12\">",
"      Kobayashi Y, Atarashi H, Ino T, et al. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1997; 30:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/13\">",
"      Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/14\">",
"      N&oslash;rgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999; 137:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/15\">",
"      Frost L, Mortensen PE, Tingleff J, et al. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int J Cardiol 1997; 58:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/16\">",
"      Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000; 21:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/17\">",
"      Torp-Pedersen C, M&oslash;ller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/18\">",
"      Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/19\">",
"      Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J 2001; 142:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/20\">",
"      Andersen HR, Wiggers H, Knudsen LL, et al. Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs. Cardiovasc Res 1994; 28:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/21\">",
"      Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001; 22:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/22\">",
"      Mazur A, Anderson ME, Bonney S, Roden DM. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 2001; 37:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/23\">",
"      Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol 2012; 23:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/24\">",
"      Wallace AA, Stupienski RF 3rd, Brookes LM, et al. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/25\">",
"      Rousseau MF, Massart PE, van Eyll C, et al. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am J Cardiol 2001; 87:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/26\">",
"      Brendorp B, Elming H, Jun L, et al. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001; 103:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/27\">",
"      K&oslash;ber L, Bloch Thomsen PE, M&oslash;ller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/28\">",
"      Ferguson JJ. Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association. Circulation 1999; 99:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/29\">",
"      Pedersen HS, Elming H, Seibaek M, et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol 2007; 100:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/30\">",
"      Pritchett EL, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J 1999; 138:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/31\">",
"      McBride BF, Min B, Kluger J, et al. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol 2006; 11:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28663/abstract/32\">",
"      Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1033 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-ADE86C94E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28663=[""].join("\n");
var outline_f27_63_28663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H678448\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTROPHYSIOLOGIC ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DRUG APPROVAL AND RESTRICTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral dofetilide for atrial arrhythmia termination and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Postmyocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9796647\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453858352\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H678448\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1033|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/34/12839\" title=\"figure 1\">",
"      Dofetilide dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_63_28664="Tinea versicolor arm";
var content_f27_63_28664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59533%7EPC%2F73839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59533%7EPC%2F73839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small salmon-colored macules are evident on the arm that coalesce in some areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor. Hypopigmented macules and patches are scattered on the shoulder and arm of this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28664=[""].join("\n");
var outline_f27_63_28664=null;
var title_f27_63_28665="Jones metroplasty CD";
var content_f27_63_28665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Jones metroplasty CD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 638px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (C) Uterine closure is begun in the lower portion of the cavity. The anterior and then the posterior walls are closed, including the endometrium and a small portion of the myometrium. The suture may be continuous or interrupted. (D) Beginning inferiorly, a row of interrupted sutures is then placed in the remaining thickness of the uterine wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28665=[""].join("\n");
var outline_f27_63_28665=null;
var title_f27_63_28666="Post-ERCP pancreatitis";
var content_f27_63_28666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-ERCP pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Silvano Loperfido, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Guido Costamagna, MD, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/63/28666/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/63/28666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation in the serum amylase concentration is common after ERCP, occurring in up to 75 percent of patients; by comparison, acute clinical pancreatitis (defined as a clinical syndrome of abdominal pain and hyperamylasemia requiring hospitalization) is much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, acute pancreatitis is the most common serious complication of ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/2\">",
"     2",
"    </a>",
"    ]. It accounted for more than one-half of complications of endoscopic sphincterotomy in two large series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and for 23 out of 39 malpractice claims for compensation due to post-ERCP complications, including seven of nine that were fatal, in a Danish report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/5\">",
"     5",
"    </a>",
"    ]. Similarly, in an analysis of 59 ERCP lawsuits in North America, 30 cases and 6 of 15 deaths involved pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/6\">",
"     6",
"    </a>",
"    ]. Among 14 autopsies performed after ERCP complications over a 13-year period, seven fatalities were caused by pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several proposed factors may act independently or in combination to induce post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical injury from instrumentation of the pancreatic duct &ndash; Prolonged manipulation around the papillary orifice, repeated instrumentation of the pancreatic duct and multiple pancreatic duct injections are common when selective bile duct cannulation is difficult [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydrostatic injury from overinjection &ndash; Hydrostatic injury from overinjection of the pancreatic duct is probably a main determinant of pancreatitis after diagnostic ERCP and sphincter of Oddi manometry [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/10\">",
"       10",
"      </a>",
"      ]. Overinjection has probably occurred when gland acinarization is apparent during pancreatography (ie, visualization of the side branches of the pancreatic duct during contrast injection).",
"     </li>",
"     <li>",
"      Chemical or allergic injury from contrast medium &ndash; The role of ionic contrast agents and the relative safety of nonionic low osmolarity contrast agents are controversial. A meta-analysis of controlled trials found no significant difference [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enzymatic injury from intestinal content &ndash; Intraluminal activation of proteolytic enzymes has been suggested in laboratory studies and clinical trials.",
"     </li>",
"     <li>",
"      Infection &ndash; Bacterial injury from a contaminated endoscope and accessories can occur, but probably does not play a major role [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thermal injury &ndash; Thermal injury from electrocautery current may produce edema of the pancreatic orifice leading to obstruction of the pancreatic duct and impairing emptying of pancreatic secretions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GRADING AND INCIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-ERCP acute pancreatitis can be graded as mild, moderate, or severe based upon a consensus definition (",
"    <a class=\"graphic graphic_table graphicRef71241 \" href=\"UTD.htm?8/52/9036\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild &ndash; Serum amylase at least three times normal more than 24 hours after the procedure, requiring admission or prolongation of a planned admission to two to three days",
"     </li>",
"     <li>",
"      Moderate &ndash; Hospitalization of 4 to 10 days",
"     </li>",
"     <li>",
"      Severe &ndash; Hospitalization of more than 10 days, hemorrhagic pancreatitis, phlegmon or pseudocyst, or required intervention (percutaneous drainage or surgery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of post-ERCP pancreatitis has been estimated in several large clinical trials and ranges from 1.6 to 15.1 percent, with most studies demonstrating rates of 4 to 5 percent (",
"    <a class=\"graphic graphic_table graphicRef58237 \" href=\"UTD.htm?12/53/13150\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3,13-23\">",
"     3,13-23",
"    </a>",
"    ]. In a series from North America, acute pancreatitis occurred in 127 of 2347 cases (5.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3\">",
"     3",
"    </a>",
"    ]. Most cases were mild (n = 53) or moderate (n = 65); only nine patients (0.4 percent) developed severe pancreatitis, including one death, three who required surgical treatment, and one who needed percutaneous drainage of a pseudocyst.",
"   </p>",
"   <p>",
"    In a summary of 21 studies involving 16,855 patients between 1987 and 2003, post-ERCP pancreatitis occurred in 585 cases (3.5 percent). Severe pancreatitis was seen in 67 patients (0.4 percent) with only 18 deaths (0.11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower overall rates (2.6 percent) of post-ERCP pancreatitis were reported in two subsequent prospective studies involving a total of 7252 patients. In those studies, cases of severe pancreatitis were again rare (0.32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a Swedish nationwide population-based study of 11,074 ERCPs performed in 2007 and 2008, the rate of post-ERCP pancreatitis was 2.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR POST-ERCP PANCREATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple operator, patient and procedure-related factors increase the risk of post-ERCP pancreatitis. When present, these factors should be considered \"warning signs\" that may deserve special care in preventing post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Prevention'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous studies have looked at risk factors for post-ERCP pancreatitis. The studies had different study designs, examined different candidate predictor variables, and took place in a variety of settings (",
"    <a class=\"graphic graphic_table graphicRef58237 \" href=\"UTD.htm?12/53/13150\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3,14,16\">",
"     3,14,16",
"    </a>",
"    ]. The strengths of some of the associations have been supported by large, multicenter prospective trials, while others have been suggested in smaller series and from clinical experience.",
"   </p>",
"   <p>",
"    As a general rule, most reports have found that the risk of pancreatitis is increased after therapeutic compared to diagnostic ERCP. In three series, for example, the incidence of pancreatitis was more than doubled in patients who underwent therapeutic ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/13,27,28\">",
"     13,27,28",
"    </a>",
"    ]. However, severe, and even fatal, pancreatitis can occur after diagnostic ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several operator, patient, and procedure-related factors were independent predictors of post-ERCP pancreatitis in multiple studies, including at least one large prospective study (",
"    <a class=\"graphic graphic_table graphicRef58237 \" href=\"UTD.htm?12/53/13150\">",
"     table 2",
"    </a>",
"    ). There is a general consensus that the following factors increase the risk of post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Operator-related factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inadequate training",
"     </li>",
"     <li>",
"      Lack of experience",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient-related factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Normal serum bilirubin",
"     </li>",
"     <li>",
"      Recurrent pancreatitis",
"     </li>",
"     <li>",
"      Prior ERCP-induced pancreatitis",
"     </li>",
"     <li>",
"      Sphincter of Oddi dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedure-related factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Difficult cannulation",
"     </li>",
"     <li>",
"      Pancreatic duct injection",
"     </li>",
"     <li>",
"      Sphincter of Oddi manometry",
"     </li>",
"     <li>",
"      Precut sphincterotomy",
"     </li>",
"     <li>",
"      Pancreatic sphincterotomy",
"     </li>",
"     <li>",
"      Minor papilla sphincterotomy",
"     </li>",
"     <li>",
"      Biliary balloon sphincteroplasty",
"     </li>",
"     <li>",
"      Ampullectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other predictors have been identified, but their roles in predisposing to post-ERCP pancreatitis have not been established. A history of pancreatitis or allergy to contrast material may increase the risk of post-ERCP pancreatitis, while the presence of common bile duct stones may decrease the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3,32,33\">",
"     3,32,33",
"    </a>",
"    ]. One study suggested that the risk of post-ERCP pancreatitis may be increased with the use of drugs that are potentially toxic to the pancreas (ie, estrogen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , valproic acid, mesalazine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    derivatives, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/34\">",
"     34",
"    </a>",
"    ]. According to a retrospective study involving 506 patients, the use of angiotensin receptor blockers and smoking were independent risk factors for post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/35\">",
"     35",
"    </a>",
"    ]. However, in a case-control study with 5254 patients, smoking and chronic liver disease were associated with a decreased risk of post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/36\">",
"     36",
"    </a>",
"    ] Biliary stenting may also be an independent risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In addition, patients who receive self-expanding metal stents for malignant biliary obstruction may be at increased risk compared with patients who receive polyethylene stents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/38\">",
"     38",
"    </a>",
"    ], but large prospective studies are needed to clarify this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for post-ERCP pancreatitis are additive, as demonstrated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. As an example, the combination of young age, female sex, suspected sphincter of Oddi dysfunction, normal bilirubin, a difficult cannulation, and the absence of bile duct stones is associated with a risk of pancreatitis of over 40 percent.",
"   </p>",
"   <p>",
"    Several risk factors thought to be associated with post-ERCP pancreatitis have not born out in studies. These include emergency procedures, a peripapillary diverticulum, Billroth II gastrectomy, the type of contrast medium (ionic versus nonionic) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/11\">",
"     11",
"    </a>",
"    ], and wire length of the sphincterotome. In addition, hypotension during ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/40\">",
"     40",
"    </a>",
"    ] and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/41\">",
"     41",
"    </a>",
"    ] were not significant predictors.",
"   </p>",
"   <p>",
"    In a large Italian prospective multicenter study involving 3635 ERCP procedures, the rate of post-ERCP pancreatitis did not differ between high- and low-volume centers (4 versus 3 percent), but high-volume centers treated a larger proportion of patients at high risk of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EARLY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pancreatitis is based upon clinical and laboratory features, which are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .) In the setting of ERCP, it is desirable to establish the diagnosis as early as possible, particularly since the procedure is frequently performed on an outpatient basis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, up to 75 percent of patients will have an elevated serum amylase level following ERCP, but only 5 percent will have clinical pancreatitis. Thus, while routine determinations of the amylase and lipase should not be obtained following ERCP, in patients with symptoms suggestive of pancreatitis, the amylase and lipase should be checked.",
"   </p>",
"   <p>",
"    The degree and rapidity of the pancreas enzyme elevations may be a way to identify patients with incipient pancreatitis. This hypothesis was supported in a study involving 231 patients in whom serum amylase and lipase determinations were obtained serially following ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/44\">",
"     44",
"    </a>",
"    ]. Values of amylase and lipase below 276",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (4.6",
"    <span class=\"nowrap\">",
"     nkat/L)",
"    </span>",
"    and 1000",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (166.7",
"    <span class=\"nowrap\">",
"     kat/liter),",
"    </span>",
"    respectively, two hours after terminating the procedure were highly predictive of the",
"    <strong>",
"     absence",
"    </strong>",
"    of pancreatitis, even in patients who had abdominal pain (negative predictive values of 97 and 98 percent, respectively). In a similarly designed study involving 409 patients who underwent endoscopic sphincterotomy, determination of serum amylase four hours after the procedure was useful for predicting subsequent clinical pancreatitis; two-thirds of patients who developed pancreatitis had a serum amylase concentration higher than five times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/45\">",
"     45",
"    </a>",
"    ]. Another study concluded that the presence of pancreatic-type pain at 24 hours in conjunction with an elevated serum amylase level (more than five times normal) was the most accurate predictor of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum and urinary trypsinogen values have also been proposed as markers of early pancreatitis. A serum trypsinogen 2 concentration more than three times greater than the upper limit of normal six hours after ERCP is an accurate indicator of pancreatitis (sensitivity 93 percent and specificity 91 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/47\">",
"     47",
"    </a>",
"    ], while a negative urinary trypsinogen 2 test strip six hours after the procedure is highly predictive of the absence of pancreatitis (negative predictive value 98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/48\">",
"     48",
"    </a>",
"    ]. Serum C-reactive protein and interleukin-6, serially determined at 12 to 24 hours and at 36 to 48 hours, were useful early markers for predicting the severity of ERCP-induced pancreatitis in a pilot study of 84 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of measures have been studied in an effort to reduce the incidence of post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/50\">",
"     50",
"    </a>",
"    ]. Of fundamental importance is attention to basic ERCP technique. The role of pharmacologic prophylaxis is unclear, though some guidelines recommend the routine use of rectally administered nonsteroidal anti-inflammatory drugs. (See",
"    <a class=\"local\" href=\"#H6618009\">",
"     'Nonsteroidal anti-inflammatory drugs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6616230\">",
"     'Society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endoscopic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following techniques should be adhered to in order to decrease the risk of post-ERCP pancreatitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of diagnostic ERCP when alternative less invasive methods are available",
"     </li>",
"     <li>",
"      Proper training and expertise of endoscopist and assistants",
"     </li>",
"     <li>",
"      Adequate case volume for endoscopy unit and individual endoscopists to acquire experience and maintain proficiency",
"     </li>",
"     <li>",
"      Correct disinfection of endoscopes and sterilization of accessories",
"     </li>",
"     <li>",
"      Selective cannulation of the bile duct, avoiding cannulation and injection of the pancreatic duct if evaluation of the pancreatic duct is not required",
"     </li>",
"     <li>",
"      When evaluating the pancreatic duct, limit cannulation time and the number of injections, and avoid pancreatic acinarization",
"     </li>",
"     <li>",
"      Careful use of electrocautery current during sphincterotomy (standard or precut)",
"     </li>",
"     <li>",
"      Use of an aspirating catheter for sphincter of Oddi manometry of the pancreatic duct",
"     </li>",
"     <li>",
"      Consider referral to specialized ERCP centers for high-risk patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cannulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instruments that facilitate cannulation (such as catheters with distal markings and a radio-opaque tip, hydrophilic coated guidewires, double-lumen sphincterotomes, and others) may decrease the risk of post-ERCP pancreatitis.",
"   </p>",
"   <p>",
"    Guidewires may reduce the risk of post-ERCP pancreatitis by facilitating cannulation of the bile duct. A number of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/51-55\">",
"     51-55",
"    </a>",
"    ] as well as prospective and retrospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/31,56,57\">",
"     31,56,57",
"    </a>",
"    ] have evaluated the effect of a guidewire technique. Most studies found that the guidewire technique improved the success rate for biliary cannulation, but not all found that it reduced the incidence of post-ERCP pancreatitis.",
"   </p>",
"   <p>",
"    A meta-analysis of 12 randomized trials with 3450 patients found that wire-guided cannulation was superior to a contrast-assisted cannulation technique [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/58\">",
"     58",
"    </a>",
"    ]. Primary cannulation rates were higher for the wire-guided technique compared with the contrast-assisted cannulation technique (84 versus 77 percent, RR = 1.07), and the risk of post-ERCP pancreatitis was lower (3.5 versus 6.7 percent, RR = 0.51). A total of 31 patients would need to undergo guidewire cannulation rather than contrast-assisted cannulation in order to prevent one case of post-ERCP pancreatitis. In addition, guidewire cannulation was less likely to result in post-ERCP pancreatitis in cases where the pancreatic duct was inadvertently manipulated (RR = 0.28). The decreased risk of post-ERCP pancreatitis was seen only in the five \"non-crossover\" trials (ie, if attempts at cannulation failed with the assigned approach, the alternative approach could not be used). In the non-crossover trials, the rate of post-ERCP pancreatitis was 1.6 percent for guidewire cannulation and 8.3 percent for contrast-assisted cannulation (RR = 0.22). In the trials that allowed crossover, the rate of post-ERCP pancreatitis was 4.6 percent for guidewire cannulation and 5.7 percent for contrast-assisted cannulation (p = 0.39). However, wire-guided cannulation may not prevent post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent prospective trial found no significant difference in post-ERCP pancreatitis rates with the guidewire technique compared with cannulation using a sphincterotome and contrast injection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/31\">",
"     31",
"    </a>",
"    ]. The study included 1249 patients, and the overall rate of post-ERCP pancreatitis was 5.2 percent for guidewire group and 4.4 percent for the contrast injection group. Factors that were associated with post-ERCP pancreatitis on multivariate analysis included more than 10 cannulation attempts, cannulation or opacification of the main pancreatic duct, suspected sphincter of Oddi dysfunction, and precut sphincterotomy.",
"   </p>",
"   <p>",
"    Two large studies examined the use of the rendezvous cannulation technique during intraoperative ERCP and found that it significantly reduces the risk of post-ERCP pancreatitis compared with conventional biliary cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Electrocautery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that have specifically addressed the issue of electrocautery for biliary sphincterotomy have reached disparate results. In two series, the incidence of pancreatitis was reduced with pure cutting current compared to blended current (3.5 versus 11.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/61\">",
"     61",
"    </a>",
"    ] and with bipolar compared to monopolar electrocautery (0 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/62\">",
"     62",
"    </a>",
"    ]. However, a subsequent large, randomized prospective study found no significant difference in the rates of pancreatitis with pure cutting current versus blended current (7.8 versus 6.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/63\">",
"     63",
"    </a>",
"    ]. A meta-analysis of four trials with a total of 804 patients comparing pure cutting current to blended current in patients undergoing sphincterotomy found no significant difference in the rates of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/64\">",
"     64",
"    </a>",
"    ]. However, pure cutting current was associated with more episodes of bleeding (mostly minor).",
"   </p>",
"   <p>",
"    Some endoscopists start with pure cutting current and complete the sphincterotomy with blended current. The value of this approach, however, has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. In one study, no statistical difference was noted in the rates of overall pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/67\">",
"     67",
"    </a>",
"    ], while another study concluded that this approach was associated with an increased rate of complications compared to using pure cutting current [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endocut&trade; (Erbe, Inc., Atlanta, GA) is another form of electrocautery that was hypothesized to decrease the risk of post-ERCP pancreatitis. It automatically varies the intensity of current and current blend according to tissue resistance. It did not, however, reduce the rate of pancreatitis in a large retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/68\">",
"     68",
"    </a>",
"    ] or in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10214?source=see_link\">",
"     \"Standard biliary sphincterotomy technique: The cutting edge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pancreatic stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a pancreatic stent or nasopancreatic catheter may have a role in prophylaxis against ERCP-pancreatitis in some high-risk settings. Examples include patients with known or suspected sphincter of Oddi dysfunction (particularly those with a common bile duct less than 5 mm), patients undergoing pancreatic sphincterotomy or pancreatic endotherapy, and patients undergoing precut sphincterotomy. The possible benefit is hypothesized to be related to a reduction in pancreatic intraductal pressure from papillary edema. However, pancreatic stenting has been associated with a number of complications (particularly stent-related ductal changes), and should only be attempted by highly experienced endoscopists, preferably in the setting of clinical trials.",
"    <strong>",
"    </strong>",
"    Prophylactic pancreatic duct stenting is less frequently used by low volume clinicians compared with high volume clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pharmacologic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The search for a prophylactic agent that can reduce the incidence of post-ERCP pancreatitis began soon after the introduction of ERCP and still continues. Several agents have been tested experimentally and in clinical trials, but none is used routinely in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef68867 \" href=\"UTD.htm?37/30/38380\">",
"     table 3",
"    </a>",
"    ). Based upon the available data, we do not recommend the regular use of any of these agents, though a 2010 guideline issued by the European Society of Gastrointestinal Endoscopy does recommend the routine use of nonsteroidal anti-inflammatory drugs to prevent post-ERCP pancreatitis. (See",
"    <a class=\"local\" href=\"#H6616230\">",
"     'Society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Agents that have been studied include drugs that suppress pancreatic exocrine secretion, such as somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/71-74\">",
"     71-74",
"    </a>",
"    ] and its long-acting analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/75-81\">",
"     75-81",
"    </a>",
"    ], drugs that have antiproteolytic activity such as gabexate mesilate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], drugs that have anti-inflammatory activity such as IL-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/84\">",
"     84",
"    </a>",
"    ], or drugs that relax the sphincter of Oddi such as glyceryl trinitrate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/85\">",
"     85",
"    </a>",
"    ]. As a general rule, promising findings from initial trials of these agents have been followed by conflicting results from subsequent studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6618009\">",
"    <span class=\"h3\">",
"     Nonsteroidal anti-inflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite conflicting results, the available data suggest that the rectal administration of NSAIDs can reduce the incidence of post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/86-91\">",
"     86-91",
"    </a>",
"    ]. However, according to a practice survey of 141 endoscopists, most respondents (n = 118, 84 percent) did not use NSAIDs for post-ERCP pancreatitis prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/92\">",
"     92",
"    </a>",
"    ]. Given the growing evidence that rectally administered NSAIDs reduce the risk of post-ERCP pancreatitis, in centers that experience higher than average rates of post-ERCP pancreatitis, the use of rectal NSAIDs should be considered for patients who are at high-risk for post-ERCP pancreatitis. Options for prophylaxis with a nonselective NSAID include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    (100 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (100 mg) 30 to 60 minutes prior to ERCP or immediately after the procedure.",
"   </p>",
"   <p>",
"    The use of NSAIDs to prevent post-ERCP pancreatitis was examined in a meta-analysis that included ten randomized trials with 2269 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/91\">",
"     91",
"    </a>",
"    ]. Overall, NSAID use decreased the risk of post-ERCP pancreatitis (RR 0.57, 95% CI 0.38-0.86) and also the incidence of moderate to severe pancreatitis (RR 0.46, 95% CI, 0.28-0.75). However, the studies included in the analysis were heterogenous with regard to the NSAID used (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , or valdecoxib) and the route of administration. NSAID use was associated with a decreased risk of post-ERCP pancreatitis in all six of the trials that used rectal administration, whereas the results of four published studies assessing orally, intramuscularly, intravenously, and intraduodenally administered NSAIDs did not. The fact that the rectal administration appears more effective than the other routes still remains unexplained. Another source of heterogeneity among the trials was the time of NSAID administration. It was given before ERCP in four trials and after ERCP in five.",
"   </p>",
"   <p>",
"    As noted above, the NSAIDs that have been studied include nonselective NSAIDs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ) and selective COX-2 inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonselective NSAIDs &ndash; A growing number of studies have evaluated nonselective NSAIDs given orally or rectally. In a randomized controlled trial with 207 patients, the prophylactic oral administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      was ineffective in terms of the frequency and severity of post-ERCP pancreatitis in high-risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/93\">",
"       93",
"      </a>",
"      ]. However, rectal administration may be more effective. A meta-analysis of four randomized controlled trials of rectal diclofenac or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      with 912 patients found a significant reduction in the incidence of pancreatitis (RR 0.36) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/86\">",
"       86",
"      </a>",
"      ], as did a second meta-analysis of six randomized trials (OR 0.46) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/87\">",
"       87",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a randomized controlled trial subsequent to the meta-analyses, 602 patients who were undergoing ERCP were assigned to receive rectal indomethacin or placebo immediately after ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/88\">",
"       88",
"      </a>",
"      ]. The majority of the patients (82 percent) had suspected sphincter of Oddi dysfunction, and were thus at increased risk of post-ERCP pancreatitis. Patients who received prophylactic indomethacin were less likely than those who received placebo to develop post-ERCP pancreatitis (9 versus 17 percent), and were less likely to develop moderate-to-severe pancreatitis (4 versus 9 percent). It was estimated that 13 patients would need to be treated to prevent one episode of pancreatitis.",
"      <br/>",
"      <br/>",
"      In another randomized controlled trial performed after the meta-analyses, 540 patients were assigned to either rectal diclofenac plus intravenous somatostatin prior to ERCP or to a placebo suppository and saline intravenous infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/90\">",
"       90",
"      </a>",
"      ]. Patients in the treatment arm had a significantly lower incidence of post-ERCP pancreatitis than those in the control arm (5 versus 10 percent). When patients were stratified by risk, there was a statistically significant difference in high-risk patients (5.8 versus 12.3 percent) but not in low-risk patients (1.5 versus 3.5 percent). The absence of treatment with diclofenac and somatostatin was an independent predictor of post-ERCP pancreatitis in a multivariate analysis.",
"     </li>",
"     <li>",
"      Selective COX-2 inhibitors &ndash; In a randomized controlled trial from India involving 380 patients, valdecoxib administered intravenously versus Glyceryl trinitrate patch and placebo was not effective for the prevention of post-ERCP pancreatitis (P = 0.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/94\">",
"       94",
"      </a>",
"      ]. Valdecoxib has been withdrawn from US and European Union markets because of anaphylactoid reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6617444\">",
"    <span class=\"h3\">",
"     Steroidal anti-inflammatory agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids &ndash; Intravenous glucocorticoids were suggested as promising therapy in initial reports [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. However, no benefit was detected in at least three subsequent controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/97-99\">",
"       97-99",
"      </a>",
"      ]. Oral corticosteroids proved equally ineffective in two prospective, controlled trials involving a total of 1415 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/100,101\">",
"       100,101",
"      </a>",
"      ]. A meta-analysis of six randomized controlled trials of intravenous or oral corticosteroids found that prophylactic corticosteroids did not reduce the incidence of post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6617487\">",
"    <span class=\"h3\">",
"     Other anti-inflammatory agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      &ndash; Studies evaluating allopurinol have produced discordant results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/100,103-106\">",
"       100,103-106",
"      </a>",
"      ], but two meta-analyses did not support its use [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/107,108\">",
"       107,108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interleukin 10 &ndash; Interleukin 10 (IL-10) is an anti-inflammatory cytokine that limited the severity of acute pancreatitis in animal models. A study in humans undergoing therapeutic ERCP found that a single intravenous dose given 30 minutes prior to the procedure significantly reduced the incidence of pancreatitis (8 versus 24 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/84\">",
"       84",
"      </a>",
"      ]. However, the positive results should be interpreted cautiously because of the very high rate of pancreatitis in the placebo group. The incidence of pancreatitis in those who received active treatment was closer to the rate of post-ERCP pancreatitis observed in the control arms of other studies. Furthermore, no benefit was detected in two subsequent placebo-controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/109,110\">",
"       109,110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Semapimod &ndash; Pre-ERCP infusion of semapimod, a mitogen-activated protein kinase inhibitor, lowered post-ERCP hyperamylasemia but not the incidence of pancreatitis in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       Pentoxifylline",
"      </a>",
"      &ndash; Pentoxifylline did not protect against post-ERCP pancreatitis or hyperamylasemia in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platelet-activating factor &ndash; Platelet-activating factor (PAF) is a potent proinflammatory mediator. In a double blind trial involving 600 patients, the PAF-acetylhydrolase did not reduce the incidence of post-ERCP pancreatitis in subjects at increased risk [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epinephrine &ndash; Studies have looked at epinephrine irrigated or sprayed onto the papilla for the prevention of pancreas damage with conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/114-117\">",
"       114-117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"       Aprepitant",
"      </a>",
"      (a neurokinin-1 receptor antagonist) did not lower the incidence of post-ERCP pancreatitis in a preliminary human study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prophylactic oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      (selective serotonin 2A antagonist) administration in combination with ulinastatin did not reduce the incidence and severity of post-ERCP pancreatitis in high-risk patients compared with ulinastatin alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Inhibitors of pancreatic secretion",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatostatin &ndash; Several controlled trials have evaluated the efficacy of somatostatin given prophylactically using various dosing schedules. A meta-analysis of nine high quality trials concluded that somatostatin was ineffective in preventing post-ERCP pancreatitis when given either short-term (&lt;6 hours) or long-term (&lt;12 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/119\">",
"       119",
"      </a>",
"      ]. However, a modest benefit was observed in studies using bolus injections (pooled absolute risk reduction of 8 percent (95% CI 0.57-0.81)). The authors concluded that additional studies were needed. Two subsequent controlled trials using bolus strategies had mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/120,121\">",
"       120,121",
"      </a>",
"      ] and the role of somatostatin remains uncertain.",
"     </li>",
"     <li>",
"      Somatostatin combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      &ndash; In a randomized trial, a combination of diclofenac plus somatostatin appeared to be effective in the prevention of post-ERCP pancreatitis (4.7 versus 10.4 percent with placebo, p = 0.015), but the authors cautioned that large-scale studies are needed to confirm their findings [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      &ndash; The long-acting somatostatin analogue octreotide may reduce the serum amylase elevation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/75,78-80,122\">",
"       75,78-80,122",
"      </a>",
"      ], but studies evaluating the incidence of acute pancreatitis have produced mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/76,77,81,97,122,123\">",
"       76,77,81,97,122,123",
"      </a>",
"      ]. One meta-analysis found no clear evidence for a benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/124\">",
"       124",
"      </a>",
"      ]. A second meta-analysis found that octreotide would be effective only at doses of at least 0.5 mg [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/125\">",
"       125",
"      </a>",
"      ]. A third meta-analysis did find evidence of prevention of pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcitonin [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/127,128\">",
"       127,128",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/129\">",
"       129",
"      </a>",
"      ] &ndash; Studies using calcitonin and glucagon failed to show a reduction in the levels of pancreatic enzymes or in the complication rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Agents that stimulate pancreatic secretion and reduce sphincter tone",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      &ndash; Secretin had a protective effect in a preliminary retrospective study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/130\">",
"       130",
"      </a>",
"      ]. Results from randomized trials have been variable. No benefit was observed on ERCP-induced hyperamylasemia in one trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/131\">",
"       131",
"      </a>",
"      ]. However, in a second trial with 869 patients who were assigned to receive synthetic secretin or placebo prior to ERCP, the incidence of post-ERCP pancreatitis was significantly lower in patients who received secretin (8 versus 15 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/132\">",
"       132",
"      </a>",
"      ]. The protective effect was particularly pronounced in patients who underwent biliary sphincterotomy (incidence of pancreatitis of 5 versus 23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Agents that reduce of sphincter tone",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      &ndash; Two controlled studies failed to demonstrate a significant effect of nifedipine in the prevention of post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/133,134\">",
"       133,134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nitrates &ndash; Glyceryl trinitrate (sublingual or transdermal) reduces sphincter of Oddi pressure, providing a rationale for evaluating its efficacy in preventing post-ERCP pancreatitis. Initial controlled trials suggested a potential benefit, but rates of pancreatitis in the control arms were unexpectedly high [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/85,135\">",
"       85,135",
"      </a>",
"      ]. No benefit was observed in three subsequent randomized controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/136-138\">",
"       136-138",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Two meta-analyses that included a total of five studies did support the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      in the prevention of post-ERCP pancreatitis. However, in these analyses, administration of nitroglycerin by the dermal route, which is the preferred route of administration, did not reach statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/139\">",
"       139",
"      </a>",
"      ]. In a randomized placebo-controlled trial involving 380 patients, Glyceryl trinitrate patch versus valdecoxib and placebo was not effective for the prevention of post-ERCP pancreatitis (P = 0.986) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Botulinum toxin &ndash; The hypothesis that botulinum toxin (BTX) injection might reduce the rate of post-ERCP pancreatitis by reducing pancreatic sphincter hypertension in patients with sphincter of Oddi dysfunction (SOD) provided the rationale for a controlled trial comparing BTX versus sham saline injection in 26 patients with elevated baseline sphincter pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/140\">",
"       140",
"      </a>",
"      ]. There was a lower rate of pancreatitis in the BTX group (25 versus 43 percent) but the results did not achieve statistical significance. A concern related to this study is that the rate of pancreatitis was much higher than other studies of similar patients. Furthermore, BTX injection without preliminary insertion of a pancreatic prosthesis may increase the risk of pancreatitis due to temporary occlusion of the pancreatic orifice [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/141\">",
"       141",
"      </a>",
"      ]. Thus, this technique may deserve evaluation in future trials, but cannot at present be recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/142\">",
"       142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      &ndash; Topical application of lidocaine reduces sphincter of Oddi spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/143\">",
"       143",
"      </a>",
"      ]. Despite this theoretical benefit, topical lidocaine did not reduce the rate of post-ERCP pancreatitis in a randomized trial involving 294 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/144\">",
"       144",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Inhibitors of protease activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple protease inhibitors have been investigated for the prevention of post-ERCP pancreatitis. In a meta-analysis with 18 studies and 4966 patients, there was a small benefit for the use of protease inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/145\">",
"     145",
"    </a>",
"    ]. However, in order to prevent one episode of pancreatitis, 35 patients would need to be treated (95% confidence interval 20&ndash;125).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gabexate mesilate &ndash; Gabexate mesilate is a protease inhibitor that has been studied for treatment of pancreatitis due to a variety of causes and in the prevention of post-ERCP pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"       \"Treatment of acute pancreatitis\"",
"      </a>",
"      .) Multiple trials have been conducted in the latter setting [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/82,83\">",
"       82,83",
"      </a>",
"      ], which have produced discordant results. A meta-analysis of five studies concluded that it was ineffective in reducing post-ERCP pancreatitis and pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nafamostat &ndash; The protease inhibitor nafamostat was compared with gabexate in a controlled trial, and the rate of post-ERCP pancreatitis was similar (9.1 versus 8.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/146\">",
"       146",
"      </a>",
"      ]. Prophylactic intravenous nafamostat mesylate reduced the frequency of post-ERCP pancreatitis in a double-blind controlled trial involving 286 patients (3 versus 9 percent; P = 0.03), but there was no significant difference between the groups in the severity of pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/147\">",
"       147",
"      </a>",
"      ]. In a second trial with 608 patients, treatment with nafamostat was associated with a decreased risk of pancreatitis compared with an infusion of saline (5 versus 13 percent), but the preventive effect of the drug was not significant in high-risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ulinastatin &ndash; Ulinastatin, another protease inhibitor, reduced hyperamylasemia and post-ERCP pancreatitis in a Japanese randomized, double blind, placebo-controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/149\">",
"       149",
"      </a>",
"      ]. By contrast, a randomized controlled trial of prophylactic low dose of ulinastatin in high-risk patients did not detect a benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/150\">",
"       150",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A meta-analysis of seven randomized trials comparing ulinastatin with placebo (five trials) or gabexate (two trials) found a decreased risk of post-ERCP pancreatitis in patients who received ulinastatin (odds ratio 0.53) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/151\">",
"       151",
"      </a>",
"      ]. Subgroup analyses suggested that ulinastatin was useful when given to patients at average risk for post-ERCP pancreatitis (as opposed to those at high-risk), when it was given prior to the ERCP, and when a dose of &gt;150,000 units was used. However, a randomized trial performed after the meta-analysis compared gabexate, ulinastatin, and placebo, and only gabexate was effective in reducing the incidence of post-ERCP pancreatitis (3.5 versus 7 and 7.3 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/152\">",
"       152",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      C1-inhibitor &ndash; Infusion of C1-inhibitor (the major inhibitor of the first component of the complement system and an inactivator of kallikrein and factor XII) prevented hyperamylasemia induced by endoscopic biliary sphincterotomy in a placebo-controlled trial involving 40 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/153\">",
"       153",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heparins &ndash; Low dose anticoagulation (unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin) prior to ERCP combined with sphincterotomy appeared to reduce the risk of postprocedure pancreatitis in a prospective study involving 815 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/154\">",
"       154",
"      </a>",
"      ]. In contrast, no benefit from low molecular weight heparin was observed in a subsequent placebo-controlled trial involving 458 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/155\">",
"       155",
"      </a>",
"      ]. A meta-analysis did not demonstrate a statistically significant benefit of prophylactic heparin use for the prevention of post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/156\">",
"       156",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous magnesium sulphate (as a calcium-antagonist) will be tested before and after ERCP in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/157\">",
"       157",
"      </a>",
"      ]. &nbsp;",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Antimicrobial agents",
"    </span>",
"   </p>",
"   <p>",
"    Antibiotics &ndash; A few studies have evaluated the efficacy of antibiotic prophylaxis on post-ERCP pancreatitis. An old study did not show a protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/158\">",
"     158",
"    </a>",
"    ], while a subsequent study concluded that an antibiotic regimen effectively decreased the risk of pancreatitis (2.6 versus 9.4 percent in the control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/159\">",
"     159",
"    </a>",
"    ]. The routine use of antibiotics is not recommended prior to ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=see_link\">",
"     \"Post-ERCP septic complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible role of oxidant stress in the pathogenesis of post-ERCP pancreatitis has led to clinical trials of several antioxidant drugs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N-acetylcysteine &ndash; N-acetylcysteine was not beneficial in a randomized controlled trial for preventing post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/160\">",
"       160",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sodium selenite &ndash; Sodium selenite did not decrease the risk of post-ERCP pancreatitis in a randomized controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/161\">",
"       161",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-carotene",
"      </a>",
"      &ndash; A trial compared a single dose of natural beta-carotene 12 hours prior to the procedure versus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/162\">",
"       162",
"      </a>",
"      ]. Although the incidence of pancreatitis was similar in the two groups (10 and 9.4 percent), the authors suggested that beta-carotene might reduce the severity of disease since four patients in the placebo group had severe pancreatitis compared with none in the beta-carotene group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to a meta-analysis of 11 randomized trials with 3010 patients, antioxidant supplementation did not significantly decrease the incidence or severity of post-ERCP pancreatitis (relative risk 0.92; 95% CI, 0.65-1.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Antimetabolites",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      5-fluorouracil &ndash; 5-fluorouracil added to contrast medium appeared to reduce hyperamylasemia and post-ERCP pancreatitis in a randomized study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/164\">",
"       164",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, only rectally administered NSAIDs have proved to decrease the incidence of post-ERCP pancreatitis in high-risk patients. Their efficacy immediately after the procedure is an advantage in comparison with other drugs that require administration before the procedure, since a number of post-ERCP risk factors are detected during the ERCP itself. The efficacy of protease inhibitors and antisecretory agents in patients at increased risk of post-ERCP pancreatitis, such as young patients with suspected sphincter of Oddi dysfunction and nondilated bile ducts, requires confirmation in further large, prospective, collaborative randomized trials that are capable of controlling for important covariates.",
"   </p>",
"   <p>",
"    Pharmacological prophylaxis of post-ERCP pancreatitis should be regarded as a potential adjuvant and but not as a substitute for proper training, experience, and technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6616230\">",
"    <span class=\"h2\">",
"     Society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, the European Society of Gastrointestinal Endoscopy released guidelines regarding prophylaxis of post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/165\">",
"     165",
"    </a>",
"    ]. While we generally agree with the ESGE guidelines, we do not believe there are enough data to recommend the regular use of NSAIDS for the prevention of post-ERCP pancreatitis and do",
"    <strong>",
"     not",
"    </strong>",
"    recommend that they be routinely administered for this purpose. (See",
"    <a class=\"local\" href=\"#H6618009\">",
"     'Nonsteroidal anti-inflammatory drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The guidelines recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine rectal administration of 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      immediately before or after ERCP",
"     </li>",
"     <li>",
"      Minimization of the number of cannulation attempts",
"     </li>",
"     <li>",
"      Minimization of the number and volume of contrast medium injections into the pancreatic duct",
"     </li>",
"     <li>",
"      Use of carbon dioxide for luminal insufflation to decrease post-procedural abdominal pain that might be confused with pancreatitis",
"     </li>",
"     <li>",
"      Use of wire-guided techniques for deep biliary cannulation",
"     </li>",
"     <li>",
"      Placement of prophylactic pancreatic stents in patients undergoing pancreatic guidewire assistance for biliary cannulation",
"     </li>",
"     <li>",
"      Precut sphincterotomies should be performed by endoscopists with expertise in standard cannulation techniques",
"     </li>",
"     <li>",
"      Use of a modified triple-lumen perfusion catheter with simultaneous aspiration or a microtransducer catheter for patients undergoing sphincter of Oddi manometry",
"     </li>",
"     <li>",
"      Prophylactic pancreatic stent placement in patients who are high-risk for developing post-ERCP pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines recommend against the use of other pharmacologic agents for the prevention of post-ERCP pancreatitis. In addition, the routine use of low-osmolality contrast agents is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of post-ERCP pancreatitis are mild, and require only a short hospital stay for bowel rest and intravenous hydration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients who develop severe pancreatitis may require prolonged hospitalization in the intensive care unit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    . The management of such patients is the same as for patients with severe pancreatitis from other causes. Endoscopic reintervention may be required in patients with a biliary cause of pancreatitis if the ERCP did not produce adequate biliary decompression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a large US retrospective study involving 1976 patients, a protocol-based management of post-ERCP pancreatis was associated with less severe pancreatitis, a shorter length of hospital stay, the need for fewer imaging studies, and decreased antibiotic use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/63/28666/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"       \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"       \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While hyperamylasemia following ERCP is seen in up to 75 percent of patients, post-ERCP pancreatitis is seen in only 5 percent. Nevertheless, it is the most common serious complication of ERCP, and methods to prevent its development are actively being sought. While some pharmacologic agents have shown promise, we do not currently recommend the routine use of any of these agents. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pharmacologic prophylaxis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6616230\">",
"     'Society guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To decrease the risk of post-ERCP pancreatitis, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid diagnostic ERCP when alternative, less invasive methods are available.",
"     </li>",
"     <li>",
"      Refer patients to experienced interventional endoscopists with high case volumes, especially in high-risk patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for post-ERCP pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In centers that experience higher than average rates of post-ERCP pancreatitis, the use of rectal NSAIDs before or immediately after the procedure should be considered for patients who are at high-risk for post-ERCP pancreatitis. (See",
"      <a class=\"local\" href=\"#H6618009\">",
"       'Nonsteroidal anti-inflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attempt selective cannulation of the bile duct if evaluation of the pancreatic duct is not required.",
"     </li>",
"     <li>",
"      During evaluation of the pancreatic duct, limit cannulation time and the number of injections and avoid pancreatic acinarization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for post-ERCP pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apply electrocautery current cautiously during sphincterotomy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Electrocautery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In high-risk patients (eg, sphincter of Oddi dysfunction), placement of a pancreatic stent or nasopancreatic catheter can be considered by highly experienced endoscopists. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pancreatic stenting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, guidelines have been issued by the European Society of Gastrointestinal Endoscopy for post-ERCP pancreatitis prophylaxis. (See",
"    <a class=\"local\" href=\"#H6616230\">",
"     'Society guidelines'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/1\">",
"      Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990; 19:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/2\">",
"      Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/3\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/4\">",
"      Rabenstein T, Schneider HT, Hahn EG, Ell C. 25 years of endoscopic sphincterotomy in Erlangen: assessment of the experience in 3498 patients. Endoscopy 1998; 30:A194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/5\">",
"      Trap R, Adamsen S, Hart-Hansen O, Henriksen M. Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals. Endoscopy 1999; 31:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/6\">",
"      Cotton PB. Analysis of 59 ERCP lawsuits; mainly about indications. Gastrointest Endosc 2006; 63:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/7\">",
"      Kerr SE, Kahaleh M, LeGallo RD, Stelow EB. Death after endoscopic retrograde cholangiopancreatography: findings at autopsy. Hum Pathol 2010; 41:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/8\">",
"      Sherman S. ERCP and endoscopic sphincterotomy-induced pancreatitis. Am J Gastroenterol 1994; 89:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/9\">",
"      Johnson GK, Geenen JE, Johanson JF, et al. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1997; 46:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/10\">",
"      Sherman S, Hawes RH, Troiano FP, Lehman GA. Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter. Gastrointest Endosc 1992; 38:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/11\">",
"      George S, Kulkarni AA, Stevens G, et al. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metanalysis. Dig Dis Sci 2004; 49:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/12\">",
"      Ratani RS, Mills TN, Ainley CC, Swain CP. Electrophysical factors influencing endoscopic sphincterotomy. Gastrointest Endosc 1999; 49:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/13\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/14\">",
"      Rabenstein T, Schneider HT, Bulling D, et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 2000; 32:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/15\">",
"      Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/16\">",
"      Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/17\">",
"      Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/18\">",
"      Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. Gastrointest Endosc 2004; 60:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/19\">",
"      Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/20\">",
"      Cheon YK, Cho KB, Watkins JL, et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 2007; 65:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/21\">",
"      Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/22\">",
"      Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/23\">",
"      Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009; 70:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/24\">",
"      Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/25\">",
"      Enochsson L, Swahn F, Arnelo U, et al. Nationwide, population-based data from 11,074 ERCP procedures from the Swedish Registry for Gallstone Surgery and ERCP. Gastrointest Endosc 2010; 72:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/26\">",
"      Kozarek RA. ERCP economics. Gastrointest Endosc 1999; 49:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/27\">",
"      Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1995; 42:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/28\">",
"      Halme L, Doepel M, von Numers H, et al. Complications of diagnostic and therapeutic ERCP. Ann Chir Gynaecol 1999; 88:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/29\">",
"      Badalov N, Tenner S, Baillie J. The Prevention, recognition and treatment of post-ERCP pancreatitis. JOP 2009; 10:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/30\">",
"      Testoni PA, Mariani A, Giussani A, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010; 105:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/31\">",
"      Mariani A, Giussani A, Di Leo M, et al. Guidewire biliary cannulation does not reduce post-ERCP pancreatitis compared with the contrast injection technique in low-risk and high-risk patients. Gastrointest Endosc 2012; 75:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/32\">",
"      Elfant AB, Bourke MJ, Alhalel R, et al. A prospective study of the safety of endoscopic therapy for choledocholithiasis in an outpatient population. Am J Gastroenterol 1996; 91:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/33\">",
"      Cotton PB, Geenen JE, Sherman S, et al. Endoscopic sphincterotomy for stones by experts is safe, even in younger patients with normal ducts. Ann Surg 1998; 227:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/34\">",
"      Perney P, Berthier E, Pageaux GP, et al. Are drugs a risk factor of post-ERCP pancreatitis? Gastrointest Endosc 2003; 58:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/35\">",
"      Li N, Tieng A, Novak S, et al. Effects of medications on post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreatology 2010; 10:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/36\">",
"      Dimagno MJ, Spaete JP, Ballard DD, et al. Risk Models for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PEP): Smoking and Chronic Liver Disease Are Predictors of Protection Against PEP. Pancreas 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/37\">",
"      Wilcox CM, Phadnis M, Varadarajulu S. Biliary stent placement is associated with post-ERCP pancreatitis. Gastrointest Endosc 2010; 72:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/38\">",
"      Cot&eacute; GA, Kumar N, Ansstas M, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc 2010; 72:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/39\">",
"      Adler DG, Baron TH. Biliary self-expandable metal stents and the risk of post-ERCP pancreatitis: the jury is still out. Gastrointest Endosc 2011; 73:1070; author reply 1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/40\">",
"      Jacobson BC, Carr-Locke DL. Hypotension during ERCP is common but not a risk factor for post-ERCP pancreatitis. HPB (Oxford) 2001; 3:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/41\">",
"      Deenadayalu VP, Blaut U, Watkins JL, et al. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis?: a retrospective, multicenter study. J Clin Gastroenterol 2008; 42:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/42\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc 1999; 49:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/43\">",
"      Ho KY, Montes H, Sossenheimer MJ, et al. Features that may predict hospital admission following outpatient therapeutic ERCP. Gastrointest Endosc 1999; 49:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/44\">",
"      Gottlieb K, Sherman S, Pezzi J, et al. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol 1996; 91:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/45\">",
"      Testoni PA, Bagnolo F, Caporuscio S, Lella F. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterol 1999; 94:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/46\">",
"      Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc 2001; 53:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/47\">",
"      Kemppainen E, Hedstr&ouml;m J, Puolakkainen P, et al. Increased serum trypsinogen 2 and trypsin 2-alpha 1 antitrypsin complex values identify endoscopic retrograde cholangiopancreatography induced pancreatitis with high accuracy. Gut 1997; 41:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/48\">",
"      Kemppainen E, Hedstr&ouml;m J, Puolakkainen P, et al. Urinary trypsinogen-2 test strip in detecting ERCP-induced pancreatitis. Endoscopy 1997; 29:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/49\">",
"      Kaw M, Singh S. Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 2001; 54:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/50\">",
"      Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/51\">",
"      Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/52\">",
"      Artifon EL, Sakai P, Cunha JE, et al. Guidewire cannulation reduces risk of post-ERCP pancreatitis and facilitates bile duct cannulation. Am J Gastroenterol 2007; 102:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/53\">",
"      Bailey AA, Bourke MJ, Williams SJ, et al. A prospective randomized trial of cannulation technique in ERCP: effects on technical success and post-ERCP pancreatitis. Endoscopy 2008; 40:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/54\">",
"      Katsinelos P, Paroutoglou G, Kountouras J, et al. A comparative study of standard ERCP catheter and hydrophilic guide wire in the selective cannulation of the common bile duct. Endoscopy 2008; 40:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/55\">",
"      Lee TH, Park do H, Park JY, et al. Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial. Gastrointest Endosc 2009; 69:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/56\">",
"      Kouklakis G, Gatopoulou A, Lirantzopoulos N, et al. Evaluation of guide wire cannulation technique in elderly patients with choledocholithiasis. J Gastrointestin Liver Dis 2009; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/57\">",
"      Adler DG, Verma D, Hilden K, et al. Dye-free wire-guided cannulation of the biliary tree during ERCP is associated with high success and low complication rates: outcomes in a single operator experience of 822 cases. J Clin Gastroenterol 2010; 44:e57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/58\">",
"      Tse F, Yuan Y, Moayyedi P, Leontiadis GI. Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev 2012; 12:CD009662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/59\">",
"      Noel R, Enochsson L, Swahn F, et al. A 10-year study of rendezvous intraoperative endoscopic retrograde cholangiography during cholecystectomy and the risk of post-ERCP pancreatitis. Surg Endosc 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/60\">",
"      Swahn F, Nilsson M, Arnelo U, et al. Rendezvous Cannulation Technique Reduces Post-ERCP Pancreatitis: A Prospective Nationwide Study of 12,718 ERCP Procedures. Am J Gastroenterol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/61\">",
"      Elta GH, Barnett JL, Wille RT, et al. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. Gastrointest Endosc 1998; 47:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/62\">",
"      Siegel JH, Veerappan A, Tucker R. Bipolar versus monopolar sphincterotomy: a prospective trial. Am J Gastroenterol 1994; 89:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/63\">",
"      Macintosh DG, Love J, Abraham NS. Endoscopic sphincterotomy by using pure-cut electrosurgical current and the risk of post-ERCP pancreatitis: a prospective randomized trial. Gastrointest Endosc 2004; 60:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/64\">",
"      Verma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastrointest Endosc 2007; 66:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/65\">",
"      Pasricha P. Current news about sphincterotomy-induced pancreatitis: does electrocautery setting make a difference? Gastroenterology 1998; 115:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/66\">",
"      Stefanidis G, Karamanolis G, Viazis N, et al. A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. Gastrointest Endosc 2003; 57:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/67\">",
"      Gorelick A, Cannon M, Barnett J, et al. First cut, then blend: an electrocautery technique affecting bleeding at sphincterotomy. Endoscopy 2001; 33:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/68\">",
"      Perini RF, Sadurski R, Cotton PB, et al. Post-sphincterotomy bleeding after the introduction of microprocessor-controlled electrosurgery: does the new technology make the difference? Gastrointest Endosc 2005; 61:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/69\">",
"      Norton ID, Petersen BT, Bosco J, et al. A randomized trial of endoscopic biliary sphincterotomy using pure-cut versus combined cut and coagulation waveforms. Clin Gastroenterol Hepatol 2005; 3:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/70\">",
"      Cot&eacute; GA, Keswani RN, Jackson T, et al. Individual and practice differences among physicians who perform ERCP at varying frequency: a national survey. Gastrointest Endosc 2011; 74:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/71\">",
"      Bordas JM, Toledo-Pimentel V, Llach J, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998; 47:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/72\">",
"      Guelrud M, Mendoza S, Viera L, Gelrud D. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1991; 37:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/73\">",
"      Persson B, Slezak P, Efendic S, H&auml;ggmark A. Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology 1992; 39:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/74\">",
"      Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/75\">",
"      Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc 1991; 37:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/76\">",
"      Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992; 87:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/77\">",
"      Binmoeller KF, Harris AG, Dumas R, et al. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992; 33:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/78\">",
"      Arcidiacono R, Gambitta P, Rossi A, et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994; 26:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/79\">",
"      Testoni PA, Lella F, Bagnolo F, et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas 1996; 13:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/80\">",
"      Tulassay Z, D&ouml;br&ouml;nte Z, Pr&oacute;nai L, et al. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998; 12:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/81\">",
"      Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, Frangou E. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology 1998; 45:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/82\">",
"      Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007; 65:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/83\">",
"      Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. N Engl J Med 1996; 335:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/84\">",
"      Devi&egrave;re J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/85\">",
"      Moret&oacute; M, Zaballa M, Casado I, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc 2003; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/86\">",
"      Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/87\">",
"      Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/88\">",
"      Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/89\">",
"      Otsuka T, Kawazoe S, Nakashita S, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol 2012; 47:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/90\">",
"      Katsinelos P, Fasoulas K, Paroutoglou G, et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy 2012; 44:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/91\">",
"      Ding X, Chen M, Huang S, et al. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc 2012; 76:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/92\">",
"      Dumonceau JM, Rigaux J, Kahaleh M, et al. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc 2010; 71:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/93\">",
"      Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007; 66:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/94\">",
"      Bhatia V, Ahuja V, Acharya SK, Garg PK. A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis. J Clin Gastroenterol 2011; 45:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/95\">",
"      Weiner GR, Geenen JE, Hogan WJ, Catalano MF. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc 1995; 42:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/96\">",
"      Sherman S, Lehman GA, Earle DE, et al. Does prophylactic steroid administration reduce the frequency and severity of post-ERCP pancreatitis? Randomized prospective multicenter study (abstract). Gastrointest Endosc 1996; 43:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/97\">",
"      Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/98\">",
"      Dumot JA, Conwell DL, O'Connor JB, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998; 93:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/99\">",
"      De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999; 94:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/100\">",
"      Budzyska A, Marek T, Nowak A, et al. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/101\">",
"      Sherman S, Blaut U, Watkins JL, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/102\">",
"      Bai Y, Gao J, Shi X, et al. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 2008; 8:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/103\">",
"      Katsinelos P, Kountouras J, Chatzis J, et al. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 2005; 61:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/104\">",
"      Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 2005; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/105\">",
"      Romagnuolo J, Hilsden R, Sandha GS, et al. Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/106\">",
"      Martinez-Torres H, Rodriguez-Lomeli X, Davalos-Cobian C, et al. Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2009; 15:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/107\">",
"      Zheng M, Chen Y, Bai J, et al. Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008; 37:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/108\">",
"      Bai Y, Gao J, Zhang W, et al. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/109\">",
"      Dumot JA, Conwell DL, Zuccaro G Jr, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/110\">",
"      Sherman S, Cheng CL, Costamagna G, et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009; 38:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/111\">",
"      van Westerloo DJ, Rauws EA, Hommes D, et al. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc 2008; 68:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/112\">",
"      Kapetanos D, Kokozidis G, Christodoulou D, et al. A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc 2007; 66:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/113\">",
"      Sherman S, Alazmi WM, Lehman GA, et al. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointest Endosc 2009; 69:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/114\">",
"      Ohashi A, Tamada K, Tomiyama T, et al. Epinephrine irrigation for the prevention of pancreatic damage after endoscopic balloon sphincteroplasty. J Gastroenterol Hepatol 2001; 16:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/115\">",
"      Matsushita M, Takakuwa H, Shimeno N, et al. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol 2009; 44:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/116\">",
"      Nakaji K, Suzumura S, Nakae Y, et al. Effects in the control of edema of the papilla of Vater by epinephrine saline irrigation after endoscopic retrograde cholangiopancreatography in an endoscopy center in Japan, 2003 to 2007: exploratory retrospective analysis to evaluate the characteristics of eligible patients with a focus on serum amylase levels. Intern Med 2009; 48:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/117\">",
"      Hua XL, Bo QJ, Gen GL, et al. Prevention of post-ERCP pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/118\">",
"      Shah TU, Liddle R, Branch MS, et al. Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial. JOP 2012; 13:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/119\">",
"      Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/120\">",
"      Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas 2008; 37:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/121\">",
"      Chan HH, Lai KH, Lin CK, et al. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography. J Chin Med Assoc 2008; 71:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/122\">",
"      Li ZS, Pan X, Zhang WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007; 102:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/123\">",
"      Thomopoulos KC, Pagoni NA, Vagenas KA, et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006; 64:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/124\">",
"      Bai Y, Gao J, Zou DW, Li ZS. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008; 37:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/125\">",
"      Zhang Y, Chen QB, Gao ZY, Xie WF. Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses. Aliment Pharmacol Ther 2009; 29:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/126\">",
"      Omata F, Deshpande G, Tokuda Y, et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2010; 45:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/127\">",
"      Odes HS, Novis BN, Barbezat GO, Bank S. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 1977; 16:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/128\">",
"      Ohnhaus EE, Witzel L, Halter F, Stauffacher W. [The effect of salmon calcitonin on pancreatic enzymes and hormones before and after retrograde cholangiopancreatography]. Schweiz Med Wochenschr 1981; 111:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/129\">",
"      Silvis SE, Vennes JA. The role of glucagon in endoscopic cholangiopancreatography. Gastrointest Endosc 1975; 21:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/130\">",
"      Mundorf J, Jowell P, Branch MS, et al. Reduced incidence of post-ERCP pancreatitis in non-pancreas divisum patients who receive intravenous secretin during ERCP (abstract). Am J Gastroenterol 1995; 90:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/131\">",
"      Tympner F, R&ouml;sch W. [Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP]. Z Gastroenterol 1982; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/132\">",
"      Jowell PS, Branch MS, Fein SH, et al. Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. Pancreas 2011; 40:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/133\">",
"      Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/134\">",
"      Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/135\">",
"      Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001; 88:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/136\">",
"      Kaffes AJ, Bourke MJ, Ding S, et al. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc 2006; 64:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/137\">",
"      Beauchant M, Ingrand P, Favriel JM, et al. Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial. Endoscopy 2008; 40:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/138\">",
"      N&oslash;jgaard C, Hornum M, Elkjaer M, et al. Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled multicenter trial. Gastrointest Endosc 2009; 69:e31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/139\">",
"      Chen B, Fan T, Wang CH. A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol 2010; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/140\">",
"      Gorelick A, Barnett J, Chey W, et al. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/141\">",
"      Cotton PB, Hawes RH. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36:744; author reply 745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/142\">",
"      Wehrmann T. Sphincter of Oddi dysfunction: cut and inject, but don't measure the pressure? Endoscopy 2004; 36:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/143\">",
"      McFarland RJ, Corbett CR, Taylor P, Nash AG. The relaxant action of hymecromone and lignocaine on induced spasm of the bile duct sphincter. Br J Clin Pharmacol 1984; 17:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/144\">",
"      Schwartz JJ, Lew RJ, Ahmad NA, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/145\">",
"      Seta T, Noguchi Y. Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis. Gastrointest Endosc 2011; 73:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/146\">",
"      Chang JH, Lee IS, Kim HK, et al. Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate. Gut Liver 2009; 3:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/147\">",
"      Yoo KS, Huh KR, Kim YJ, et al. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. Pancreas 2011; 40:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/148\">",
"      Park KT, Kang DH, Choi CW, et al. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? Pancreas 2011; 40:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/149\">",
"      Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/150\">",
"      Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas 2008; 37:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/151\">",
"      Chen S, Shi H, Zou X, Luo H. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp? Pancreas 2010; 39:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/152\">",
"      Yoo YW, Cha SW, Kim A, et al. The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Gut Liver 2012; 6:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/153\">",
"      Testoni PA, Cicardi M, Bergamaschini L, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/154\">",
"      Rabenstein T, Roggenbuck S, Framke B, et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/155\">",
"      Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/156\">",
"      Li S, Cao G, Chen X, Wu T. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2012; 24:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/157\">",
"      Fluhr G, Mayerle J, Weber E, et al. Pre-Study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. BMC Gastroenterol 2013; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/158\">",
"      Brandes JW, Scheffer B, Lorenz-Meyer H, et al. ERCP: Complications and prophylaxis a controlled study. Endoscopy 1981; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/159\">",
"      R&auml;ty S, Sand J, Pulkkinen M, et al. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/160\">",
"      Katsinelos P, Kountouras J, Paroutoglou G, et al. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005; 62:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/161\">",
"      Wollschl&auml;ger S, P&auml;tzold K, Bulang T, et al. [Effect of preventive selenium administration on development of ERCP-induced acute pancreatitis]. Med Klin (Munich) 1999; 94 Suppl 3:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/162\">",
"      Lavy A, Karban A, Suissa A, et al. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004; 29:e45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/163\">",
"      Gu WJ, Wei CY, Yin RX. Antioxidant supplementation for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Nutr J 2013; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     Fan WT, Wang QW, Li QL. [Preventive effect of 5-fluorouracil on post-ERCP pancreatitis] Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004; 29:201 (article in Chinese).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/165\">",
"      Dumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/63/28666/abstract/166\">",
"      Reddy N, Wilcox CM, Tamhane A, et al. Protocol-based medical management of post-ERCP pancreatitis. J Gastroenterol Hepatol 2008; 23:385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 629 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28666=[""].join("\n");
var outline_f27_63_28666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GRADING AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS FOR POST-ERCP PANCREATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EARLY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cannulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Electrocautery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pancreatic stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pharmacologic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6618009\">",
"      - Nonsteroidal anti-inflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6617444\">",
"      - Steroidal anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6617487\">",
"      - Other anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Inhibitors of pancreatic secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Agents that stimulate pancreatic secretion and reduce sphincter tone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Agents that reduce of sphincter tone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Inhibitors of protease activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Antimicrobial agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Antimetabolites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6616230\">",
"      Society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/629|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/52/9036\" title=\"table 1\">",
"      Grading of ERCP complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/53/13150\" title=\"table 2\">",
"      Risk factors ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/30/38380\" title=\"table 3\">",
"      Drugs prevent ERCP pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=related_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=related_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=related_link\">",
"      Post-ERCP septic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10214?source=related_link\">",
"      Standard biliary sphincterotomy technique: The cutting edge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_63_28667="Mohs versus standard excision";
var content_f27_63_28667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mohs surgery versus standard excision",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mohs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Standard excision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tissue excision",
"        </strong>",
"       </td>",
"       <td>",
"        Initial narrow margin",
"       </td>",
"       <td>",
"        Wider margin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tissue grossing",
"        </strong>",
"       </td>",
"       <td>",
"        On site (oriented/inked/mapped)",
"       </td>",
"       <td>",
"        Sent to pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tissue sectioning",
"        </strong>",
"       </td>",
"       <td>",
"        Oblique/horizontal",
"       </td>",
"       <td>",
"        Vertical (\"bread-loafing\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Margin evaluation",
"        </strong>",
"       </td>",
"       <td>",
"        Total margin (lateral and deep)",
"       </td>",
"       <td>",
"        Small percentage of true margin sampled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Histologic evaluation",
"        </strong>",
"       </td>",
"       <td>",
"        Mohs surgeon",
"       </td>",
"       <td>",
"        Pathologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tumor assessment",
"        </strong>",
"       </td>",
"       <td>",
"        Tumor mapped/immediate excision",
"       </td>",
"       <td>",
"        Tumor presence communicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28667=[""].join("\n");
var outline_f27_63_28667=null;
var title_f27_63_28668="Involved sites in untreated HL";
var content_f27_63_28668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of involved sites in pathologically staged untreated patients with Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Nodal sites, spleen, and liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">",
"        Cervical nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Left side",
"       </td>",
"       <td class=\"sublist_other\">",
"        60-70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Right side",
"       </td>",
"       <td class=\"sublist_other\">",
"        50-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mediastinal nodes",
"       </td>",
"       <td>",
"        50-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paraaortic nodes",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">",
"        Axillary nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Left side",
"       </td>",
"       <td class=\"sublist_other\">",
"        30-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Right side",
"       </td>",
"       <td class=\"sublist_other\">",
"        25-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spleen",
"       </td>",
"       <td>",
"        30-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hilar nodes",
"       </td>",
"       <td>",
"        15-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iliac nodes",
"       </td>",
"       <td>",
"        15-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inguinal nodes",
"       </td>",
"       <td>",
"        8-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver",
"       </td>",
"       <td>",
"        2-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mesenteric nodes",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Waldeyer's ring",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Extranodal sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Total extranodal",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        10-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bone marrow",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Other (eg, lungs, bone)",
"       </td>",
"       <td class=\"sublist_other\">",
"        10-12",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gupta, RK, Gospodarowicz, MK, Lister, TA. Clinical evaluation and staging of Hodgkin's disease. In; Hodgkin's disease, Mauch, PM, Armitage, JO, Diehl, V, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28668=[""].join("\n");
var outline_f27_63_28668=null;
var title_f27_63_28669="Contents: Neurology calculators";
var content_f27_63_28669=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neurology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neurology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17874\">",
"           Calculator: Epworth Sleepiness Scale (ESS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10642\">",
"           Calculator: Stroke Risk in Female Patients 55-84 Years Old (Framingham data)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9906\">",
"           Calculator: Stroke Risk in Male Patients 55-84 Years Old (Framingham data)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-1D287C8F3F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_63_28669=[""].join("\n");
var outline_f27_63_28669=null;
var title_f27_63_28670="Nodular melanoma PI";
var content_f27_63_28670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular melanomas present as discrete nodules, usually with dark pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28670=[""].join("\n");
var outline_f27_63_28670=null;
var title_f27_63_28671="Dorsal penile nerve block2";
var content_f27_63_28671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal penile nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEZAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3XdSFqi3UhYV4jZ9AS7qN1QF8CjzKVwJ91NL4qEvUbygCi4FkyYFZmp6kluhywzVPU9VW3RgG5rjr+/e5c5Y4pXNadJyLGqarJOxCMcVlFmHJprkge1NZ8rSud0Kdh+ec9qUMB061F5mfpQo70rm6SRaV8jPpSBstxUIOMmpUYEcGpuOxLk5yKTccU5CCQc0pHXApk3Grwc0/aCvSmhOcHoaVGYHaRSHe4mMYINPGP4iM01sHnpULPntwKTdg3Ji3HPFISeSBkCmja6fN+FJnaODkUAAPfmlD5GGphJPA4pZOACKLgOZ8KBjNAcGo2yVzikJG2lcCfO7pzUZOD6VGkgXinscDJ70XC1gdsLUDSDFOkkwMYqrLkHPak2NIS6feQar6bN9g1mGYHCscGpnIKiqFx8rBv7pzWlKfLJMxr0ueDiesSqtxbJJ1yM1n/dJXtSeGrwXmlqc8gYpZWwxUjBzXvQldHx1SPLJoeAOlK4HrUPJIHenbiTzxW6Zix+MA80w9CM804kHpUJY7iKu4iOY4GDVVyKsynI5qjKDu4rRGcireHKHFcVrWEnDdwc12lyNqHmuN19GO40pbFU3ZjppPMhVs9qoucVdWJvsCOvJxWfM4xnvXh4iNmfU4OfNFEkW1hUpiIGQarw1OGPSuW56Ng3MBioJmNSO/rVaaQVDZcUVrg8Vnt8zgDucVauHzVOA7r2NfehMtrQ7LS1WOBcDpWn5pUZ4A61lW7FUAA/CrMCmdsHIUelNSOeaSV2FzcFzjk/Smw2e8F5WI9BWpa2S4yUFSXCBFreMbas4p1L6RPWTLSGWqZkpvmVhYwuXTJ703zKpGWk83imK5dMuOtZer6gsERweaivr1YYzzg1xupX7XEh+bihm9Gm5sdeXrzyMSTiqiOS9RByBnrUsfJyetSeioqKJ87hioimcinKwXODzTC5YH1pMuI6NetOKHt1qNX2kA9KkOAvGc1Iwb7vTnvSJ16UqviP5+tKPl5FAbaE68DOKTzG8zjpUJlIBNRGRt2eQDSbElcubiec4pvRuDk1FGw2Dc3epMk7uQMcikGwFyvHWnZ2Y9DVJmIYjr3oMpPrSKsWHb+6c0okGecGqu/OMGnYxIpzkd6YWLpIIBFNlO5QAeRULuinHINPDbxkMKNyPMaHwQrEilA25NQSMS2e4pTMSCcdqRVh3JbPFSb/kKn7w6VXMgGCKNxaTOeaEDJWYMvPUVFJjpUdyWV8r0NM8zcnJ5pMpLqJJkLxVOYZ61cBwvWqwIZiGoQM3/AIfXWyaW3J4zkV1l9GFlz2rzfRZ2sdZjdT8rHBr0q8JltlkXk4zXtYSpeB8rmNLkqt9yqsmD05FKzZI9agjJf5jwakRRnJruizzWPc8DFRyKT92nuATkHimb+SDVpkMjdePeqcvHerUrZqlccg461pFkSKtw4INcrr/3DxXSuuFya57XiNpGKctgg9SGwmV9PQenFZ99GBllPFR6VcDLwk4z0rQmtkS0dieT0ry8RG9z3MHU5WkZMUhU1cV1Zc96oLwcVMpIHNeZY98lmxiqE1TyyEVSlbvmpsaR0K1wcd6q2MmdSSnXL9ao2suzUoj71SWg5SPQbQk7SBkniulitggjRRxjJ965XT5sBD6V3MDpLaxygjkYpU9WcmJurDcBEwAKy9QYkECr07EH2rMuW3ZzWspdDljHqeitdp6ikFwrd65tbnPen+eQM5Ne88vpM+SWaVTohKmOtVrq5EakhqwWvWGfmqhdXzucbq87FUaVFWT1PYwEq+Jd2rIk1W8adiM8VlsvGRSlyzHNG8Zwe1ea2fSU4qKsiNmZTx0p8c+F9CKUlSOKjOCCeKm5smmPMm5S2af5i7OetVhGG4PFPAYMAcYpD0JAdxHWpgGAzzioGJAAU1Isj92pBdkg4I3c5p7AKM9vSmg7sFunak8wBiPWgQ1nGc9qe5DoowetC7cnpjvSggyBT0PQ0BcSRgBjbkCot2WJB49Km2E98j3prKcfdFJq4J2G78sAFXNQsAGOcg1IygJ0wT0NMUEP8xG31qRryGIpDHaTzSrJ1D9RVgEOhBXDDpiqjkg9OKGCdyXzWcDFKk4VsH8ahDlRx0qCQgrknnPIoCxoM+Dk8qehqIsOxqmLkrhTgqf0phlaN8MQc9DRYFFlyTpgUgc446iqnmkc5zmjzTkEUFWL7uJowBwwqL/lmR3qsJSGyDzU7PkbhwR1oJ2AkgCo3OcnHNRtKc5JzSFyUPr60imiOVirBxwVOa9N0K4F3pUbZycV5ZISa7PwFd5tnhY8qeld2DnZ2PGzWleCl2N2UbHOBxSbgcAVHcyFJyD0NN5Xkd69aLPnWiSQlT1ppkDY4oZ89RUBdSa1RDHyEZ9qqynI4FTORt45qlcSHHoK0izORDOwKmuf1cqUY4rXZ/xzWVqkZMbGqZMdzkLYn+1EHTJrpL8EqFB4xXM8pqUZ/wBqunuBuYZ7iuCutGj1cK7NMwmQq5ye9PLHGB1qS4jIk4oSFj0ryXufTx+FMpykiqsoJ61qvCFPzdqoXAAzyAPWktdhOaRk3S4GayJCRcIyj7prq00i4uxlE4PesqPRb2S9mtnaOF15GRnIreNPTU46mJSeh0OmzEwowPaup0K/GHgkbH8S1y+kWb2tr5NxJ5kg6HGKmHmROGU/Mtck04SOuMlWidRdahvJPbpiqjzhhWb53mJvXr/EKEcmmpXJ9mkjrg3PFDTBV+ZgKzmuSy7kJx3qNpEcDeTmvYxGZOelPQ+dwmSKm+arqye4nIJwapmQn5s59qkCK33Xpwg+hry3eTuz34JQVkio7yAgkGml2PHNWJIiAccU1FJGCKnlOiMgicc5zmpipK5GMU5IQy89e1OEJwMmlYtNEPOOmfenqucZqQR468f1pSu3PpUlXECY555qSKI4y3SnqQV24NNMpB2+1AtWPEagnkH0pVQFunIqJeH5J6VImc53ZNILDsx85BHrTWC4DDihiWJ3dKcMGPuR6UrhykZLEgikO7cMHn0NKgCnnO30pzqN2Rk+lAAPnGG6io2UNlStSxgbiDke9SlcAZ6EU9xbMosWC98jikYb1OBV0QjafWmeV06CpaGmjOKHd8vSoHVtzDtW0ERdysMHsaie3AGcc0WK5kYUsW0HjpUJYt94cDpW20YPDjNVZbMAfJnmkVczN/PB6UebkdcGp7iwftxVCa2njyVBNFhXJ/Mwc5qaK43NtJ61im4ZCRIpFKtyAQQ1Ow3qbLHDHnpSiQFCuazWuc4wetIk3zcGiwt1qXwfXrWx4QuTDqxj/haueMmO/NXNGnMV/C5PfFbUfdkjixseekz0m/XkEVWWRuh7VYu5M2yOPTNVQRKMjg17UT5NjjLgc9aUlSPc1GAGB3daaeR1rVGbBvlOarSnfninsWB5NVp5B2NaJkNEE5CjI61lX0pMbA9as3U4XOTzWRfTl4zgVbJSOcvGxeoenzV0ksg2J64rnDpt5eXIkAEaIdxZjjiuv0vTft/EcqSBAA205xXFV3PRoOxlkK0g3d6vW8ayP5UWzzD2Jq7rWlPp0KTrFJcR42vHEMuM9xWbpOjX15oxja3GnTiYMszfNIyA559DXnyoq9z1frbcbIuX3h25a0ldCDKFyqmuQXTryfUyiadNKNmD5p2ojevvXrFhdxX0MgjLfuW8ty4xyKZKsasccmqSSWhhKpJvVnO6HDHpVrDYXcyvduC4AHH0FOvYIzL5gQb8YzjmtOaJHlEhRd68A45FV5lGMnAHvRexG5zlxARJuHWmsoOMipNX1jT9PUmaZSw7CuOuvGAupTHaqET1NYzp+0OmlWcDqXhdG3p0pAdx+UYPpWLZeIWhAFyu9P7wrVj1TT7nlZQje9c0qcoPVHbGtGZsglRwcGkYgkZxmkY+v6UxhkU7ndKnfUkV9o4796tRSHoD0rN8xlb6/rU0cnykg80yGu5pCQMMgZGeaVQm/OePSqKTcgZ609ZGB5NHMLkL+AB8vGaQHHDcjtVNLnBweasJKjcGlcpJomGGHzcinFV6AZpsbDGQeKnGCAVOaYyDGOnTNNO127hhUsnXgCnfLuwtAysA2drHipEAXgmiROc5xSBUAzu5qWVa4vmhTwv6UzzR1zikm4HBycVTEjbsEcVDZahcueYG9/elilAwDVMPkHaeabluvekmDgaQkDH3NTqA6AE/MOlZKzc88Gp45xjkn14qkzOUGXUcq6q3Bq0QrDsGFUVlEq7t2HqYFuJeCO4q0ZsmdUZMjpTYl+XGcimFt6Z7GmqdqDbkGgXQcYNhJxlTUJCq2QRip0uCiDeM84INNdU3Hb0YZ+lJpdCk31K8kYcjnmoGiGSCKtR/dYHFIe4PWpsX5GbcadDMuGQZrKuPD8Z3FCVNdK2OnemHAXDUJgcXPpd3F9z5sVRY3ELYkjYe9d4xCsdw+hqKWGKQHegOfaquJ3RxYu8uMnFXobkjYy9QQa07vSbdwcKBms6TTGi/1TdK0juc9Z3iz07T3NxpMZPXbUCkoSrcehqPwvIx0pVf7wFLI/muVIwQetexDVHyVRWkx4k2feOaYZg2SD0qKUAcE8CqzXEaNsyAT0zWt0tWZ2b0Q+5uiDxWbLPIHJIOKgv9UtorlbbzP9IdSyqB1+hrzzWtd1K2a4kinZNpIIU7mFL20ehosPN6vQ72+mihQSXM8MG7oZWx+lc3c+IJtL1ZBexxS2Z58xWG0r6iuKTWru+kluELmTy/L3zHe34Z6VHbwzXNkba6Ds6gurscBTUTrPq7FwoxWq1PUTYXWsg3NlfQ3Gny8rCMoMehxWv4Vt7vw1ZX8t+sRtd4aNLdSWUHjHvXF/CXWIbK9l0uSbzRIN6AdAR1r1cXDONqqAtccpNux1x2VjQbY8auzYDDIFRGVV4jX8TUSqzDJ6VWu7+1tFPmSDd6CockWosnxycDGeTioJ3jiUtI4UD1rDvdeldSLWMKPU1zd/NeXDbpZGYelZOr2N4YdvV6G7qfiS3twywKZH7Yrjdc12+uIXYsY09BUk13FEuPLy1c/rmprLH5aAD1qqSc2FVQpxOX1Od5GLOxJPqaoRSlSCDUmoScmqCvXdKJxU52Oq03UQ6hJDWg8WfmT9K4qOYowIPNdFo+qqcJKaycbG6kmew7sfjRwc9zSSqUIz0IphPT0rybn08WpK6B14yD07VXOQc5IP1qweuM9ahcZOM/jTTG43HK/AJJwKcsmR14FRbvbP8AKo2OOBxntVXuZcrRa3Hkg4NO8xuM/h71Vz0IPPrT1cgc8j+VIpMvRXDKfUVajulODkg1kbiQADinBifr2oHY3RMj4zwaepUP61hJKykc5xVuG6wAWII/Wi4cprBV3DHI6nNLJGACxwVPpVFLjLZDcetWVmXHTI7ihu4rNDWUBBt/KqciliSFIrSwgUugJX09KqylWwUOah6GkWUACDkcGniUrw3OKZKG3Zpj5XHI98VFzVq46Y7jmgk7Rg4qFmYHIoMuAT+lCdhOJOspVeSfrU0V3kYz36VQ8wYyc49KQfMTg/SqTIcL7nQwShnYNwMcUkkwH3GyR696wY5pUcA5IFWkushvMHetE7nNKm4u5otPu2sw4/lQsysCCSBniqJmBCleVzyKUyx4fdkAngUWuCLUc+xvmpbiQjlT0FUJZGRFJx160v2nIwSMj+VLyLW90WlkDJ/tY4pgfdHnv3qs8oyNhwBzSSSHzPlOAeaRRJ5mdyufpTBIS23071BM4D7gcioJJ8Scd6EG5YklOfUUxmBGRUSJI8yrgqHOAWGAfxrRj09I/wDXSF2/urW0ItnJXrQirNmpoF2scLBiAKL/AFextEa4nuYo4/Vjise/kVLd4YJvsrkcOgDMPzrmNK054r6eS5jF0+QYrmc7nPrx0H4V6MZNKx4E6MXJyZ17avFdWy3EDbonGQzDb/OuH8WS3sl2JohPd223Ahik8sIfU9yK3JrXUpdSgRLfzLN0YyTFsbGHQYqNBFDpk7XJ8wgkcUr666i0ivdMNdBl1GGKVLq8CRnzFiR84I7A1R1izZIEvZQ1ssyndHIPmyOOa7nQZ3Qm2ChVKh047VF4w0iS908yKNzx/MKtJvyM3PU8kt9Ut7GRltIN7Hu1OCapq8uI0chuyjAra0vQ4bnxPbSXC+VZrhpc8Dgc16Bca7pmlwmLSLZNwGA5FZt2fuK7Goae87I85+GWnTp40t/NGxYi28ntgV7LqvijSNIU75lklH8K8mvIbm+kSSRoXKtISWK8ZzWTKxdiWJJ9TTlTc5XYQmoRsjtdd+Il9dlksVEEfr3rBj8T3Y5l/eE9STWExpp6VXso2tYSrSTumdSvi6QLjyqrT+KLp3BQAL6VztGaSoQXQp4mo+ps3+ty3KYChT3NY8j5BLcmkzUU7YQmtowUdEZSqSnqzKv3y5qoDT7lsyGoqohMfmnK5U5Bwajpamxake+tf7wit1q0WBXAPFY2pMkeo+WnSrUcm3rnBFeElpc+vo7Fwnpg96GA3fKfvDNRo27HvTnIEXXkHH4UjoQ0+/WkcfKR3oyTj+dO46YwadxNEPU4zyP1p4w3s3ce1I47rnd60qgSIeMMOtUmZuIKTnr+NODcHmogTGwSTkdmqUrkcU9xaocrY/KlJJGOnFREEdRSnpg0uUakSrMyEenpVuK5468Y6elZpyB603leQaVi1JG9DdfNkcr0Iz+tLKPNBaLG4dh0YVhLOy9ODVm2vyp9MHpSsPbVFzIZPmPSo5FAI5zmnkrcKHj4fvUbMuOevcelTY0jK4hXj5eT60xYi34UpbnHSl83y14PNIojeEg/L3qu4dWBHFWJJ2yc1XkmJxjmlcLMf55AUd+5NP8APDA5HNU3ZuMDH1oLsBlulUmTKmmXOMgq+3PWka78sFGAZexqp5gPGM0MBmrTMHS7j5rzdGqrnIOTmq7Sv5m4Nio5bdhzGc+1VJZGibLZH1pjjpojR+2MmQeaet4ZCqrknoAKq2lje6gAYITtP8R4FdfoPg2RXjnmdmYdQBwKuNFzZjVxNOmtXqUdP0a+u8ZUIh/E10Vp4etYMNctvYdutbEOltA2IlbaPvHHQetXW08W0irMDK5UMMHjFdKpQp6s8ueJnU0k7GW9hDdReVbJyOAo9a4vUPtcV5JauChU42qOfxr0DWNa02y8hI2SO527ZFVs7jngj0rlNWuPPuTJCBuY5JPU1bnzK8Tkj8XKc1fWrRItxIwjCtk+pFH9t2UB/wBHQyv6mtC+05r23aNmOT0pun+G4YDucDA6lqI2a94KkGtjVtXe7t0kHCuM4Fc/qOhXP2oxxZ8iRt2PQ966T+07GwhKL+8deAF6fnWDqmvz3JIjIiT0Xr+dbRv0RzS5VuzYaKysDBLcSqjRrjA5JH0rL1fxOjo0NpHhTxvb/Cuburkk5ckkn1rOu7hQDt61aXcycuw+7nVQzAjJ61izTZyB0pZpGbvVcjPWquSRSEmq79atNxVaQGiwrkLc0nalIppoFcTNITR3pKpBcWqt6+ENWe1UL5utMDKc5c0gpSOaTFBItLSYpKB3PXi7SahlmySa3I13RH2rlNJdpbgMecV1cTYTA6Yrw5K2h9nS2HR5QnPQc09XDFsdxTQ3HNMiBWUe+azNyVmAGSacWzg8dar5zlcHINO/iyehoKJm9smmK5imVucH5W+lOGMjnOKY6bgcnJ6UJiaLFzEOg6YyD61FbSHHlOfmXke4qeyPn2gJ+8vyn8Kr3a7HWRRyMEfSnewkr6FgqSTTSpHXHFSxtuXKnNLtAGevOadxclyuVHamsPwAqcpgdeR1pjRnk1VxOBDszxjr0NMMX0qxt6YyPSjaOvIz6UXJsyukrxsCM4q6kyTjOQrgc571CVDBs8VBJGecAYNFkF2jQzwFccjikdSpP0rPLyBhlicepp63UhIBCn05xUuJSqW3JpBuJPQGoioB61G94Nx3KQc9uaQzKc9fbIqeRmqrR7iuWU/SmtMGXFJ5ik4Byc4AHOarTTRHOXAPpRyvsDqw6slYgd6YZWHHUVReYDo4NN+0heS2Peq5JdhOrDe6NITntxXT2GmwL5AeFZpmG9i54Uewrj7aGe4AYYSI9JJPlH4Z6/hXU2OqGJonA82B4/LaQHgMBjit6ELP3jzcwre6uRnpWn6ZGkCyLDs46yduKspqNjYOJbthIq9RnAryufxVfWtq6wEuC+ADyBx1/SsORtT1aTdcSuQTwM4FdElNvsjyVJtaHpnin4kW625gtFHPZO/1Ncpe6rqN3HDGs8iRsuWCHGR25rGfTLa1WBbi4TzcnK/eIH4cVPqGr2djDEvml3UYAUZ4+vSpailvccacm9jQsNHE0gdsD1LGtG8a0sXU3NwiooySx6n2Fef3vim8dStqfJX1By1Ykl1LPLvmkd2PUsc1mm2zp+r8quz0o+JLbeVsYi4H/LR+B+VZ13qVzcsS8mR6DgVjaWu62yKnmkVEwp5rtjFRVzy6k5Sdh00pAxVKaQKvJpk1xVCaRmPNPmM+US4nJGBxVJyTUzjNQuKaVyWyEikVOalRCTVhY+OlbRiYykU3j44qjOCCa1pV4PFZtwMGqaJTKZzUZqVzUZqC7keKWlwTViCynnYCONj+FJuw0mys3ArMvPmOBXcWHhK8usblKg+1dLpvw8jyGnGazlWijVU29zxyO0lk+5Gx/CrKaRdN/wAsmH4V9BWXg6zgUARD8qvf8I1a44iX8qydd9DRUo9T53j0OY/eUirkOg9Nwr3eTwtbt/yzH5VXPhODP3RWbrTZrGFNHA6ND5SkkVvW5GDms+3j2gAD61dts5NcM3c+npxsiYEbOetKhwQe+aj25/OpFxu9cc1Bt0GScE4PJqNmKqMjn1qRySx6UhwYwGxxSGPWTKgg5OaXeDlTkEiqpGxiFPTFAlKnDHB9aYmXdLkPn3EQwcgMKs3UfBGeDWZp0irqYA5DKQa2bgAgkdOcZokJPUqWB+QqeqnFXgFIORzWbA2y5kBA5Ga0VYFQc8dzSNHuIY+OvTrTCOcnrn9Km4ZwG4yvNQ7gWHPOKdw3GeX8uAabjBI46dqd5gHXr0puQSTg5FO4rCnoD1FMcBRT93X0pGIwfyoTBogEYz7Y61BIvzYUYX9atZyBgdqglVtoOOrcVaZlKI1YMt0FWGs8R7yRUtuhL4Azjr7VdcYjwcYPSnzGLijmbqIBjtUY9uKzzFJNJ5cUTvIewBNdHcqgBEmBwetc5JIVnbaSPlPTvVwmzGpSVrof/Z6xkm8uFjbg+XH87fpx+tLHdRQkiytApHSWf5m/AdB+VZ6SMCg6kYBJ981IHAK5PO0mtrnNyj7x5bsl5J2+YDp61d0LUZNHjuE2C5tpSD5TjhW9QaywSsUQxwyj8OaWV90RJP3cZ/OjmsP2Se5uz6jJMu1Y440PzAKO9QefIxj+YnOagjxJKFX7uAR71Mg/fSRt/B8o+prNyubwpxiIZWDtk1AzlkUuMg9Aae4G1wxPpx1zjmq9w/7+JRgg5I9sd6SYSsRvDE2P3QGe4OKrvagEFGJ9jUjz7G2BdzcAc5ye9SwTIGAdgJDz/wDWrRdzCWqtcuWcvkQ4zzUMsxdyamZPMiG0ZJ7+lRNbFF3Ahl/UVqqnNoebVw0qeu6IGyTUZWrO3AzUTda2jE4pSK7rUezJqwVJNWba2LMM10Ric8pleC3J7VfS3XZ0q7Da8A4qWS3wOK3UbIwcm2YV3EFzisO7XBNdomkXF22EQ49cVqWHgXzWDXGfpXPUrwj1OmlQnLXY8tjtZZmxHGW+gra03wlfXZBZCqn2r2TTfClpagYiXI9q3IdOjiACoB+FccsQ3sdcaEVueYaT4BRdrTjJ9662w8M2tuBiJePautjtemFq3HY+tYyn3Zqo9jAh0+NB8qgVZW3Udq1ZrTaOKqshBwaFJMTTW5AIgO1G0VIaTFUSM2j0ppUVIRSYpoR47F0JqaHA5qEHCU9TtFcDPrUiXcDTkIw3rioeKezAcdOKksGOWx39aa2dqg+tEjDoOTTX/hJ4FAyQLw2eh6ioZFHpyBTxnDEHinA4JwM8GmhMpwFk1SDrhs54rddmZ8nsePesizUyavCO4Ga2nQBHPAbPFEiFozMR9+oNyAcdK0o8bQCeOpNZ8EedRY47dK1RCVC8Ag889vWkaEDOVwWPX07VEcjcD/FVqWJcl1Py56UySErklsk4IA54pDuVWY8jJ470wygEAcHuO9OkRjvxnnmq+wq249fX1qkBY8w456Z9afvBU+9VOSQT1HFSrIdueueh9DQBMOEX8qlnj2xBiQSMHGagLDPysfvADPrVm7kQwDgAoM9e9UjGb2HQIwZ9wG3G4nNTzypsQAnCgk1nS3a7SOMOOAKgNyDGcEAbutNmVm9WM1OUSP5Yyp25BrAuWKsSDxyB+FaFxJulxuGShwffNZTSAl93Vlf8TnAq4IVSVkV3JSd8HcoKk+3NWJpAJ9pwSI8g+oPAqrO/75XUgNuQEZ46Z/nVee4zdBwMjaR19+K3SuccpamuoQx2iZPLkEj+72/lUQZQtykihd+8AdhgVnedtRlQ4Ee0rk8/55p91eJ9ohC4CA5x19vxosJysatnOjWdqXbGDj9Ooqe1nhFw4zmNZC+7+9ngVzUM5WNl4JVjjmnpdZZlQ4BAHPalymnPdG/LfpscKFwJGOT15rLurrMm5TgBMH8eKzprhlDdcE5qvvLtlSTleQaqMTGUy5LcGMJg/KpHX608Th1AP51R+0Ap5TAHB4Pf6VHvKZPOT6VXKYup3Ogh1B48ZYsPXrV2C+RnLKwOa5aPd1LHBGfSrawo9rJ5TMjhSQfepcEOFWWx0gZZF+RgT3A9aBDk1Q8KCWdXDjKKo59666x0qa4YCOM/WuujNKF5Hm42i41uWCMiG0yRWpa2bMQEQn8K67S/CjHDT/lXUWOiW9uBhBRLGKOkEYwwTes2cNY6DcTYyu0V0Nl4ZjXBlG411aW6oPlUVOkDN0Fck8ROe7OuFCEPhRj2+mQwgBUAq4luB0Fakdmf4qsJAiduawc0bcjZmR2jNjirMdmo61d4FJ3qHNsagiERKo4FLgU80w1Nx2GMARVaW3VqtnpTMZqk30JaT3M17Q9qiNq1a2MU04HatFUZDgjMFm1SR2oB5q9nim0+diUEeAMMLTgwJFNJ+XmhPmYmuY+nFY5J9KQncOajl+XHpTt3ApDHt6KaXqBz3qInBORSk56ZFAyZclCAPyoQ4XOcE96Yp+uPUU8DhT0Gc0xMl0kb9WGOqrWrIdu5iAcE9apeHVIubiXpgYyRUt7MI4mbINKRMdZEOnR755X5Az1rWVRtOc49Pf1rP0c/IC38XzVeaUPyuRngUi3uMcbXIXp0z61EQTjccDpjpUhcljgfKOeaimBADMeSO/pSLRAy/Jznk9QaglG78KlZsEe3TFQsQQP7xPamirEIGTlsgdDjvSMNvXIHb2qTI3D3puQeCcnHeqRLQ15MkO/UmmTXKCKNJWOxW+Y4ycGo3ZvkHv8AlVS7k8uJnAz5Z+6elUjKaJhOG7nAGR9O1RSSZjxnqKowSYj5bHOcZokl+U7foauxk3YfPIGxkcYIrIupljn2k/KpIx7EVZe5IJHUexrJ1hgFRwD6E/yrWmtTlrS0ILiZuCCSAQfxFRmbLEN0xgc1TmmJjPNQ+aM/UV1KB586upoGYurD1H6ilFwC0bSDcvcA47VnCfkc00zfLjPQ0+Ql1TVinBJHHIyaXzPnO04zxxWSJ8Nn2xTluMN1pchSrI1nZDkDkYFV5JAh+U4+lUmuucCopJh1FNQZE6qLxumCkDGG6+9RLLtO7oc1SM3J5FIJhgButaKBzOpqaoumYYY9OhqexuiZgi5OTjHrWPHMijLEkkZ4q/YyhJhIo2jpnuPWolHQ0p1Ls938AeElTSoridQvn4kCDsO1eiWWmwwKAiAVg/Caf+0fB1oQys8JMTYPIHUZ/A13UdqB1rzJztudVm3cppFjhRViO1ZutXERV7U/dis/aj9miCO2VfvVKAo6ClLUwmjmuHLYeTxTeKbmgmmmSxCc0lITRQAhpCM07vSmqSIbIiMUHilI5oxVITI256U3aalxSEU7EkWKaVxT8UYppAfO6vkY7U4OEUDvVdDzjtSv2rE+jH7iTz0zS7h5mWpvAQHvTQR1PegdybJ5I70gY7h703dtyR0xSQk7gxHSgZMchivTNOJ9yVUZNMBJYlx1pHLYESjmVsUITZraVuj0t5WxiVsiql7MGTaO/H41ZuGCIsSEqqDke9ZZKzXcaZ4zmk9WENNTobCECBAGHTmnMQd+0gAcZHeow2Io8DC5496azgykAgAjB96GC7jpWGAF7fqKrSSbiPQDGKSWbBIBxzjIFQSSYGePqKRqh8jYJUHp3FQFj75H6VHu+XIY+uaa7MBj8z60FXH7tpJ6KRxSB/lA4PGarM5HU8U1G29OpPT1pibJpGJxnjB7Gq1yCVkUnGMHHrT2fLE4wKrTSfOGBJyMVSMpmSH2uVzzTJ5c5w2COQTUF3mO6YA4Dc1XmJUbSeoGRnNdMY9TinMJJjt9DSMEuYSjciq0rjI4pFkCMcEYPTFbKJxyqJ6Myry2uLV2DKzRjuBVBpsAeorsI50ZdsgyD2NRzadbysPkAyeT+Ga2jVt8SOGpQb1izj/PPUZpfMc52qx79K6gaZBtJ2+/P8qkisYEeJNrEtnOOfwrT2sexh7Cp3OUXzmPEbVIkdw65CGurtrVVmMXlh2wWGTjIAp0dugKTrCqpIuGGevPOPQ1LrLsaxwkn1OYhs7hyBgKT0B71ZGkzE/vHI9cL0rqY4opfMRTG64bYD14HY0lsVntWJIDKmCAOTiodZ9EbLBpfEznk0FhJtlLBgpbBPBH+c1Yh02GEkybQDwD1rcvLqMWtuwYMy4JDDgHp16mqyXKh18wKEQv8xGQSe9L2kmNYeCMoaeCWY7cE4yKjgtWS4U84HUVe80l0VFO9iB+Of8A69OhdQRySSw69R1p8z6i9mk9D2L4Can9k1C60xv9Vcp5sfqGXt+Wfyr24tXzL8Mo5T4w0lreTYwmyeeq4ORX0qWrysQrT0OiGxIWprPgZpmSaM1gUOzRnmkpM1SIY7NJniiitESxDR0opKYhc0A4pRikOKpE2E70EUEUlNMTQowaQiloBq0yGiE5DYobNS4GaawqkgPmlm54pyfMSTUK56ipNxzjoBWDR9DcezZ4z0pOVYE1GGyfYc0u7cCcewosNMfu5Oaep45GKr7uD6ip0famG6mkO5KGPy9PepdPw9wZGHyRj9arsQEGDkmrQT7PEEJyDy2PWgT10HXM3ylh9ai0pTLdGXaCo4qreTYj4/WrmnDy7Xbg7mGSaF3Ke1jSdsYK9DnGKiklJAJHJpvm+WB3xUQl9cHtzSGhZJc55wM0xpAxIx8uKjkcbcDByc496aGZEzxQUIz7QQT70x3AAAPB7Uhbd34zUDdSB1zTHcczDGcjA7VE0hB59eoocgttByo5/GoJGJXBHQfrTSJbHSSdu/UVE0oC8E5POaZIeF3jHfAqrNN1APFWkZSkVNVXcjSLwVO7ArL80bfvGtVjkHJyCMVg3aGCbn7rHIPp7V10lfQ8vEScXcklfrj7o4qMt61CHGeRweDUbybcc5+v8q6FE8+dQurMQcg89cVNHdBCjL1BBOfWskzYxzyDx9KUylQc80cglWsbRuUIxKDjOMA9jSyTeW8ZV8x56+hxWXBOCQr4P17ipYpF2urAMqk4B/nScbGkZ3NJbhS2WP7yPIwOhU8cVFFPKh+zsQUPT/8AXWcXAjjkV8sp2ke1STNIUWRecdx6VPKdEahqrcyQukL/ACLGDngc+9QLMESRQQPmyKqPICiStLvkBwVI7Upm8yM+UuWJ5OOSanlNHNNFmXJiVsllbOVHao5GEkqkJ+7z90dxTHnlZtu1UX+6RtH5VHFOqxqroDjoQO/vTSIlJMtB9u0NHgDqw65H+RTlbdGv97d9Cag80oqgYK9Tnv8A/Wp6A7lwc89PT2osZN6nc/DC5eLxjpjYBzKFOe2QRX0rmvl34egHxfpKNwTcL0NfUS8dRXm4r4zaL0FFOpBRiucYoopaOKpIkKXpRQatEsTbmkIp4patIRGQaADTyeKb16U7CEINJinZ9aWqSuJjCMCm5xUuM0xxTsTcZmkJzS/WjFNAfL4Yg1KW+XPrVdSSzU8MSBjpUHu3Hq2R7U/cPu0yNhjDcCnLjeT2pMESxYzj86f99jgcdKaq4GV545py5WPGcbjSKJbSMNLub7i/zp88jYJyOae58qIKvJAyapXrhY+T2pMafUrLuur9I15A5NdCwVTgcBeh96ydEjKB5mXBbp9Ku3DtsJGNo96cuwLVjpH/AHZBOCeue9RgjKgkAAYqB5Tlc8heeaY2fMw2MdfwpFk5ILt0x60zzFLH26CmScE7D7ZqLb8x54HJoAWVsdBg9RimZ2Ak9cdT60pOB1+pNQTEle2KdhXGCXuPXgetMeXjLcDNIcj5lPzGqk75+UtkDqcVaREpEjsXbOcetVJmyc8cUSSnGFOBjpVN3+brzWsYmE5D2cjoeKgukWdCril3HPP5UhPHTB9fSto6HFVs1qYc4kgZkc8NxnHUVGQQNrdGGRWtdKkqFXAz61jTKYm2kkr2NdcHzI8qpHlYYJBV+nrRG5U4PJH8qaSTgg9O1ITu6cMOlWZExzGw67CeKsblikDIoKkAncKpLJlCrU+N2YAFsEcc1LRpGRc3lxKqKELfMB2I9KWOceVtAxuGBVcth8jCleDg5pGKq5KklTz9DU2NlKxchnlabb3PJzQs0cbPw+d2dueD9ahWUu2/+JeKRnMnz92PJpWL5tNCfeZxlwee+c4pyyEgq5xuOSOxqqsgUnKkljyamLuCDkHj5c+lJoFIkJUgjd8xOcY6U+I7QCBuOemarSMd4JK4I4HoakDliSyjjjPrSsDlrc9K+DNot347skkyywq0nPOCBx/OvpuW22gFTkV87fBSFrW6a+PDOQqeuO9fSmm3lrdIBITHKenoa8qparUdnsbOThFNmdsI7UYrcnsDhSAMHoe1Z01uUJBFYuLi7McakZ7FXFIRg1MVK1E1MoCKSl9KXFUhDRTx0ppozVolisKYacTxTTTEIaM0ZoNADximMeaM4pC1Xcmw00nSlzQTxQmFj5YB+XPrUiHIz0piLk81KQMgDgCke0OO3bUioRtPr2pseC4OM4qxndyRj0qWUhm4KTjqe1WIEyS7kFQOKrMNzgdc1bIXy9i+lIpjZJcA478VQuB9ouY4FPBPNTXMvlRjkZWpNFh3LJcy8E8imlbUlsuyIIYhGDz0wKrsW2lR2qRpCWBYEk8CogcMM8N0qTVaDMlvlGMDrmmkYAJwWHanOSMjGSaUcAAjrQA1yCAen0pCV2rwfX605PUj5QeKRsn8famIgY5Uj8qhkJOA2M1NN8o5HtVfkuxzkimkJshnbarADB7kVnytknJ+pq3cHORnPNUZiBj0raCMKkrEbt2z+NQsV7VFNLtzVNrje20ZLe1dEYHFOokXN4HHHFODqfvcr+tV4bW7uGxFC5P0wK0ofDuoSDJKID6nNN8q3Zl70tkUniDj5HA9iKzLy2lBZTsI9j1rsIfCzgZmuW9wgx/OrC6DZqCXDyYP8TUKvGJE8HUqdDzF2ZGIANAkbPKkGvTpdLs1XCRBc9xWdc6RC4+UDB6ArWixcGYPLKq1ucH5gPXg05ZBXS3Ohpk/u/xWsqfRWU5jJH1rWNWEjCeGqw6FIPyTngjFSK/ocZ6imSWFzF23D2qAl14dSKvR7GTco/Ei0Tz8pwvtUzMzAYVVXHIXvVFZh0zipFfkYNJxKjURZXBbJOBjnPakHQjd9Kj3jHU4NP8AvcY9s1NjRSJYSydMMoOOlXLdB5mHXg+lVolHH0xV+3+8PrWNSdloawV9z2HwM4U2yrwAo4r1e0uSMc1454Hf94h9AK9Nt7jgc14lNWudtZ3Z3Wl63Lb7QSJE/utW8bmxvowY/kl7g9K85t7g461oQXR4wa6FVaVpao5ZUVJ8y0Z1U9qQenHrVKa3I6CorTVWUBXO5fetGOeGcfK20+lJwUvhKUpR3MsqR2xS9q0ZYQe1VJISOVqLNbmikmQHmkpSMHpS00xsjNJT2FMPWqFYKCPWignNVcQhpppTQMUIBtNPFS4FNYVQj5cjXby3WnlcqcHrSKckk9KmQALkUj2BVVVChTz3p7nIwKhDbWIHOe9SRDfgZ6ck1LKJY8ImT1oD5+YdRUUzqDt7+1QTz7enHHFNK4NiMpurpU7ZycVqORGgjTgdqpacjQIXbG5+TntUpkyWJ60S7BDXUkJZXHOWXmiTLBiQCSetRRv8+FbHGWNPGOqqf9n1+tSWEaclsc9AKkZcD7vHqfWkAIG5gQB0oBY53An27UFWGlj269Bimn5RySakzgDzDg9QRVWeXapHUmgRFcMWO1RljTJMohVfxNWo4jEm9uXI/Kqc7kE4B3HoB3q0iXrqUrg7BnIzVSOzurwnyQdv949K6Gw0gzATXgwo6JW7BaZj4TavbFX7RR2IVB1NzjofDiswNwxkYdQOlbNpodvFjESj6Ct3yBGuMAmmPubIAxiodaT6m0cLCPQrJDHCPuKB7UhYKOn0qVkAByO3UVCR71m53NVSRDNITxnAPaq55wKssvDbh3o8rcflGaVxuKRRKZyCck1H5RbnHSr5tz1645pyw5+6ODTuQ4ozTDkDjrUb2qnhlBrVaPDDI7UzYDwBz70KTIdJPoYcunxsT8uD7VSuNGRyeAR7ium8nnkDnmmmLjIrSNaS6mE8LCW6OGuPDwJJVCp9qoy6TLDnMYYeuMGvRPKBGCvNRvbqyjK1vHFyW5yTy6D1R5k0RjfDKVPuKkUV3k+lwTpteMHNc9qWgzW2ZLfMkY5K9x/jW8cRGejOKpgp09VqjLjq9bfeXPrVGPrWjYLvmRfelU2M6a1PTfBZwgau6t5/euN8OR+VbLgY4roopcYrzLG03dnRwXHvV6G4BOAelc5BPV6CYA5HU0WJOjin96uQ3BB4Nc/DP71cimosM6a31BhwxyPeriXCSexrmI5verMU5HQ1fN3JsbzqGqJ0x0qlFdkdTVpLhX6nmlbsUn3GkGmkCpjg0xlBpaooiNNNPKkUn1FO4hnWkNOamk0wENJupTTTVJiPmNVyct0Hak3/ADcdD2puD1U8CnAAAHuaZ7A5TyVHelDeWp5xSYwMn7x6VFMTnB7UWHcSSTaM9zUdvukuVwRsXrmq8rMxCnqeladpEtrAA3zFuarZXM2+Z2LEjhgF6AdxUYLbgAOvAzQCGIyMAfrUiKGY/NgLzmszZDlQJjPIU/N71IBgeZkjP8PpTY/3kpA/1Y5yalbDNsU5U9fpSKsKqtLLhRlM9aBgg/NgenvSuDGNsZ+XqBUUjmNOcFj29KAGXT8nGAep+lNs4Mnz5fuj7oPf3p1rAZW3EEr71omAuqg8L6U9gtczpEkuGIjGB3Par+l6YA4kYFiD1NXLe1ErBUG2Nf1rWiTy0KjH4elDlZFcpWSzyd0g+UdBipSgAOAR2qXfzgEkVFNKC2c4A6DFZNmiKsiY+vp61C4AHQc9asSFmXJBI9aj3KuPl5NSXcqsFbGccVBKVJ6YqaZmYdAtVXRsjBzTQ0hrrz6ClXpgnNIwIHUmmqpPXH40wJedmQR6U0SAADPfGAKUKAMKetJ5WV+YHNFidAL7iOw96hkIZsAgfhU2I1JLMoqMuOQnOeeFp2AjOADySKYzqrdTjHepSszfcjY+5wKVLSaThtqdsdaYmytJKqjO4c1GZ0b+IVpf2ZnhmZvpxmo5NLgH3lz70zPQoBwWGDSFgTnrV46bGBwpx2OajNiMHG4Y96LktHM63o6yhrm0UCQcug/i9x71S8PxGW7XjpXZfY2Byr5Poaq2mm+RfGUKFDckDpmtlUbjys83EYdRfPE6jT/kiUVpRvWXA2AKuRtWTRxGlHJg1bilx3rLR8dasRv71NgNiKf3q7FPWEknvVmObFMDoI5896tRze9YEU/vVuKf3oA3Um96nSb3rGjn96sxzUAbUVwR3qxHMDWKktTpLTA2NwI4pCBVBJ/epklB60rDuTMKYQKUODSEjvQMYRTTUmPSmMOaaA+XypXFKjrhs8ntSn7lRDq1Weux+4gcGqs020EnmpX6D6VSn6iqirsibsixZQ+Ywmkzt/hFaJ5wcZXsKii/49o/pUsX+qX8aJO7CmtLjwu84JAA9KkALN5SAbT1qKD/AFxqeD/WvWbOhEpTGxVHA44qQjyDnaeaYnT/AIFT7n7wqRkRfaNz9e2aiiR5m3sD83Ap97/q1q5b/ej/AN2qQFy3hCxhF6dzVuKDPbg8c0yz/wBW1Xm/1S1LGtNBqhYwAMZ7UkjYYANzio1/1lJ/Gal6miQ51bPH/jtNdty8jmpYuh+lQyf60/SpaC5GCyYBIweeTUbng7gCabcf6wUxulIoifaxyRg+1QysoHQ09fvmq8/U/WmikM39wMDODmlMmOg6+1RHofrUyfcFUgY1GmboDipVtXkkCyyEj68CpLb/AFg+tX/+WTfWnYlytsVEsYlAKqSfU81cWzVSGUhR3BqWHoPrT5/9aKVzNttlYhF7E+lOK7ueAMUS9vrT3/1P/AhQOxEMttC5HqSaRoip55/GpB94/Sk7tQFiNkGORgVG8akAA4qxH/qz9agl+8KEOxEYsH+tMZcnIxVpuh+lQnoPrTuQ4oarlDkgkVeikBAIOap/wt9afa/fb8KuLvoebiaMYrmRoo1TI+KrJUy0NHAWkkqZJOetVFqVOtIZdSSrEc1UV6VKnWkBpxz1bin96yYqtRVQjVjn96spNWXFVmOgRpLLUqy+9UY+oqdelIZeSb3qUS5FUUqVaALqyA8Gl3ZFVV7VKKaGf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_63_28671=[""].join("\n");
var outline_f27_63_28671=null;
